Collimator and energy degrader

Description

TECHNICAL FIELD

This disclosure relates generally to elements of a particle beam scanning system, such as a collimator and an energy degrader.

BACKGROUND

Particle therapy systems use an accelerator to generate a particle beam for treating afflictions, such as tumors. In operation, particles are accelerated in orbits inside a cavity in the presence of a magnetic field, and are removed from the cavity through an extraction channel. A magnetic field regenerator generates a magnetic field bump near the outside of the cavity to distort the pitch and angle of some orbits so that they precess towards, and eventually into, the extraction channel. A beam, comprised of the particles, exits the extraction channel.

A scanning system is down-beam of the extraction channel. In this context, “down-beam” means closer to an irradiation target (here, relative to the extraction channel). The scanning system moves the beam across at least part of the irradiation target to expose various parts of the irradiation target to the beam. For example, to treat a tumor, the particle beam may be “scanned” over different cross-sections of the tumor.

SUMMARY

An example particle therapy system comprises a particle accelerator to output a particle beam; and a scanning system for the particle accelerator to scan the particle beam across at least part of an irradiation target. The scanning system is configured to scan the particle beam in two dimensions that are at an angle relative to a direction of the particle beam. A structure defines an edge. The structure is controllable to move in the two dimensions relative to the irradiation target such that at least part of the structure is between at least part of the particle beam and the irradiation target. The structure comprises a material that inhibits transmission of the particle beam. The example particle therapy system may include one or more of the following features, either alone or in combination.

The structure may be rotatable at least in the two dimensions so that the edge can be moved between different parts of the irradiation target and the particle beam. The edge may comprise a curve that has a radius that varies on at least one side of the structure. The curve may be a French curve. The structure may define an aperture and the edge may comprise an edge of the aperture. The structure may be movable to track a direction of the particle beam. The structure may comprise multiple elements that are adjustable to vary a size of the edge. The multiple elements may comprise fingers that are individually movable relative to the irradiation target.

The structure may be part of a collimator system. The structure may comprise a first structure in the collimator system and the edge may comprise a first edge. The collimator system may comprise a second structure comprising a second edge. The first edge and the second edge may be controllable to move along different edges of the irradiation target.

The scanning system may comprise at least one magnet to control movement of the particle beam to scan the particle beam. The at least one magnet may be for generating a magnetic field in response to applied current. The magnetic field may affect the movement.

The scanning system may be configured to scan the particle beam more quickly in interior sections of the irradiation target than at edges of the irradiation target. The particle beam may be movable within an area of a plane at a location of the structure. The structure may have an area that is less than the area of the plane. The structure may have an area that is less than half the area of the plane. The structure may have an area that is less than a quarter the area of the plane. The structure may have an area that is less than an eighth the area of the plane. The structure may have an area that is less than ten times a cross-sectional area of the particle beam.

The scanning system may be configured to scan the particle beam from different incident angles. The structure may be controllable to move based on movement of the particle beam as the particle beam is scanned from different incident angles. The scanning system may comprise: a magnet to affect a direction of the particle beam to scan the particle beam across at least part of an irradiation target; and a degrader to change an energy of the beam prior to output of the particle beam to the irradiation target, where the degrader is down-beam of the magnet relative to the particle accelerator. The particle accelerator may be a variable-energy device.

The particle accelerator may comprise: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, where the cavity has a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity; an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity; and a regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel. The magnetic field may be between 4 Tesla (T) and 20 T and the magnetic field bump is at most 2 Tesla.

An example particle therapy system comprises: a particle accelerator to output a particle beam; and a scanning system to receive the particle beam from the particle accelerator and to perform scanning of at least part of an irradiation target with the particle beam. The scanning system comprises a structure defining an edge. The structure is controllable to move in the two dimensions and to move based on movement of the particle beam so that the edge is between at least part of the particle beam and the irradiation target. The structure comprises a material that inhibits transmission of the particle beam. The example system also comprises a gantry on which the particle accelerator and the scanning system are mounted. The gantry may be configured to move the particle accelerator and the scanning system around the irradiation target.

An example particle therapy system comprises: a synchrocyclotron to output a particle beam; a magnet to affect a direction of the particle beam to move the particle beam across a cross-section of an irradiation target; a degrader to change an energy of the particle beam prior to moving the particle beam across the cross-section of the irradiation target, where the degrader is down-beam of the magnet relative to the synchrocyclotron; and one or more processing devices to control movement of the degrader so that the degrader at least partly tracks movement of the particle beam at an irradiation plane. The example particle therapy system may include one or more of the following features, either alone or in combination.

The particle beam may be movable within an area of a plane at a location of the degrader. The degrader may have an area that is less than the area of the plane. The degrader may comprise multiple pieces, with each piece comprised of beam-energy absorbing material, and with each piece being movable into a path of the particle beam. The one or more processing devices may be programmed to receive an energy of the particle beam to apply to the irradiation target, and to move one or more of the pieces of the beam-energy absorbing material into the path of the particle beam so that a resulting energy of the particle beam approximates the energy of the particle beam to apply to the irradiation target. The one or more processing devices may be programmed to control movement of the one or more pieces of the beam-energy absorbing material to at least partly track movement of the particle beam.

The degrader may have an area that is less than half the area of the plane. The degrader may have an area that is less than one-quarter the area of the plane. The particle beam has a spot size at a location of the degrader; and the degrader may have an area that is less than ten times an area of the spot size. The degrader may have an area that is less than twice an area of the spot size.

The particle therapy system may comprise memory to store a treatment plan. The treatment plan may comprise information to define a scanning pattern for the irradiation target. The scanning pattern may define movement of the particle beam in the two dimensions and movement of the degrader so that the degrader at least partly tracks movement of the particle beam.

The synchrocyclotron may comprise: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, where the cavity has a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity; an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity as part of the particle beam; and a regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel. The magnetic field may be between 4 Tesla (T) and 20 T and the magnetic field bump may be at most 2 Tesla, and the synchrocyclotron may be a variable-energy device.

The magnet and the degrader may be part of a scanning system. The particle therapy system may comprise a gantry on which the synchrocyclotron and the scanning system are mounted. The gantry may be configured to move the synchrocyclotron and the scanning system around the irradiation target.

The scanning system may be a raster scanning system, a spot scanning system, or any other type of scanning system

An example particle therapy system may comprise a particle accelerator to output a particle beam; and a scanning system to receive the particle beam from the synchrocyclotron and to perform scanning of at least part of an irradiation target with the particle beam. The scanning system may comprise a degrader to change an energy of the particle beam prior to scanning the at least part of the irradiation target. The degrader may be down-beam of the magnet relative to the synchrocyclotron. The example particle therapy system may comprise one or more processing devices to control movement of the degrader so that the degrader at least partly tracks movement of the particle beam during; and a gantry on which the particle accelerator and the scanning system are mounted. The gantry may be configured to move the synchrocyclotron and the scanning system around the irradiation target. The example particle therapy system may include one or more of the following features, either alone or in combination.

The degrader may have an area that is less than half the area of the plane. The degrader may have an area that is less than one-quarter the area of the plane. The particle beam has a spot size at a location of the degrader, and the degrader may have an area that is less than ten times an area of the spot size. The degrader may have an area that is less than twice an area of the spot size. The particle accelerator may be a variable-energy synchrocyclotron.

An example proton therapy system may include the foregoing particle accelerator and scanning system; and a gantry on which the particle accelerator and scanning system are mounted. The gantry is rotatable relative to a patient position. Protons are output essentially directly from the particle accelerator and through the scanning system to the position of an irradiation target, such as a patient. The particle accelerator may be a synchrocyclotron.

Two or more of the features described in this disclosure, including those described in this summary section, may be combined to form implementations not specifically described herein.

Control of the various systems described herein, or portions thereof, may be implemented via a computer program product that includes instructions that are stored on one or more non-transitory machine-readable storage media, and that are executable on one or more processing devices. The systems described herein, or portions thereof, may be implemented as an apparatus, method, or electronic system that may include one or more processing devices and memory to store executable instructions to implement control of the stated functions.

The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF THE DRAWINGS

FIGS. 1 and 2 are a cross-sectional views of an example synchrocyclotron for use in a particle therapy system.

FIG. 3 is a side view of an example scanning system.

FIG. 4 is a perspective view of components of an example scanning system, excluding scattering material for spot size variation.

FIG. 5 is a front view of an example magnet for use in a scanning system of the type shown in FIGS. 3 and 4.

FIG. 6 is a perspective view of an example magnet for use in a scanning system of the type shown in FIGS. 3 and 4.

FIG. 7 is a perspective view of an example energy degrader (range modulator) for use in a scanning system of the type shown in FIGS. 3 and 4.

FIG. 8 is a perspective view of a process for moving a plate of an energy degrader in the path of a particle beam

FIG. 9 is a side view of an example particle beam and collimator.

FIG. 10 is a top view show an example cross-section of an irradiation target, an example collimator that is movable along the edge of the cross-section, and an example beam scanning path along an interior of the irradiation target.

FIG. 11 is a top view of an example collimator.

FIG. 12 is a top view of components of an example collimator.

FIG. 13 is a top view showing the components of FIG. 12 combined to form an example collimator.

FIG. 14 is a top view show an example cross-section of an irradiation target, and an example multi-leaf collimator that is movable along the edge of the cross-section during particle beam scanning.

FIG. 15 is a top view show an example cross-section of an irradiation target, and an example straight-edge collimator that is movable and rotatable along the edge of the cross-section during particle beam scanning.

FIG. 16 is a top view show an example cross-section of an irradiation target, an example multi-part collimator that is movable along the edges of the cross-section during particle beam scanning, and an example beam scanning paths along an interior of the irradiation target.

FIG. 17 is a top view of an example curved collimator.

FIG. 18 is a view show an example cross-section of an irradiation target, and an example of how intensity-modulated proton therapy is performed on the irradiation target.

FIG. 19 is a perspective view of an example irradiation field of a particle beam scanning system.

FIG. 20 is a perspective view of multiple pieces of an example energy degrader in the beam path to an irradiation target.

FIG. 21 is a perspective view illustrating movement of pieces of an energy degrader to track scanning of a particle beam.

FIG. 22 is a perspective view illustrating situations where movement of pieces of an energy degrader is required, and is not required, to track scanning of a particle beam.

FIG. 23 is a perspective view of an example therapy system.

FIG. 24 is an exploded perspective view of components of an example synchrocyclotron for use in the particle therapy system.

FIG. 25 is a cross-sectional view of the example synchrocyclotron.

FIG. 26 is a perspective view of the example synchrocyclotron.

FIG. 27 is a cross-sectional view of an example ion source for use in the synchrocyclotron.

FIG. 28 is a perspective view of an example dee plate and an example dummy dee for use in the synchrocyclotron.

FIG. 29 shows a patient positioned within an example inner gantry of the example particle therapy system in a treatment room.

FIG. 30 is a conceptual view of an example particle therapy system that may use a variable-energy particle accelerator.

FIG. 31 is an example graph showing energy and current for variations in magnetic field and distance in a particle accelerator.

FIG. 32 is a side view of an example structure for sweeping voltage on a dee plate over a frequency range for each energy level of a particle beam, and for varying the frequency range when the particle beam energy is varied.

FIG. 33 is a perspective, exploded view of an example magnet system that may be used in a variable-energy particle accelerator.

Like reference symbols in the various drawings indicate like elements.

DETAILED DESCRIPTION

Described herein is an example of a particle accelerator for use in a system, such as a proton or ion therapy system. The example particle therapy system includes a particle accelerator—in this example, a synchrocyclotron—mounted on a gantry. The gantry enables the accelerator to be rotated around a patient position, as explained in more detail below. In some implementations, the gantry is steel and has two legs mounted for rotation on two respective bearings that lie on opposite sides of a patient. The particle accelerator is supported by a steel truss that is long enough to span a treatment area in which the patient lies and that is attached at both ends to the rotating legs of the gantry. As a result of rotation of the gantry around the patient, the particle accelerator also rotates.

In an example implementation, the particle accelerator (e.g., the synchrocyclotron) includes a cryostat that holds one or more superconducting coils, each for conducting a current that generates a magnetic field (B). In this example, the cryostat uses liquid helium (He) to maintain each coil at superconducting temperatures, e.g., 4° Kelvin (K). Magnetic yokes or smaller magnetic pole pieces are located inside the cryostat, and define a cavity in which particles are accelerated.

In this example implementation, the particle accelerator includes a particle source (e.g., a Penning Ion Gauge—PIG source) to provide a plasma column to the cavity. Hydrogen gas is ionized to produce the plasma column. A voltage source provides a radio frequency (RF) voltage to the cavity to accelerate pulses of particles from the plasma column.

As noted, in an example, the particle accelerator is a synchrocyclotron. Accordingly, the RF voltage is swept across a range of frequencies to account for relativistic effects on the particles (e.g., increasing particle mass) when accelerating particles from the plasma column. The magnetic field produced by running current through a superconducting coil causes particles accelerated from the plasma column to accelerate orbitally within the cavity. In other implementations, a particle accelerator other than a synchrocyclotron may be used. For example, a cyclotron, a synchrotron, a linear accelerator, and so forth may be substituted for the synchrocyclotron described herein.

In the synchrocyclotron, a magnetic field regenerator (“regenerator”) is positioned near the outside of the cavity (e.g., at an interior edge thereof) to adjust the existing magnetic field inside the cavity to thereby change locations (e.g., the pitch and angle) of successive orbits of the particles accelerated from the plasma column so that, eventually, the particles output to an extraction channel that passes through the cryostat. The regenerator may increase the magnetic field at a point in the cavity (e.g., it may produce a magnetic field “bump” at an area of the cavity), thereby causing each successive orbit of particles at that point to precess outwardly toward the entry point of the extraction channel until it reaches the extraction channel. The extraction channel receives particles accelerated from the plasma column and outputs the received particles from the cavity as a particle beam.

The superconducting (“main”) coils can produce relatively high magnetic fields. The magnetic field generated by a main coil may be within a range of 4 T to 20 T or more. For example, a main coil may be used to generate magnetic fields at, or that exceed, one or more of the following magnitudes: 4.0 T, 4.1 T, 4.2 T, 4.3 T, 4.4 T, 4.5 T, 4.6 T, 4.7 T, 4.8 T, 4.9 T, 5.0 T, 5.1 T, 5.2 T, 5.3 T, 5.4 T, 5.5 T, 5.6 T, 5.7 T, 5.8 T, 5.9 T, 6.0 T, 6.1 T, 6.2 T, 6.3 T, 6.4 T, 6.5 T, 6.6 T, 6.7 T, 6.8 T, 6.9 T, 7.0 T, 7.1 T, 7.2 T, 7.3 T, 7.4 T, 7.5 T, 7.6 T, 7.7 T, 7.8 T, 7.9 T, 8.0 T, 8.1 T, 8.2 T, 8.3 T, 8.4 T, 8.5 T, 8.6 T, 8.7 T, 8.8 T, 8.9 T, 9.0 T, 9.1 T, 9.2 T, 9.3 T, 9.4 T, 9.5 T, 9.6 T, 9.7 T, 9.8 T, 9.9 T, 10.0 T, 10.1 T, 10.2 T, 10.3 T, 10.4 T, 10.5 T, 10.6 T, 10.7 T, 10.8 T, 10.9 T, 11.0 T, 11.1 T, 11.2 T, 11.3 T, 11.4 T, 11.5 T, 11.6 T, 11.7 T, 11.8 T, 11.9 T, 12.0 T, 12.1 T, 12.2 T, 12.3 T, 12.4 T, 12.5 T, 12.6 T, 12.7 T, 12.8 T, 12.9 T, 13.0 T, 13.1 T, 13.2 T, 13.3 T, 13.4 T, 13.5 T, 13.6 T, 13.7 T, 13.8 T, 13.9 T, 14.0 T, 14.1 T, 14.2 T, 14.3 T, 14.4 T, 14.5 T, 14.6 T, 14.7 T, 14.8 T, 14.9 T, 15.0 T, 15.1 T, 15.2 T, 15.3 T, 15.4 T, 15.5 T, 15.6 T, 15.7 T, 15.8 T, 15.9 T, 16.0 T, 16.1 T, 16.2 T, 16.3 T, 16.4 T, 16.5 T, 16.6 T, 16.7 T, 16.8 T, 16.9 T, 17.0 T, 17.1 T, 17.2 T, 17.3 T, 17.4 T, 17.5 T, 17.6 T, 17.7 T, 17.8 T, 17.9 T, 18.0 T, 18.1 T, 18.2 T, 18.3 T, 18.4 T, 18.5 T, 18.6 T, 18.7 T, 18.8 T, 18.9 T, 19.0 T, 19.1 T, 19.2 T, 19.3 T, 19.4 T, 19.5 T, 19.6 T, 19.7 T, 19.8 T, 19.9 T, 20.0 T, 20.1 T, 20.2 T, 20.3 T, 20.4 T, 20.5 T, 20.6 T, 20.7 T, 20.8 T, 20.9 T, or more. Furthermore, a main coil may be used to generate magnetic fields that are within the range of 4 T to 20 T (or more, or less) that are not specifically listed above.

In some implementations, such as the implementation shown in FIGS. 1 and 2, large ferromagnetic magnetic yokes act as a return for stray magnetic field produced by the superconducting coils. For example, in some implementations, the superconducting magnet can generate a relatively high magnetic field of, e.g., 4 T or more, resulting in considerable stray magnetic fields. In some systems, such as that shown in FIGS. 1 and 2, the relatively large ferromagnetic return yoke 100 are used as a return for the magnetic field generated by superconducting coils. A magnetic shield surrounds the yoke. The return yoke and the shield together dissipated stray magnetic field, thereby reducing the possibility that stray magnetic fields will adversely affect the operation of the accelerator.

In some implementations, the return yoke and shield may be replaced by, or augmented by, an active return system. An example active return system includes one or more active return coils that conduct current in a direction opposite to current through the main superconducting coils. In some example implementations, there is an active return coil for each superconducting coil, e.g., two active return coils—one for each superconducting coil (referred to as a “main” coil). Each active return coil may also be a superconducting coil that surrounds the outside of a corresponding main superconducting coil.

Current passes through the active return coils in a direction that is opposite to the direction of current passing through the main coils. The current passing through the active return coils thus generates a magnetic field that is opposite in polarity to the magnetic field generated by the main coils. As a result, the magnetic field generated by an active return coil is able to dissipate at least some of the relatively strong stray magnetic field resulting from the corresponding main coil. In some implementations, each active return may be used to generate a magnetic field of between 2.5 T and 12 T or more. An example of an active return system that may be used is described in U.S. patent application Ser. No. 13/907,601, filed on May 31, 2013, the contents of which are incorporated herein by reference.

Referring to FIG. 3, at the output of extraction channel 102 of particle accelerator 105 (which may have the configuration shown in FIGS. 1 and 2), is an example scanning system 106 that may be used to scan the particle beam across at least part of an irradiation target. FIG. 4 shows examples of components of the scanning system. These include, but are not limited to, a scanning magnet 108, an ion chamber 109, and an energy degrader 110. Other components that may be incorporated into the scanning system are not shown in FIG. 4, including, e.g., one or more scatterers for changing beam spot size.

In an example operation, scanning magnet 108 is controllable in two dimensions (e.g., Cartesian XY dimensions) to direct the particle beam across a part (e.g., a cross-section) of an irradiation target. Ion chamber 109 detects the dosage of the beam and feeds-back that information to a control system to adjust beam movement. Energy degrader 110 is controllable to move material into, and out of, the path of the particle beam to change the energy of the particle beam and therefore the depth to which the particle beam will penetrate the irradiation target.

FIGS. 5 and 6 shows views of an example scanning magnet 108. Scanning magnet 108 includes two coils 111, which control particle beam movement in the X direction, and two coils 112, which control particle beam movement in the Y direction. Control is achieved, in some implementations, by varying current through one or both sets of coils to thereby vary the magnetic field(s) produced thereby. By varying the magnetic field(s) appropriately, the particle beam can be moved in the X and/or Y direction across the irradiation target. In some implementations, the scanning magnet is not movable physically relative to the particle accelerator. In other implementations, the scanning magnet may be movable relative to the accelerator (e.g., in addition to the movement provided by the gantry). In some implementations, the scanning magnets may be controllable to move the particle beam continuously. In other implementations, the scanning magnets are controllable at intervals or specific times. In some implementations, there may be different scanning magnets to control movement of the beam in the X and/or Y directions. In some implementations, there may be different scanning magnets to control partial movement of the beam in either the X and/or Y direction.

In some implementations, ion chamber 109 detects dosage applied by the particle beam by detecting the numbers of ion pairs created within a gas caused by incident radiation. The numbers of ion pairs correspond to the dosage provided by the particle beam. That information is fed-back to a computer system that controls operation of the particle therapy system. The computer system (not shown), which may include memory and one or more processing devices, determines if the dosage detected by ion chamber is the intended dose. If the dosage is not as intended, the computer system may control the accelerator to interrupt production and/or output of the particle beam, and/or control the scanning magnet to prevent output of the particle beam to the irradiation target. For example, to prevent or modify output of the particle beam, the computer system may turn the ion source off/on, change the frequency of the RF sweep, activate one or more mechanisms (such as a fast kicker magnet (not shown)) to divert the beam to an absorber material and thereby prevent the beam output, and so forth.

FIG. 7 shows a range modulator 115, which is an example implementation of energy degrader 110. In some implementations, such as that shown in FIG. 7, range modulator includes a series of plates 116. The plates may be made of one or more of the following example materials: carbon, beryllium or other material of low atomic number. Other materials, however, may be used in place of, or in addition to, these example materials.

One or more of the plates is movable into, or out of, the beam path to thereby affect the energy of the particle beam and, thus, the depth of penetration of the particle beam within the irradiation target. For example, the more plates that are moved into the path of the particle beam, the more energy that will be absorbed by the plates, and the less energy the particle beam will have. Conversely, the fewer plates that are moved into the path of the particle beam, the less energy that will be absorbed by the plates, and the more energy the particle beam will have. Higher energy particle beams penetrate deeper into the irradiation target than do lower energy particle beams. In this context, “higher” and “lower” are meant as relative terms, and do not have any specific numeric connotations.

Plates are moved physically into, and out of, the path of the particle beam. For example, as shown in FIG. 8, a plate 116a moves along the direction of arrow 117 between positions in the path of the particle beam and outside the path of the particle beam. The plates are computer-controlled. Generally, the number of plates that are moved into the path of the particle beam corresponds to the depth at which scanning of an irradiation target is to take place. For example, the irradiation target can be divided into cross-sections, each of which corresponds to an irradiation depth. One or more plates of the range modulator can be moved into, or out of, the beam path to the irradiation target in order to achieve the appropriate energy to irradiate each of these cross-sections of the irradiation target. Traditionally, the range modulator was stationary relative to the particle beam during scanning of a part of (e.g., cross-section of) an irradiation target, except for its plates moving in and out of the path of the particle beam.

In some implementations, the range modulator of FIGS. 7 and 8 may be replaced with a range modulator that, at least some of the time, tracks movement of the particle beam. This type of energy degrader is described in more detail below.

In some implementations, the particle accelerator may be a variable-energy particle accelerator, such as the example particle accelerator described in U.S. patent application Ser. No. 13/916,401, filed on Jun. 12, 2013, the contents of which are incorporated herein by reference. In example systems where a variable-energy particle accelerator is used, there may be less need for an energy degrader of the type described herein, as the energy level of the particle beam may be controlled by the particle accelerator. For example, in some systems that employ a variable-energy particle accelerator, an energy degrader may not be needed. In some systems that employ a variable-energy particle accelerator, an energy degrader may still be used to change beam energy levels.

In some implementations, a treatment plan is established prior to treating the irradiation target. The treatment plan may specify how scanning is to be performed for a particular irradiation target. In some implementations, the treatment plan specifies the following information: a type of scanning (e.g., spot scanning or raster scanning); scan locations (e.g., locations of spots to be scanned); magnet current per scan location; dosage-per-spot, spot size; locations (e.g., depths) of irradiation target cross-sections; particle beam energy per cross-section; plates or other types of pieces to move into the beam path for each particle beam energy; and so forth. Generally, spot scanning involves applying irradiation at discrete spots on an irradiation target and raster scanning involves moving a radiation spot across the radiation target. The concept of spot size therefore applies for both raster and spot scanning.

In some implementations, the overall treatment plan of an irradiation target includes different treatment plans for different cross-sections of the irradiation target. The treatment plans for different cross-sections may contain the same information or different information, such as that provided above.

In some implementations, the scanning system may include a collimator 120 (FIG. 3) to collimate the particle bean, which may include an aperture that is placeable relative to the irradiation target to limit the extent of the particle beam and thereby alter the shape of the spot applied to the irradiation target. For example, the collimator may be placed in the beam path down-beam of the energy degrader and before the particle beam hits the irradiation target. The collimator may contain an area (e.g., a hole or a transmissive material) through which the particle beam passes and another material (e.g., brass) around the hole that inhibits or prevents passage of the particle beam.

In some implementations, the collimator may include a structure defining an edge. The structure may include a material, such as brass, that inhibits transmission of the particle beam. The structure may be controllable to move in two dimensions relative to the irradiation target so that at least part of the structure is between at least part of the particle beam and the irradiation target. For example, the structure may be movable in the X and Y directions of a plane that intersects the particle beam and that is parallel, or substantially parallel to, a cross-section of the irradiation target that is being treated. Use of a collimator in this manner may be beneficial in that it can be used to customize the cross-sectional shape of the particle beam that reaches the patient, thereby limiting the amount of particle beam that extends beyond the radiation target. For example, as shown in FIG. 9, a structure 220 in a collimator prevents portion 221 of particle beam 222 from reaching a target 224, thereby limiting the beam to the irradiation target and reducing exposure of healthy tissue 225 to radiation. By placing a structure with an edge between part of the particle beam and the patient, the example collimator also provides a defined, or sharp, edge to the particle beam portion that reaches the patient, thereby promoting more precise dose applications.

Positioning and movement of the collimator may be controlled by a control computer system that controls other features of the particle therapy system described herein. For example, the collimator may be controlled in accordance with the treatment plan to track (e.g., follow) motion of the particle beam across at least part of the irradiation target. In some implementations, the collimator track is controlled to track all motion of the particle beam relative to the irradiation target. For example, in some implementations, the collimator may be controlled to track motion of the particle beam throughout the entirety of the irradiation target, e.g., both at edges of the irradiation target and at interiors of the irradiation target. In some implementations, the collimator is controlled to track only some motion of the particle beam relative to the irradiation target. For example, the collimator may be controlled to track movement of the particle beam only along the edges of the irradiation target relative to when the particle beam reaches those edges.

Referring to FIG. 10, for instance, a particle beam may follow a path in an irradiation target 229 shown by arrowed lines 230. Collimator 231 may not track motion of the particle beam on the interior 233 of irradiation target 229. But, collimator 231 may track motion of the particle beam along only the edges of the irradiation target (e.g., roughly along arrow 232). For example, each time the particle beam reaches an edge 234 of the irradiation target, the collimator may move, or may have previously moved, to intercept the particle beam at the edge, and thereby limit exposure of surrounding tissue 235 to the beam. When, and by how much, the collimator moves may depend on the size of the particle beam cross-section (spot) and the speed at which the particle beam scans. In this example, there is no need to limit exposure to the particle beam at the interior of the irradiation target; hence, the collimator need not track the beam at the interior.

The movement of a collimator may be controlled in various ways. For example, the current through magnet 108 may correspond to the deflection of the particle beam by the magnet and, thus, the location of the particle beam spot on the irradiation target. So, for example, knowing the current through the magnet and the location of the irradiation target relative to the magnet, a computer system controlling operation of the scanning system can determine the projected location of the irradiation spot. And, knowing the location of the radiation spot, the computer system can control the scanning system, in particular the collimator, to track movement of the irradiation spot along all or part of its motion, as described herein. In some implementations, the computer system can control the scanning system, in particular the collimator, so that the collimator arrives at a location before the particle beam spot arrives at that location, as described in more detail below.

Use of a collimator, such as is described above, can have advantages. For example, in some cases, goals of particle beam scanning may include achieving accuracy at the edges of an irradiation target and uniformity of dosage or coverage in the interior of the irradiation target. The use of a collimator can help to further these goals by enabling use of a relatively large particle beam spot for scanning. In this context, a spot size may be considered “large” if it has an area that is within a specified percentage of the area of the irradiation target. This percentage might typically be 2.5%, but values between, e.g., 0.25% and 25%, could also be used. Scanning using a relative large spot size increases the fractional areal coverage of the irradiation target for each beam pulse. Typically, the larger the size of this spot, the less adversely affected the target uniformity will be due to target (patient) motion. At the edges, however, the collimator reduces the chances that radiation from the large spot will impact tissue (e.g., healthy tissue) outside the radiation target by reducing the lateral penumbra. Traditionally, smaller spot sizes were preferred, since they enabled more precise dosage at the edges as compared to a larger spot size. But, compared to a collimated edge, those smaller spot sizes could result in slower treatment times for a given treatment volume, and reduced edge conformality due to reduced edge resolution and increased penumbra.

The collimator may have any number of different shapes or configurations and may, or may not, include one or more moving parts. In an example implementation, the collimator is comprised of brass and/or other radiation-blocking material, and has a thickness on the order of several centimeters. However, different collimators may have different compositions and thicknesses.

In example implementation, the collimator is a structure that has one or more defined edges. For example, the collimator may be a structure containing an aperture, or hole. FIG. 11 shows an example of this type of collimator 239. Collimator 239 may have any appropriate shape, with an aperture therein. The edges of the aperture may be used to limit application of the particle beam, as shown in FIG. 9 for example, thereby allowing application of beam 222 to the irradiation target 224 but not to tissue covered by collimator 220 that is otherwise in the beam path. As explained above, the aperture may track (e.g., follow) the particle beam throughout all or part of the scanning operation. For example, the aperture may track movement of the particle beam only at edges of the irradiation target or throughout the entire motion of the beam. That is, the collimator itself may move along the edge of the irradiation target to track movement of the particle beam (e.g., so that the location of the collimator coincides with the particle beam when the particle beam reaches the irradiation target edge).

In some implementations, the collimator may include two or more apertures that are controlled to overlap and thereby achieve a specific size. For example, as shown in FIG. 12, apertures 244 and 245 are part of respective structures 246 and 247. The structures move relative to each other, as shown in FIG. 13, thereby causing the apertures 244, 245 to overlap and change the size and, in some cases, the shape of resulting hole 248 through which the particle beam is allowed to pass. Shapes other than those shown may be used.

In some implementations, the collimator may track the movement of the particle beam during the particle beam's motion in the interior of the irradiation target. For example, in some implementations, the aperture may have a diameter that is less than the diameter of the particle beam spot. In some systems, it may be desirable to use a spot having a specific diameter at all irradiation positions (including those on the interior of the irradiation target). In these systems, therefore, the aperture may track all movement of the particle beam spot so as to achieve the appropriate particle beam spot diameter for treatment. In some implementations, the aperture of the collimator may vary in size and/or shape. For example, the collimator may have one or more moving parts to vary the size and shape of the aperture (e.g., to reduce its diameter, surface area, or the like).

In example implementations, the collimator may be a structure having one or more straight edges. For example, the collimator may include square, rectangular, or substantially linear structures, each having at least one edge that can be placed in the path of the particle beam.

In an example implementation that employs straight edges, the collimator may have a multi-leaf structure, as in FIG. 14. In FIG. 14, collimator 250 tracks movement along the edge of irradiation target 251. Fingers 252 move up or down, or towards or away from the irradiation target, in order to achieve an edge shape 253 that substantially matches the edge shape of the irradiation target and that blocks the particle beam from reaching healthy tissue (or tissue that should not be irradiated). For example, each finger can be moved up or down, or extended and retracted, or a combination of such movements to substantially match the edge shape. Collimator 250 itself may move along the edge of the irradiation target 251 (e.g., roughly in the direction of arrow 255) to track movement of the particle beam (e.g., so that the location of the collimator coincides with the particle beam when the particle beam reaches the irradiation target edge). In some implementations, collimator 250 may, or may not, move into the interior of the irradiation target during scanning operations.

Traditional multi-leaf collimators are stationary relative to the irradiation target and include two sets of fingers that face each other and that move relative to each other to attain the appropriate collimation. There may be tens, hundreds, or even thousands of fingers used in such collimators, and their size may be as large as the irradiation field itself. In some implementations, the irradiation field may be defined by a plane, which is at an angle to the beam, and which defines the maximum extent that a particle beam can move in the X and Y directions relative to the irradiation target. However, in the example implementations described herein, the collimator moves relative to (e.g., tracks or moves along the edge of) the irradiation target, and need only provide a defined edge at the point of the irradiation target where and when the spot hits that point. Accordingly, the multi-leaf collimator (in addition to being only a single set of fingers) may be made considerably smaller than its conventional counterparts. For example, the multi-leaf collimators described herein may include ten or less (e.g., two, three, four, five, six, seven, eight or nine) fingers (or more, if desired).

In an example implementation that employs straight edges, as shown in FIG. 15, collimator 260 may be rectangular in shape, and move along the edge of irradiation target 261. Collimator 260 may move along the edge of the irradiation target to track movement of the particle beam (e.g., so that the location of the collimator coincides with the particle beam when the particle beam reaches the irradiation target edge). During motion along the edge of the irradiation target, collimator 260 may also rotate in two or three dimensions, e.g., in the XY dimensions of arrow 262 and also in the Z dimension. This rotation allows at least a portion of an edge of collimator 260 to match the edge of the irradiation target relative closely. Thus, collimator 260 may be appropriately positioned so that, when the particle beam reaches the edge of the irradiation target, the collimator blocks the tissue extending beyond the edge. As a result, the collimator provides a defined radiation edge relative to the irradiation target and protects adjacent tissue from the particle beam. Movement of the collimator to the appropriate point on the edge of the irradiation target may coincide with movement of the particle beam or precede movement of the particle beam.

In some implementations, the collimator may include a single structure with one or more straight edges, as shown in FIG. 15. In other implementations, the collimator may include two or more such structures at different (e.g., opposing) edges of the irradiation target, as shown in FIG. 16. There, the collimator includes two structures 265, 266. Each of structures 265 and 266 tracks movement of the particle beam. That is, structure 265 moves so that the location of structure 265 coincides with the particle beam when the particle beam reaches edge 269 of the irradiation target, and structure 266 moves so that the location of structure 266 coincides with the particle beam when the particle beam reaches edge 270 of the irradiation target. Movement of each structure to the appropriate point on the edge of the irradiation target may coincide with movement of the particle beam or precede movement of the particle beam. For example, structure 266 can be moved as the spot is scanned in the direction of arrow 271, so that structure 266 is in the appropriate location when the spot returns to edge 270; and structure 265 can be moved as the spot is scanned in the direction of arrow 272, so that structure 265 is in the appropriate location when the spot returns to edge 269. Structures 265 and 266 may move at the same times, at different times, or there may be overlap in the times of their movement. An arrangement of this type enables the particle beam to be moved from edge to edge of the irradiation target, with the collimator enabling a defined irradiation field at both edges. And, since the collimator is comprised of multiple structures, scanning need not be significantly slowed waiting for movement of the collimator. In some implementations, the collimator may include more than two (e.g., three, four, etc.) structures of the type and operation shown in FIG. 16. In some implementations, the two or more structures that make up the collimator may be structures that include holes, such as that shown in FIG. 11. The operation of the two-structure collimator is otherwise as described above.

In some implementations, the collimator need not have a straight edge, but rather its edge(s) may be curved, as shown in FIG. 17. A collimator may include only one such structure or two or more such structures. In some implementations, the two or more structures that make up the collimator may be structures that include curved edges. For example, two structures of the type shown in FIG. 17 may replace the two structures of FIG. 16. The operation of the two-structure collimator is otherwise as described above.

In this regard, in example implementations, the collimator may be a structure having a curved shape having a radius of curvature that varies continuously along its edge, thereby enabling at least part of the edge to closely match the edge of an irradiation target, either directly or by rotating the edge at an appropriate angle. In this example, collimator 275 is a French curve that can be moved to track the beam, either partly or fully, and that can be rotated in two or three dimensions relative to the irradiation target to control application of the particle beam. Any appropriately curved structure may be include in the collimator. As was the case above, collimator 275 may only move along the edge of the irradiation target to track movement of the particle beam (e.g., so that the location of the collimator coincides with the particle beam when the particle beam reaches the irradiation target edge). As was the case above, the collimator may, or may not, track movement of the particle beam at the interior of the irradiation target.

A collimator may include only one structure of the type shown in FIG. 17 or the collimator may include two or more such structures. For example, two structures of the type shown in FIG. 17 may replace the two structures of FIG. 16. The operation of the two-structure collimator is otherwise as described above.

In some implementations, the treatment planning system may be designed so that the scanning speed (e.g., the rate at which the particle beam spot traverses the irradiation target) is different in the interior of the irradiation target than at the edges of the irradiation target. For example, the scanning speed may be faster at the interior of the irradiation target than at the edges of the irradiation target. This arrangement allows for higher precision scanning at the edges of the irradiation target than at the interior of the irradiation target. This type of variable-speed scanning may be implemented using any appropriate type of collimator, including those described herein, or this type of variable-speed scanning may be implemented without using any collimator. In either case, the slower speed at the irradiation target edge may enable more precise scanning there, which may reduce the chances that the particle beam will impact outside the irradiation target.

In some implementations, the collimator described herein may be used in an intensity-modulated proton therapy process. In such as process, the proton beam is projected at the radiation target from different directions so that a percentage of the overall dose is delivered from each direction. As a result, the amount of dose delivered to volumes outside of the irradiation target can be reduced. For example, FIG. 18 shows a particle beam 280 applied to the irradiation target 281 from three different angles. In this example, ⅓ of the total dose may be applied from one angle; ⅓ of the total dose may be applied from another angle; and ⅓ of the total dose may be applied from yet another angle. That is, the particle beam may be scanned at angle 282 relative to horizontal 285 to apply ⅓ of the dose; the particle beam may be scanned at angle 283 to apply ⅓ of the dose; and the particle beam may be scanned at angle 284 to apply ⅓ of the dose. As a result, the amount of radiation applied to surrounding tissue 287 is spread out at the appropriate angles, thereby reducing the chances that surrounding tissue will be exposed to harmful amounts of radiation. Any appropriate number of angles and appropriate dosage per angle may be employed.

Irradiation targets, such as tumors, typically are not symmetric. Accordingly, different beam collimation is typically required for the different angles of application of the particle beam. The example collimators described herein can be positioned at the appropriate locations along the irradiation target's edge (as described above) to provide appropriate collimation given the angle of irradiation. In some implementations, the example collimators can track motion of the particle beam, either only at the irradiation target's edge or throughout some portion (e.g., all) of the motion of the particle beam at all angles of application.

In some implementations, the example collimators described herein prevent transmission of the particle beam to surrounding tissue by blocking the particle beam. In some implementations, the example collimators may enable partial transmission of the particle beam, thereby resulting in application of lower-levels of radiation to the surrounding tissue than to the irradiation target. Any of the example collimators described herein may be produced in this manner.

The example collimators described herein may be mounted to one or more computer-controlled robotic arms or other structures to control their movement relative to the irradiation target. A collimator may be mounted to the scanning system itself as well. Typically, the collimator is mounted closest to the patent relative to other elements of the particle beam scanning system (e.g., down-beam of other elements of the scanning system). In implementations where the collimator includes more than one piece (e.g., FIG. 16), there may be more than one robotic arm or other structure to independently control the different pieces of the collimator in accordance with the treatment plan. In some implementations, a single robotic arm may be configured to control the different pieces of the collimator independently or to control a combination of pre-assembled pieces.

In some implementations, the energy degrader may also configured to track motion of the particle beam. In this regard, in some implementations, such as the example implementation described with respect to FIGS. 7 and 8, the energy degrader may include multiple plates that are movable into the path of the particle beam to control the amount of energy in the beam and thereby control the depth to which the particle beam penetrates the irradiation target. In this way, the energy degrader is used to perform depth (the direction of the particle beam or Z-direction) scanning in the irradiation target. Typically, each plate absorbs an amount of energy in the particle beam. Accordingly, the more plates that are placed in front of the particle beam, the less energy the beam has, and the less deep the beam will penetrate into the irradiation target. Conversely, the fewer plates that are placed in front of the particle beam, the more energy the beam has (since less energy is absorbed by the plate(s)), and the more deep the beam will penetrate into the irradiation target. In some implementations, each plate has about the same thickness, and therefore absorbs about the same amount of beam energy. In other implementations, different plates may have different thicknesses, with the thickness of a plate corresponding to the amount of energy that the plate absorbs.

In some implementations, the plates each have a surface area that is about the size of the irradiation field. In this context, the irradiation field may be defined by a plane that defines the maximum extent that a particle beam can move in the X and Y directions relative to the irradiation target. For example, FIG. 19 shows an irradiation field 290 in front of an irradiation target 291. Due to physical system limitations, a particle beam is movable across, but not beyond, the plane defining the irradiation field. Accordingly, to ensure that the energy degrader can be applied to any location within the irradiation field, in some implementations the plates in the energy degrader each have a surface are that is at least as big as, and in some cases that exceeds, the size of the irradiation field. This configuration, however, can result in plates that are large (e.g., possibly a square meter or square meters), and thus that can be heavy and relative slow to move. Slow movement of the plates can result in slower treatment.

In some implementations, the energy degraders may be smaller than the size of the irradiation field, and track at least part of the motion of the particle beam. As a result, the energy degrader may be lighter, which can reduce the amount of time that it takes to position the energy degrader plates in the path of the particle beam and thus reduce the treatment time. The energy degrader may track the particle beam in two directions (e.g., XY) or in three directions (e.g., XYZ). That is, the energy degrader may move in a plane perpendicular to the particle beam, or the energy degrader may move in a plane perpendicular to the particle beam and along a longitudinal direction of the particle beam. In this regard, any of the collimators described herein may also move in a plane perpendicular to the particle beam, or any of the collimators described herein may also move in a plane perpendicular to the particle beam and along a longitudinal direction of the particle beam. Movement of the collimator(s) and energy degrader(s) may be independent or coordinated.

For example, an energy degrader may be comprised of multiple pieces, which may be plates or other structures constructed to absorb particle beam energy during treatment. Each piece may have the same area (XY) and thickness (Z) or different pieces may have different areas and thicknesses. Referring to FIG. 20, two or more pieces 294 having the same or different thicknesses may be placed in front an irradiation target 295 in the particle beam 293 path to achieve a particular amount of energy absorption. Alternatively, a single piece having a specified thickness may be placed in front of the beam to achieve a particular amount of energy absorption. For example, if a particular energy absorption is needed, the control computer may select a piece with the appropriate thickness to achieve that absorption.

In examples where two or more pieces are placed in front of the beam, those pieces may be assembled prior to placement or assembled dynamically during placement. For example, the control computer may select two pieces, arrange them, and then move the combination of the two pieces into the beam path. Alternatively, the control computer may select two pieces and then move the combination of the two pieces into the beam path simultaneously but not in combination (e.g., each may be moved with a separate robotic arm).

The energy degrader, or pieces thereof, may track movement of the particle beam across at least part of the irradiation field so as to achieve appropriate energy absorption, and thus beam depth penetration, at various points on the irradiation target. The treatment plan may dictate where the energy degrader needs to be at any particular time during treatment, and feedback from the ionization chamber may be used for positioning and position correction, if necessary. In some implementations, the precision with which the energy degrader needs to track the particle beam is based on the size of the degrader and the spot size of the particle beam at the point where the particle beam intersects the energy degrader.

More specifically, in some examples, the smaller that the surface area of the energy degrader is, the more closely movement of the energy degrader should track movement of the particle beam. Conversely, in other examples, the larger that the surface area of the energy degrader is, the less closely movement of the energy degrader needs to track movement of the particle beam. For example referring to FIG. 21, if the energy degrader 299 has a surface area that is close to a surface area of spot 300 at the point where the particle beam intersects the energy degrader, the energy degrader should track motion of the particle beam rather closely in order to ensure that the energy degrader is in front of the particle beam relative to irradiation target 301 at appropriate times during treatment. For example, motion of particle beam 304 from location 302 to location 303 would also require energy degrader 299 to move in the direction of arrow 305 to remain in the beam path, since the areas of the spot and the degrader are relatively close in size. As indicated, motion of the particle beam may be dictated by the treatment plan and detected through use of the ionization chamber and feedback to the control computer. This information may also be used to control movement of the energy degrader.

In some implementations, the moveable energy degrader may be considerably larger than the particle beam spot. In these cases, the energy degrader need not track motion of the particle beam as closely in order to ensure that the energy degrader is in front of the particle beam at appropriate times during treatment. In fact, depending upon the size of the energy degrader, the energy degrader need not move at all in some cases where the particle beam moves. That is, for some motion of the particle beam, the energy degrader may remain stationary, but for other motion of the particle beam, the energy degrader also moves to intercept the particle beam. For example, FIG. 22 shows a case where the energy degrader 310 is considerably larger than particle beam spot 311 at the point where the particle beam intersects the energy degrader. As the particle beam spot moves from point 314a to point 314b, the energy degrader remains in the beam path even though the energy degrader has not moved. The control computer system, knowing the size of the degrader and the two spot positions, does not move the energy degrader in this case. Accordingly, in this case, the energy degrader need not track movement of the particle beam spot. However, when the spot moves to point 314c, the energy degrader (or piece(s) thereof) will move to track and intercept the beam so as to remain in the beam path. Accordingly, the size of the energy degrader relative to the beam spot is a factor in determining when, and by how much, the energy degrader is required to move during scanning.

In some implementations, the energy degrader may include multiple parts or pieces. For example, one part or piece may be used to track movement of the particle beam across part of an irradiation target (e.g., irradiation applied from the top of the irradiation target) and another part or piece may be used to track movement of the particle beam across another part of an irradiation target (e.g., irradiation applied from the bottom of the target).

The energy degrader (or pieces thereof) may have any shape, e.g., square, rectangular, circular, oval, irregular, regular, polygonal, spherical, cubical, tetrahedral, and so forth. The energy degrader (or pieces thereof) may have any appropriate size. For example, the energy degrader (or pieces thereof) may have a surface area this less than the area of the irradiation field, that is less than ¾ the area of the irradiation field, that is less than ½ the area of the irradiation field, that is less than ⅓ the area of the irradiation field, that is less than ¼ the area of the irradiation field, that is less than ⅕ the area of the irradiation field, or so forth. The energy degrader (or pieces thereof) may have a surface area that is less than twenty times the area of the particle beam spot at the irradiation field, that is less than fifteen times the area of the particle beam spot at the irradiation field, that is less than ten times the area of the particle beam spot at the irradiation field, that is less than nine times the area of the particle beam spot at the irradiation field, that is less than eight times the area of the particle beam spot at the irradiation field, that is less than seven times the area of the particle beam spot at the irradiation field, that is less than six times the area of the particle beam spot at the irradiation field, that is less than five times the area of the particle beam spot at the irradiation field, that is less than four times the area of the particle beam spot at the irradiation field, that is less than three times the area of the particle beam spot at the irradiation field, or that is less than two times the area of the particle beam spot at the irradiation field. In some implementations, the energy degrader (or pieces thereof) may have a surface area that is a multiple of the spot size, e.g., two times the spot size, three times the spot size, five times the spot size, ten times the spot size, and so forth.

In some implementations, each piece (e.g., layer of multiple layers) has a same size, shape, thickness and composition. In other implementations, different pieces may have different sizes, shapes thicknesses and compositions.

The movement of the example energy degraders described herein may be controlled in various ways. For example, the current through magnet 108 may correspond to the deflection of the particle beam by the magnet and, thus, the location of the particle beam spot on the irradiation target. So, for example, knowing the current through the magnet and the location of the irradiation target relative to the magnet, a computer system controlling operation of the scanning system can determine the projected location of the irradiation spot. And, knowing the location of the radiation spot, and the size of the energy degrader relative to the spot size, the computer system can control the energy degrader, to track (if necessary) movement of the irradiation spot along all or part of its motion, as described herein.

The example movable energy degraders described herein may be mounted to one or more computer-controlled robotic arms or other structures that also contain elements of the scanning system to control movement relative to the irradiation target. In implementations where the energy degrader includes more than one piece (e.g., multiple pieces or plates), there may be more than one robotic arm to independently control the different pieces of the energy degrader in accordance with the treatment plan. In some implementations, a single robotic arm may be configured to control the different pieces independently.

Different cross-sections of the irradiation target may be scanned according to different treatment plans. As described above, an energy degrader is used to control the scanning depth. In some implementations, the particle beam may be interrupted or redirected during configuration of the energy degrader. In other implementations, this need not be the case.

Described herein are examples of treating cross-sections of an irradiation target. These may be cross-sections that are roughly perpendicular to the direction of the particle beam. However, the concepts described herein are equally applicable to treating other portions of an irradiation target that are not cross-sections perpendicular to the direction of the particle beam. For example, an irradiation target may be segmented into spherical, cubical or other shaped volumes, and those volumes may be treated using the example processes, systems, and/or devices described herein.

The processes described herein may be used with a single particle accelerator, and any two or more of the features thereof described herein may be used with the single particle accelerator. The particle accelerator may be used in any type of medical or non-medical application. An example of a particle therapy system that may be used is provided below. Notably, the concepts described herein may be used in other systems not specifically described.

Referring to FIG. 23, an example implementation of a charged particle radiation therapy system 400 includes a beam-producing particle accelerator 402 having a weight and size small enough to permit it to be mounted on a rotating gantry 404 with its output directed straight (that is, essentially directly) from the accelerator housing toward a patient 406. Particle accelerator 402 also includes a scanning system of a type described herein (e.g., FIGS. 3 to 22).

In some implementations, the steel gantry has two legs 408, 410 mounted for rotation on two respective bearings 412, 414 that lie on opposite sides of the patient. The accelerator is supported by a steel truss 416 that is long enough to span a treatment area 418 in which the patient lies (e.g., twice as long as a tall person, to permit the person to be rotated fully within the space with any desired target area of the patient remaining in the line of the beam) and is attached stably at both ends to the rotating legs of the gantry.

In some examples, the rotation of the gantry is limited to a range 420 of less than 360 degrees, e.g., about 180 degrees, to permit a floor 422 to extend from a wall of the vault 424 that houses the therapy system into the patient treatment area. The limited rotation range of the gantry also reduces the required thickness of some of the walls (which are not directly aligned with the beam, e.g., wall 430), which provide radiation shielding of people outside the treatment area. A range of 180 degrees of gantry rotation is enough to cover all treatment approach angles, but providing a larger range of travel can be useful. For example the range of rotation may be between 180 and 330 degrees and still provide clearance for the therapy floor space. In other implementations, rotation is not limited as described above.

The horizontal rotational axis 432 of the gantry is located nominally one meter above the floor where the patient and therapist interact with the therapy system. This floor is positioned about 3 meters above the bottom floor of the therapy system shielded vault. The accelerator can swing under the raised floor for delivery of treatment beams from below the rotational axis. The patient couch moves and rotates in a substantially horizontal plane parallel to the rotational axis of the gantry. The couch can rotate through a range 434 of about 270 degrees in the horizontal plane with this configuration. This combination of gantry and patient rotational ranges and degrees of freedom allow the therapist to select virtually any approach angle for the beam. If needed, the patient can be placed on the couch in the opposite orientation and then all possible angles can be used.

In some implementations, the accelerator uses a synchrocyclotron configuration having a high magnetic field superconducting electromagnetic structure. Because the bend radius of a charged particle of a given kinetic energy is reduced in direct proportion to an increase in the magnetic field applied to it, the high magnetic field superconducting magnetic structure permits the accelerator to be made smaller and lighter. The synchrocyclotron uses a magnetic field that is uniform in rotation angle and falls off in strength with increasing radius. Such a field shape can be achieved regardless of the magnitude of the magnetic field, so in theory there is no upper limit to the magnetic field strength (and therefore the resulting particle energy at a fixed radius) that can be used in a synchrocyclotron.

The synchrocyclotron is supported on the gantry so that the beam is generated directly in line with the patient. The gantry permits rotation of the synchrocyclotron about a horizontal rotational axis that contains a point (isocenter 440) within, or near, the patient. The split truss that is parallel to the rotational axis, supports the synchrocyclotron on both sides.

Because the rotational range of the gantry is limited in some example implementations, a patient support area can be accommodated in a wide area around the isocenter. Because the floor can be extended broadly around the isocenter, a patient support table can be positioned to move relative to and to rotate about a vertical axis 442 through the isocenter so that, by a combination of gantry rotation and table motion and rotation, any angle of beam direction into any part of the patient can be achieved. In some implementations, the two gantry arms are separated by more than twice the height of a tall patient, allowing the couch with patient to rotate and translate in a horizontal plane above the raised floor.

Limiting the gantry rotation angle allows for a reduction in the thickness of at least one of the walls surrounding the treatment room. Thick walls, typically constructed of concrete, provide radiation protection to individuals outside the treatment room. A wall downstream of a stopping proton beam may be about twice as thick as a wall at the opposite end of the room to provide an equivalent level of protection. Limiting the range of gantry rotation enables the treatment room to be sited below earth grade on three sides, while allowing an occupied area adjacent to the thinnest wall reducing the cost of constructing the treatment room.

In the example implementation shown in FIG. 23, the superconducting synchrocyclotron 402 operates with a peak magnetic field in a pole gap of the synchrocyclotron of 8.8 Tesla. The synchrocyclotron produces a beam of protons having an energy of 250 MeV. In some implementations, the synchrocyclotron is a variable-energy machine, and is capable of outputting proton beams having different energies. In some implementations, the synchrocyclotron may produce a beam having a fixed energy. In some implementations the field strength could be in the range of 4 T to 20 T and the proton energy could be in the range of 150 to 300 MeV.

The radiation therapy system described in this example is used for proton radiation therapy, but the same principles and details can be applied in analogous systems for use in heavy ion (ion) treatment systems.

As shown in FIGS. 1, 2, 24, 25, and 26, an example synchrocyclotron 10 (e.g., 402 in FIG. 23) includes a magnet system 122 that contains a particle source 190, a radiofrequency drive system 191, and a beam extraction system 318. In this example, the magnetic field established by the magnet system has a shape appropriate to maintain focus of a contained proton beam using a combination of a split pair of annular superconducting coils 140, 142 and a pair of shaped ferromagnetic (e.g., low carbon steel) pole faces 144, 146.

The two superconducting magnet coils are centered on a common axis 147 and are spaced apart along the axis. The coils may be formed by of Nb₃Sn-based superconducting 0.8 mm diameter strands (that initially comprise a niobium-tin core surrounded by a copper sheath) deployed in a twisted cable-in-channel conductor geometry. After seven individual strands are cabled together, they are heated to cause a reaction that forms the final (brittle) superconducting material of the wire. After the material has been reacted, the wires are soldered into the copper channel (outer dimensions 3.18×2.54 mm and inner dimensions 2.08×2.08 mm) and covered with insulation (in this example, a woven fiberglass material). The copper channel containing the wires is then wound in a coil having a rectangular cross-section. The wound coil is then vacuum impregnated with an epoxy compound. The finished coils are mounted on an annular stainless steel reverse bobbin. Heater blankets may be placed at intervals in the layers of the windings to protect the assembly in the event of a magnet quench.

The entire coil can then be covered with copper sheets to provide thermal conductivity and mechanical stability and then contained in an additional layer of epoxy. The precompression of the coil can be provided by heating the stainless steel reverse bobbin and fitting the coils within the reverse bobbin. The reverse bobbin inner diameter is chosen so that when the entire mass is cooled to 4 K, the reverse bobbin stays in contact with the coil and provides some compression. Heating the stainless steel reverse bobbin to approximately 50 degrees C. and fitting coils at a temperature of 100 degrees Kelvin can achieve this.

The geometry of the coil is maintained by mounting the coils in a “reverse” rectangular bobbin to exert a restorative force that works against the distorting force produced when the coils are energized. As shown in FIG. 25, in some implementations, coil position is maintained relative to corresponding magnet pole pieces and the cryostat using a set of warm-to-cold support straps 402, 404, 406. Supporting the cold mass with thin straps reduces the heat leakage imparted to the cold mass by the rigid support system. The straps are arranged to withstand the varying gravitational force on the coil as the magnet rotates on board the gantry. They withstand the combined effects of gravity and the large de-centering force realized by the coil when it is perturbed from a perfectly symmetric position relative to the magnet yoke. Additionally the links act to reduce dynamic forces imparted on the coil as the gantry accelerates and decelerates when its position is changed. Each warm-to-cold support may include one S2 fiberglass link and one carbon fiber link. The carbon fiber link is supported across pins between the warm yoke and an intermediate temperature (50-70 K), and the S2 fiberglass link 408 is supported across the intermediate temperature pin and a pin attached to the cold mass. Each pin may be made of high strength stainless steel.

Referring to FIG. 1, the field strength profile as a function of radius is determined largely by choice of coil geometry and pole face shape; the pole faces 144, 146 of the permeable yoke material can be contoured to fine tune the shape of the magnetic field to ensure that the particle beam remains focused during acceleration.

The superconducting coils are maintained at temperatures near absolute zero (e.g., about 4 degrees Kelvin) by enclosing the coil assembly (the coils and the bobbin) inside an evacuated annular aluminum or stainless steel cryostatic chamber 170 (the cryostat) that provides a free space around the coil structure, except at a limited set of support points 171, 173. In an alternate version (e.g., FIG. 2) the outer wall of the cryostat may be made of low carbon steel to provide an additional return flux path for the magnetic field.

In some implementations, the temperature near absolute zero is achieved and maintained using one single-stage Gifford-McMahon cryo-cooler and three two-stage Gifford McMahon cryo-coolers. Each two stage cryo-cooler has a second stage cold end attached to a condenser that recondenses Helium vapor into liquid Helium. In some implementations, the temperature near absolute zero is achieved and maintained using a cooling channel (not shown) containing liquid helium, which is formed inside a superconducting coil support structure (e.g., the reverse bobbin), and which contains a thermal connection between the liquid helium in the channel and the corresponding superconducting coil. An example of a liquid helium cooling system of the type described above, and that may be used is described in U.S. patent application Ser. No. 13/148,000 (Begg et al.).

In some implementations, the coil assembly and cryostatic chambers are mounted within and fully enclosed by two halves 181, 183 of a pillbox-shaped magnet yoke 100. The yoke 100 provides a path for the return magnetic field flux 184 and magnetically shields the volume 186 between the pole faces 144, 146 to prevent external magnetic influences from perturbing the shape of the magnetic field within that volume. The yoke also serves to decrease the stray magnetic field in the vicinity of the accelerator. In other implementations, the coil assembly and cryostatic chambers are mounted within and fully enclosed by a non-magnetic enclosure, and the path for return magnetic field flux is implemented using an active return system, an example of which is described above.

As shown in FIGS. 1 and 27, the synchrocyclotron includes a particle source 190 of a Penning ion gauge geometry located near the geometric center 192 of the magnet structure 182. The particle source may be as described below, or the particle source may be of the type described in U.S. patent application Ser. No. 11/948,662 incorporated herein by reference.

Particle source 190 is fed from a supply 399 of hydrogen through a gas line 393 and tube 394 that delivers gaseous hydrogen. Electric cables 294 carry an electric current from a current source to stimulate electron discharge from cathodes 392, 390 that are aligned with the magnetic field 400.

In this example, the discharged electrons ionize the gas exiting through a small hole from tube 394 to create a supply of positive ions (protons) for acceleration by one semicircular (dee-shaped) radio-frequency plate that spans half of the space enclosed by the magnet structure and one dummy dee plate. In the case of an interrupted particle source (an example of which is described in U.S. patent application Ser. No. 11/948,662), all (or a substantial part, e.g., a majority) of the tube containing plasma is removed at the acceleration region.

As shown in FIG. 28, the dee plate 500 is a hollow metal structure that has two semicircular surfaces 503, 505 that enclose a space 507 in which the protons are accelerated during half of their rotation around the space enclosed by the magnet structure. A duct 509 opening into the space 507 extends through the enclosure (e.g., the yoke or pole piece(s)) to an external location from which a vacuum pump can be attached to evacuate the space 507 and the rest of the space within a vacuum chamber in which the acceleration takes place. The dummy dee 502 comprises a rectangular metal ring that is spaced near to the exposed rim of the dee plate. The dummy dee is grounded to the vacuum chamber and magnet yoke. The dee plate 500 is driven by a radio-frequency signal that is applied at the end of a radio-frequency transmission line to impart an electric field in the space 507. The radio frequency electric field is made to vary in time as the accelerated particle beam increases in distance from the geometric center. The radio frequency electric field may be controlled in the manner described in U.S. patent application Ser. No. 11/948,359, entitled “Matching A Resonant Frequency Of A Resonant Cavity To A Frequency Of An Input Voltage”, the contents of which are incorporated herein by reference.

For the beam emerging from the centrally located particle source to clear the particle source structure as it begins to spiral outward, a large voltage difference may be applied across the radio frequency plates. 20,000 Volts is applied across the radio frequency plates. In some versions from 8,000 to 20,000 Volts may be applied across the radio frequency plates. To reduce the power required to drive this large voltage, the magnet structure is arranged to reduce the capacitance between the radio frequency plates and ground. This may be done by forming holes with sufficient clearance from the radio frequency structures through the outer yoke and the cryostat housing and making sufficient space between the magnet pole faces.

The high voltage alternating potential that drives the dee plate has a frequency that is swept downward during the accelerating cycle to account for the increasing relativistic mass of the protons and the decreasing magnetic field. The dummy dee does not require a hollow semi-cylindrical structure as it is at ground potential along with the vacuum chamber walls. Other plate arrangements could be used such as more than one pair of accelerating electrodes driven with different electrical phases or multiples of the fundamental frequency. The RF structure can be tuned to keep the Q high during the required frequency sweep by using, for example, a rotating capacitor having intermeshing rotating and stationary blades. During each meshing of the blades, the capacitance increases, thus lowering the resonant frequency of the RF structure. The blades can be shaped to create a precise frequency sweep required. A drive motor for the rotating condenser can be phase locked to the RF generator for precise control. One bunch of particles may be accelerated during each meshing of the blades of the rotating condenser.

The vacuum chamber in which the acceleration occurs is a generally cylindrical container that is thinner in the center and thicker at the rim. The vacuum chamber encloses the RF plates and the particle source and is evacuated by a vacuum pump. Maintaining a high vacuum reduces the chances that accelerating ions are not lost to collisions with gas molecules and enables the RF voltage to be kept at a higher level without arcing to ground.

Protons (or other ions) traverse a generally spiral orbital path beginning at the particle source. In half of each loop of the spiral path, the protons gain energy as they pass through the RF electric field. As the protons gain energy, the radius of the central orbit of each successive loop of their spiral path is larger than the prior loop until the loop radius reaches the maximum radius of the pole face. At that location a magnetic and electric field perturbation directs protons into an area where the magnetic field rapidly decreases, and the protons depart the area of the high magnetic field and are directed through an evacuated tube, referred to herein as the extraction channel, to exit the synchrocyclotron. A magnetic regenerator may be used to change the magnetic field perturbation to direct the protons. The protons exiting will tend to disperse as they enter an area of markedly decreased magnetic field that exists in the room around the synchrocyclotron. Beam shaping elements 607, 609 in the extraction channel 138 (FIG. 25) redirect the protons so that they stay in a straight beam of limited spatial extent.

As the beam exits the extraction channel it is passed through a beam formation system 525 (FIG. 25), which may include a scanning system of the type described herein. Beam formation system 525 may be used in conjunction with an inner gantry that controls application of the beam.

Stray magnetic fields exiting from the synchrocyclotron may be limited by both a magnet yoke (which also serves as a shield) and a separate magnetic shield 514 (e.g., FIG. 1). The separate magnetic shield includes of a layer 517 of ferromagnetic material (e.g., steel or iron) that encloses the pillbox yoke, separated by a space 516. This configuration that includes a sandwich of a yoke, a space, and a shield achieves adequate shielding for a given leakage magnetic field at lower weight. As described above, in some implementations, an active return system may be used in place of, or to augment, the operation of the magnetic yoke and shield.

Referring to FIG. 23, the gantry allows the synchrocyclotron to be rotated about a horizontal rotational axis 432. The truss structure 416 has two generally parallel spans 480, 482. The synchrocyclotron is cradled between the spans about midway between the legs. The gantry is balanced for rotation about the bearings using counterweights 622, 624 mounted on ends of the legs opposite the truss.

The gantry is driven to rotate by an electric motor mounted to one or both of the gantry legs and connected to the bearing housings by drive gears. The rotational position of the gantry is derived from signals provided by shaft angle encoders incorporated into the gantry drive motors and the drive gears.

At the location at which the ion beam exits the synchrocyclotron, the beam formation system 525 acts on the ion beam to give it properties suitable for patient treatment. For example, the beam may be spread and its depth of penetration varied to provide uniform radiation across a given target volume. The beam formation system may include active scanning elements as described herein.

All of the active systems of the synchrocyclotron (the current driven superconducting coils, the RF-driven plates, the vacuum pumps for the vacuum acceleration chamber and for the superconducting coil cooling chamber, the current driven particle source, the hydrogen gas source, and the RF plate coolers, for example), may be controlled by appropriate synchrocyclotron control electronics (not shown), which may include, e.g., one or more processing devices executing instructions from memory to effect control.

As explained above, referring to system 602 of FIG. 29, a beam-producing particle accelerator, in this case synchrocyclotron 604 (which may include any and all features described herein), may be mounted on rotating gantry 605. Rotating gantry 605 is of the type described herein, and can angularly rotate around patient support 606. This feature enables synchrocyclotron 604 to provide a particle beam essentially directly to the patient from various angles. For example, as in FIG. 29, if synchrocyclotron 604 is above patient support 606, the particle beam may be directed downwards toward the patient. Alternatively, if synchrocyclotron 604 is below patient support 606, the particle beam may be directed upwards toward the patient. The particle beam is applied essentially directly to the patient in the sense that an intermediary beam routing mechanism is not required. A routing mechanism, in this context, is different from a shaping or sizing mechanism in that a shaping or sizing mechanism does not re-route the beam, but rather sizes and/or shapes the beam while maintaining the same general trajectory of the beam.

Further details regarding an example implementation of the foregoing system may be found in U.S. Pat. No. 7,728,311, filed on Nov. 16, 2006 and entitled “Charged Particle Radiation Therapy”, and in U.S. patent application Ser. No. 12/275,103, filed on Nov. 20, 2008 and entitled “Inner Gantry”. The contents of U.S. Pat. No. 7,728,311 and in U.S. patent application Ser. No. 12/275,103 are hereby incorporated by reference into this disclosure. In some implementations, the synchrocyclotron may be a variable-energy device, such as that described in U.S. patent application Ser. No. 13/916,401, filed on Jun. 12, 2013, the contents of which are incorporated herein by reference.

Variable-Energy Particle Accelerator

The particle accelerator used in the example particle therapy systems and example scanning systems described herein may be a variable-energy particle accelerator, an example of which is described below

The energy of an extracted particle beam (the particle beam output from the accelerator) can affect the use of the particle beam during treatment. In some machines, the energy of the particle beam (or particles in the particle beam) does not increase after extraction. However, the energy may be reduced based on treatment needs after the extraction and before the treatment. Referring to FIG. 30, an example treatment system 910 includes an accelerator 912, e.g., a synchrocyclotron, from which a particle (e.g., proton) beam 914 having a variable energy is extracted to irradiate a target volume 924 of a body 922. Optionally, one or more additional devices, such as a scanning unit 916 or a scattering unit 916, one or more monitoring units 918, and an energy degrader 920, are placed along the irradiation direction 928. The devices intercept the cross-section of the extracted beam 914 and alter one or more properties of the extracted beam for the treatment.

A target volume to be irradiated (an irradiation target) by a particle beam for treatment typically has a three-dimensional configuration. In some examples, to carry-out the treatment, the target volume is divided into layers along the irradiation direction of the particle beam so that the irradiation can be done on a layer-by-layer basis. For certain types of particles, such as protons, the penetration depth (or which layer the beam reaches) within the target volume is largely determined by the energy of the particle beam. A particle beam of a given energy does not reach substantially beyond a corresponding penetration depth for that energy. To move the beam irradiation from one layer to another layer of the target volume, the energy of the particle beam is changed.

In the example shown in FIG. 30, the target volume 924 is divided into nine layers 926a-926i along the irradiation direction 928. In an example process, the irradiation starts from the deepest layer 926i, one layer at a time, gradually to the shallower layers and finishes with the shallowest layer 926a. Before application to the body 922, the energy of the particle beam 914 is controlled to be at a level to allow the particle beam to stop at a desired layer, e.g., the layer 926d, without substantially penetrating further into the body or the target volume, e.g., the layers 926e-926i or deeper into the body. In some examples, the desired energy of the particle beam 914 decreases as the treatment layer becomes shallower relative to the particle acceleration. In some examples, the beam energy difference for treating adjacent layers of the target volume 924 is about 3 MeV to about 100 MeV, e.g., about 10 MeV to about 80 MeV, although other differences may also be possible, depending on, e.g., the thickness of the layers and the properties of the beam.

The energy variation for treating different layers of the target volume 924 can be performed at the accelerator 912 (e.g., the accelerator can vary the energy) so that, in some implementations, no additional energy variation is required after the particle beam is extracted from the accelerator 912. So, the optional energy degrader 920 in the treatment system 10 may be eliminated from the system. In some implementations, the accelerator 912 can output particle beams having an energy that varies between about 100 MeV and about 300 MeV, e.g., between about 115 MeV and about 250 MeV. The variation can be continuous or non-continuous, e.g., one step at a time. In some implementations, the variation, continuous or non-continuous, can take place at a relatively high rate, e.g., up to about 50 MeV per second or up to about 20 MeV per second. Non-continuous variation can take place one step at a time with a step size of about 10 MeV to about 90 MeV.

When irradiation is complete in one layer, the accelerator 912 can vary the energy of the particle beam for irradiating a next layer, e.g., within several seconds or within less than one second. In some implementations, the treatment of the target volume 924 can be continued without substantial interruption or even without any interruption. In some situations, the step size of the non-continuous energy variation is selected to correspond to the energy difference needed for irradiating two adjacent layers of the target volume 924. For example, the step size can be the same as, or a fraction of, the energy difference.

In some implementations, the accelerator 912 and the degrader 920 collectively vary the energy of the beam 914. For example, the accelerator 912 provides a coarse adjustment and the degrader 920 provides a fine adjustment or vice versa. In this example, the accelerator 912 can output the particle beam that varies energy with a variation step of about 10-80 MeV, and the degrader 920 adjusts (e.g., reduces) the energy of the beam at a variation step of about 2-10 MeV.

The reduced use (or absence) of the energy degrader, such as a range modulator, may help to maintain properties and quality of the output beam from the accelerator, e.g., beam intensity. The control of the particle beam can be performed at the accelerator. Side effects, e.g., from neutrons generated when the particle beam passes the degrader 920 can be reduced or eliminated.

The energy of the particle beam 914 may be adjusted to treat another target volume 930 in another body or body part 922′ after completing treatment in target volume 924. The target volumes 924, 930 may be in the same body (or patient), or in different patients. It is possible that the depth D of the target volume 930 from a surface of body 922′ is different from that of the target volume 924. Although some energy adjustment may be performed by the degrader 920, the degrader 912 may only reduce the beam energy and not increase the beam energy.

In this regard, in some cases, the beam energy required for treating target volume 930 is greater than the beam energy required to treat target volume 924. In such cases, the accelerator 912 may increase the output beam energy after treating the target volume 924 and before treating the target volume 930. In other cases, the beam energy required for treating target volume 930 is less than the beam energy required to treat target volume 924. Although the degrader 920 can reduce the energy, the accelerator 912 can be adjusted to output a lower beam energy to reduce or eliminate the use of the degrader 920. The division of the target volumes 924, 930 into layers can be different or the same. The target volume 930 can be treated similarly on a layer by layer basis to the treatment of the target volume 924.

The treatment of the different target volumes 924, 930 on the same patient may be substantially continuous, e.g., with the stop time between the two volumes being no longer than about 30 minutes or less, e.g., 25 minutes or less, 20 minutes or less, 15 minutes or less, 10 minutes or less, 5 minutes or less, or 1 minute or less. As explained herein, the accelerator 912 can be mounted on a movable gantry and the movement of the gantry can move the accelerator to aim at different target volumes. In some situations, the accelerator 912 can complete the energy adjustment of the output beam 914 during the time the treatment system makes adjustment (such as moving the gantry) after completing the treatment of the target volume 924 and before starting treating the target volume 930. After the alignment of the accelerator and the target volume 930, the treatment can begin with the adjusted, desired beam energy. Beam energy adjustment for different patients can also be completed relatively efficiently. In some examples, all adjustments, including increasing/reducing beam energy and/or moving the gantry are done within about 30 minutes, e.g., within about 25 minutes, within about 20 minutes, within about 15 minutes, within about 10 minutes or within about 5 minutes.

In the same layer of a target volume, an irradiation dose may be applied by moving the beam across the two-dimensional surface of the layer (which is sometimes called scanning beam) using a scanning unit 916. Alternatively, the layer can be irradiated by passing the extracted beam through one or more scatterers of the scattering unit 16 (which is sometimes called scattering beam).

Beam properties, such as energy and intensity, can be selected before a treatment or can be adjusted during the treatment by controlling the accelerator 912 and/or other devices, such as the scanning unit/scatterer(s) 916, the degrader 920, and others not shown in the figures. In example implementations, system 910 includes a controller 932, such as a computer, in communication with one or more devices in the system. Control can be based on results of the monitoring performed by the one or more monitors 918, e.g., monitoring of the beam intensity, dose, beam location in the target volume, etc. Although the monitors 918 are shown to be between the device 916 and the degrader 920, one or more monitors can be placed at other appropriate locations along the beam irradiation path. Controller 932 can also store a treatment plan for one or more target volumes (for the same patient and/or different patients). The treatment plan can be determined before the treatment starts and can include parameters, such as the shape of the target volume, the number of irradiation layers, the irradiation dose for each layer, the number of times each layer is irradiated, etc. The adjustment of a beam property within the system 910 can be performed based on the treatment plan. Additional adjustment can be made during the treatment, e.g., when deviation from the treatment plan is detected.

In some implementations, the accelerator 912 is configured to vary the energy of the output particle beam by varying the magnetic field in which the particle beam is accelerated. In an example implementation, one or more sets of coils receives variable electrical current to produce a variable magnetic field in the cavity. In some examples, one set of coils receives a fixed electrical current, while one or more other sets of coils receives a variable current so that the total current received by the coil sets varies. In some implementations, all sets of coils are superconducting. In other implementations, some sets of coils, such as the set for the fixed electrical current, are superconducting, while other sets of coils, such as the one or more sets for the variable current, are non-superconducting. In some examples, all sets of coils are non-superconducting.

Generally, the magnitude of the magnetic field is scalable with the magnitude of the electrical current. Adjusting the total electric current of the coils in a predetermined range can generate a magnetic field that varies in a corresponding, predetermined range. In some examples, a continuous adjustment of the electrical current can lead to a continuous variation of the magnetic field and a continuous variation of the output beam energy. Alternatively, when the electrical current applied to the coils is adjusted in a non-continuous, step-wise manner, the magnetic field and the output beam energy also varies accordingly in a non-continuous (step-wise) manner. The scaling of the magnetic field to the current can allow the variation of the beam energy to be carried out relatively precisely, although sometimes minor adjustment other than the input current may be performed.

In some implementations, to output particle beams having a variable energy, the accelerator 912 is configured to apply RF voltages that sweep over different ranges of frequencies, with each range corresponding to a different output beam energy. For example, if the accelerator 912 is configured to produce three different output beam energies, the RF voltage is capable of sweeping over three different ranges of frequencies. In another example, corresponding to continuous beam energy variations, the RF voltage sweeps over frequency ranges that continuously change. The different frequency ranges may have different lower frequency and/or upper frequency boundaries.

The extraction channel may be configured to accommodate the range of different energies produced by the variable-energy particle accelerator. For example the extraction channel may be large enough to support the highest and lowest energies produced by the particle accelerator. That is, the extraction channel may be sized or otherwise configured to receive and to transmit particles within that range of energies. Particle beams having different energies can be extracted from the accelerator 912 without altering the features of the regenerator that is used for extracting particle beams having a single energy. In other implementations, to accommodate the variable particle energy, the regenerator can be moved to disturb (e.g., change) different particle orbits in the manner described above and/or iron rods (magnetic shims) can be added or removed to change the magnetic field bump provided by the regenerator. More specifically, different particle energies will typically be at different particle orbits within the cavity. By moving the regenerator, it is possible to intercept a particle orbit at a specified energy and thereby provide the correct perturbation of that orbit so that particles at the specified energy reach the extraction channel. In some implementations, movement of the regenerator (and/or addition/removal of magnetic shims) is performed in real-time to match real-time changes in the particle beam energy output by the accelerator. In other implementations, particle energy is adjusted on a per-treatment basis, and movement of the regenerator (and/or addition/removal of magnetic shims) is performed in advance of the treatment. In either case, movement of the regenerator (and/or addition/removal of magnetic shims) may be computer controlled. For example, a computer may control one or more motors that effect movement of the regenerator and/or magnetic shims.

In some implementations, the regenerator is implemented using one or more magnetic shims that are controllable to move to the appropriate location(s).

As an example, table 1 shows three example energy levels at which example accelerator 912 can output particle beams. The corresponding parameters for producing the three energy levels are also listed. In this regard, the magnet current refers to the total electrical current applied to the one or more coil sets in the accelerator 912; the maximum and minimum frequencies define the ranges in which the RF voltage sweeps; and “r” is the radial distance of a location to a center of the cavity in which the particles are accelerated.

TABLE 1

Examples of beam energies and respective parameters.

Magnetic
Magnetic

Beam
Magnet
Maximum
Minimum
Field at
Field at

Energy
Current
Frequency
Frequency
r = 0 mm
r = 298 mm

(MeV)
(Amps)
(MHz)
(MHz)
(Tesla)
(Tesla)

250
1990
132
99
8.7
8.2

235
1920
128
97
8.4
8.0

211
1760
120
93
7.9
7.5

Details that may be included in an example particle accelerator that produces charged particles having variable energies are described below. The accelerator can be a synchrocyclotron and the particles may be protons. The particles may be output as pulsed beams. The energy of the beam output from the particle accelerator can be varied during the treatment of one target volume in a patient, or between treatments of different target volumes of the same patient or different patients. In some implementations, settings of the accelerator are changed to vary the beam energy when no beam (or particles) is output from the accelerator. The energy variation can be continuous or non-continuous over a desired range.

Referring to the example shown in FIG. 1, the particle accelerator (e.g., synchrocyclotron 502), which may be a variable-energy particle accelerator like accelerator 912 described above, may be configured to output particle beams that have a variable energy. The range of the variable energy can have an upper boundary that is about 200 MeV to about 300 MeV or higher, e.g., 200 MeV, about 205 MeV, about 210 MeV, about 215 MeV, about 220 MeV, about 225 MeV, about 230 MeV, about 235 MeV, about 240 MeV, about 245 MeV, about 250 MeV, about 255 MeV, about 260 MeV, about 265 MeV, about 270 MeV, about 275 MeV, about 280 MeV, about 285 MeV, about 290 MeV, about 295 MeV, or about 300 MeV or higher. The range can also have a lower boundary that is about 100 MeV or lower to about 200 MeV, e.g., about 100 MeV or lower, about 105 MeV, about 110 MeV, about 115 MeV, about 120 MeV, about 125 MeV, about 130 MeV, about 135 MeV, about 140 MeV, about 145 MeV, about 150 MeV, about 155 MeV, about 160 MeV, about 165 MeV, about 170 MeV, about 175 MeV, about 180 MeV, about 185 MeV, about 190 MeV, about 195 MeV, about 200 MeV.

In some examples, the variation is non-continuous and the variation step can have a size of about 10 MeV or lower, about 15 MeV, about 20 MeV, about 25 MeV, about 30 MeV, about 35 MeV, about 40 MeV, about 45 MeV, about 50 MeV, about 55 MeV, about 60 MeV, about 65 MeV, about 70 MeV, about 75 MeV, or about 80 MeV or higher. Varying the energy by one step size can take no more than 30 minutes, e.g., about 25 minutes or less, about 20 minutes or less, about 15 minutes or less, about 10 minutes or less, about 5 minutes or less, about 1 minute or less, or about 30 seconds or less. In other examples, the variation is continuous and the accelerator can adjust the energy of the particle beam at a relatively high rate, e.g., up to about 50 MeV per second, up to about 45 MeV per second, up to about 40 MeV per second, up to about 35 MeV per second, up to about 30 MeV per second, up to about 25 MeV per second, up to about 20 MeV per second, up to about 15 MeV per second, or up to about 10 MeV per second. The accelerator can be configured to adjust the particle energy both continuously and non-continuously. For example, a combination of the continuous and non-continuous variation can be used in a treatment of one target volume or in treatments of different target volumes. Flexible treatment planning and flexible treatment can be achieved.

A particle accelerator that outputs a particle beam having a variable energy can provide accuracy in irradiation treatment and reduce the number of additional devices (other than the accelerator) used for the treatment. For example, the use of degraders for changing the energy of an output particle beam may be reduced or eliminated for all or part of the treatment. The properties of the particle beam, such as intensity, focus, etc. can be controlled at the particle accelerator and the particle beam can reach the target volume without substantial disturbance from the additional devices. The relatively high variation rate of the beam energy can reduce treatment time and allow for efficient use of the treatment system.

In some implementations, the accelerator, such as the synchrocyclotron 502 of FIG. 1, accelerates particles or particle beams to variable energy levels by varying the magnetic field in the accelerator, which can be achieved by varying the electrical current applied to coils for generating the magnetic field. As explained above, an example synchrocyclotron (e.g., 502 in FIG. 1) includes a magnet system that contains a particle source, a radiofrequency drive system, and a beam extraction system. FIG. 33 shows an example of a magnet system that may be used in a variable-energy accelerator. In this example implementation, the magnetic field established by the magnet system 1012 can vary by about 5% to about 35% of a maximum value of the magnetic field that two sets of coils 40a and 40b, and 42a and 42b are capable of generating. The magnetic field established by the magnet system has a shape appropriate to maintain focus of a contained proton beam using a combination of the two sets of coils and a pair of shaped ferromagnetic (e.g., low carbon steel) structures, examples of which are provided above.

Each set of coils may be a split pair of annular coils to receive electrical current. In some situations, both sets of coils are superconducting. In other situations, only one set of the coils is superconducting and the other set is non-superconducting or normal conducting (also discussed further below). It is also possible that both sets of coils are non-superconducting. Suitable superconducting materials for use in the coils include niobium-3 tin (Nb3 Sn) and/or niobium-titanium. Other normal conducting materials can include copper. Examples of the coil set constructions are described further below.

The two sets of coils can be electrically connected serially or in parallel. In some implementations, the total electrical current received by the two sets of coils can include about 2 million ampere turns to about 10 million ampere turns, e.g., about 2.5 to about 7.5 million ampere turns or about 3.75 million ampere turns to about 5 million ampere turns. In some examples, one set of coils is configured to receive a fixed (or constant) portion of the total variable electrical current, while the other set of coils is configured to receive a variable portion of the total electrical current. The total electrical current of the two coil sets varies with the variation of the current in one coil set. In other situations, the electrical current applied to both sets of coils can vary. The variable total current in the two sets of coils can generate a magnetic field having a variable magnitude, which in turn varies the acceleration pathways of the particles and produces particles having variable energies.

Generally, the magnitude of the magnetic field generated by the coil(s) is scalable to the magnitude of the total electrical current applied to the coil(s). Based on the scalability, in some implementations, linear variation of the magnetic field strength can be achieved by linearly changing the total current of the coil sets. The total current can be adjusted at a relatively high rate that leads to a relatively high-rate adjustment of the magnetic field and the beam energy.

In the example reflected in Table 1 above, the ratio between values of the current and the magnetic field at the geometric center of the coil rings is: 1990:8.7 (approximately 228.7:1); 1920:8.4 (approximately 228.6:1); 1760:7.9 (approximately 222.8:1). Accordingly, adjusting the magnitude of the total current applied to a superconducting coil(s) can proportionally (based on the ratio) adjust the magnitude of the magnetic field.

The scalability of the magnetic field to the total electrical current in the example of Table 1 is also shown in the plot of FIG. 31, where BZ is the magnetic field along the Z direction; and R is the radial distance measured from a geometric center of the coil rings along a direction perpendicular to the Z direction. The magnetic field has the highest value at the geometric center, and decreases as the distance R increases. The curves 1035, 1037 represent the magnetic field generated by the same coil sets receiving different total electrical current: 1760 Amperes and 1990 Amperes, respectively. The corresponding energies of the extracted particles are 211 MeV and 250 MeV, respectively. The two curves 1035, 1037 have substantially the same shape and the different parts of the curves 1035, 1037 are substantially parallel. As a result, either the curve 1035 or the curve 1037 can be linearly shifted to substantially match the other curve, indicating that the magnetic field is scalable to the total electrical current applied to the coil sets.

In some implementations, the scalability of the magnetic field to the total electrical current may not be perfect. For example, the ratio between the magnetic field and the current calculated based on the example shown in table 1 is not constant. Also, as shown in FIG. 31, the linear shift of one curve may not perfectly match the other curve. In some implementations, the total current is applied to the coil sets under the assumption of perfect scalability. The target magnetic field (under the assumption of perfect scalability) can be generated by additionally altering the features, e.g., geometry, of the coils to counteract the imperfection in the scalability. As one example, ferromagnetic (e.g., iron) rods (magnetic shims) can be inserted or removed from one or both of the magnetic structures (e.g., yokes, pole pieces, and the like). The features of the coils can be altered at a relatively high rate so that the rate of the magnetic field adjustment is not substantially affected as compared to the situation in which the scalability is perfect and only the electrical current needs to be adjusted. In the example of iron rods, the rods can be added or removed at the time scale of seconds or minutes, e.g., within 5 minutes, within 1 minute, less than 30 seconds, or less than 1 second.

In some implementations, settings of the accelerator, such as the current applied to the coil sets, can be chosen based on the substantial scalability of the magnetic field to the total electrical current in the coil sets.

Generally, to produce the total current that varies within a desired range, any appropriate combination of current applied to the two coil sets can be used. In an example, the coil set 42a, 42b can be configured to receive a fixed electrical current corresponding to a lower boundary of a desired range of the magnetic field. In the example shown in table 1, the fixed electrical current is 1760 Amperes. In addition, the coil set 40a, 40b can be configured to receive a variable electrical current having an upper boundary corresponding to a difference between an upper boundary and a lower boundary of the desired range of the magnetic field. In the example shown in table 1, the coil set 40a, 40b is configured to receive electrical current that varies between 0 Ampere and 230 Amperes.

In another example, the coil set 42a, 42b can be configured to receive a fixed electrical current corresponding to an upper boundary of a desired range of the magnetic field. In the example shown in table 1, the fixed current is 1990 Amperes. In addition, the coil set 40a, 40b can be configured to receive a variable electrical current having an upper boundary corresponding to a difference between a lower boundary and an upper boundary of the desired range of the magnetic field. In the example shown in table 1, the coil set 40a, 40b is configured to receive electrical current that varies between −230 Ampere and 0 Ampere.

The total variable magnetic field generated by the variable total current for accelerating the particles can have a maximum magnitude greater than 4 Tesla, e.g., greater than 5 Tesla, greater than 6 Tesla, greater than 7 Tesla, greater than 8 Tesla, greater than 9 Tesla, or greater than 10 Tesla, and up to about 20 Tesla or higher, e.g., up to about 18 Tesla, up to about 15 Tesla, or up to about 12 Tesla. In some implementations, variation of the total current in the coil sets can vary the magnetic field by about 0.2 Tesla to about 4.2 Tesla or more, e.g., about 0.2 Tesla to about 1.4 Tesla or about 0.6 Tesla to about 4.2 Tesla. In some situations, the amount of variation of the magnetic field can be proportional to the maximum magnitude.

FIG. 32 shows an example RF structure for sweeping the voltage on the dee plate 500 over an RF frequency range for each energy level of the particle beam, and for varying the frequency range when the particle beam energy is varied. The semicircular surfaces 503, 505 of the dee plate 500 are connected to an inner conductor 1300 and housed in an outer conductor 1302. The high voltage is applied to the dee plate 500 from a power source (not shown, e.g., an oscillating voltage input) through a power coupling device 1304 that couples the power source to the inner conductor. In some implementations, the coupling device 1304 is positioned on the inner conductor 1300 to provide power transfer from the power source to the dee plate 500. In addition, the dee plate 500 is coupled to variable reactive elements 1306, 1308 to perform the RF frequency sweep for each particle energy level, and to change the RF frequency range for different particle energy levels.

The variable reactive element 1306 can be a rotating capacitor that has multiple blades 1310 rotatable by a motor (not shown). By meshing or unmeshing the blades 1310 during each cycle of RF sweeping, the capacitance of the RF structure changes, which in turn changes the resonant frequency of the RF structure. In some implementations, during each quarter cycle of the motor, the blades 1310 mesh with the each other. The capacitance of the RF structure increases and the resonant frequency decreases. The process reverses as the blades 1310 unmesh. As a result, the power required to generate the high voltage applied to the dee plate 103 and necessary to accelerate the beam can be reduced by a large factor. In some implementations, the shape of the blades 1310 is machined to form the required dependence of resonant frequency on time.

The RF frequency generation is synchronized with the blade rotation by sensing the phase of the RF voltage in the resonator, keeping the alternating voltage on the dee plates close to the resonant frequency of the RF cavity. (The dummy dee is grounded and is not shown in FIG. 32).

The variable reactive element 1308 can be a capacitor formed by a plate 1312 and a surface 1316 of the inner conductor 1300. The plate 1312 is movable along a direction 1314 towards or away from the surface 1316. The capacitance of the capacitor changes as the distance D between the plate 1312 and the surface 1316 changes. For each frequency range to be swept for one particle energy, the distance D is at a set value, and to change the frequency range, the plate 1312 is moved corresponding to the change in the energy of the output beam.

In some implementations, the inner and outer conductors 1300, 1302 are formed of a metallic material, such as copper, aluminum, or silver. The blades 1310 and the plate 1312 can also be formed of the same or different metallic materials as the conductors 1300, 1302. The coupling device 1304 can be an electrical conductor. The variable reactive elements 1306, 1308 can have other forms and can couple to the dee plate 100 in other ways to perform the RF frequency sweep and the frequency range alteration. In some implementations, a single variable reactive element can be configured to perform the functions of both the variable reactive elements 1306, 1308. In other implementations, more than two variable reactive elements can be used.

The control of the gantry, the patient support, the active beam shaping elements, and the synchrocyclotron to perform a therapy session is achieved by appropriate therapy control electronics (not shown).

Control of the particle therapy system described herein and its various features may be implemented using hardware or a combination of hardware and software. For example, a system like the ones described herein may include various controllers and/or processing devices located at various points. A central computer may coordinate operation among the various controllers or processing devices. The central computer, controllers, and processing devices may execute various software routines to effect control and coordination of testing and calibration.

System operation can be controlled, at least in part, using one or more computer program products, e.g., one or more computer program tangibly embodied in one or more non-transitory machine-readable media, for execution by, or to control the operation of, one or more data processing apparatus, e.g., a programmable processor, a computer, multiple computers, and/or programmable logic components.

A computer program can be written in any form of programming language, including compiled or interpreted languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment. A computer program can be deployed to be executed on one computer or on multiple computers at one site or distributed across multiple sites and interconnected by a network.

Actions associated with implementing all or part of the operations of the particle therapy system described herein can be performed by one or more programmable processors executing one or more computer programs to perform the functions described herein. All or part of the operations can be implemented using special purpose logic circuitry, e.g., an FPGA (field programmable gate array) and/or an ASIC (application-specific integrated circuit).

Processors suitable for the execution of a computer program include, by way of example, both general and special purpose microprocessors, and any one or more processors of any kind of digital computer. Generally, a processor will receive instructions and data from a read-only storage area or a random access storage area or both. Elements of a computer (including a server) include one or more processors for executing instructions and one or more storage area devices for storing instructions and data. Generally, a computer will also include, or be operatively coupled to receive data from, or transfer data to, or both, one or more machine-readable storage media, such as mass PCBs for storing data, e.g., magnetic, magneto-optical disks, or optical disks. Non-transitory machine-readable storage media suitable for embodying computer program instructions and data include all forms of non-volatile storage area, including by way of example, semiconductor storage area devices, e.g., EPROM, EEPROM, and flash storage area devices; magnetic disks, e.g., internal hard disks or removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks.

Any “electrical connection” as used herein may imply a direct physical connection or a connection that includes intervening components but that nevertheless allows electrical signals to flow between connected components. Any “connection” involving electrical circuitry mentioned herein, unless stated otherwise, is an electrical connection and not necessarily a direct physical connection regardless of whether the word “electrical” is used to modify “connection”.

Any two more of the foregoing implementations may be used in an appropriate combination in an appropriate particle accelerator (e.g., a synchrocyclotron). Likewise, individual features of any two more of the foregoing implementations may be used in an appropriate combination.

Elements of different implementations described herein may be combined to form other implementations not specifically set forth above. Elements may be left out of the processes, systems, apparatus, etc., described herein without adversely affecting their operation. Various separate elements may be combined into one or more individual elements to perform the functions described herein.

The example implementations described herein are not limited to use with a particle therapy system or to use with the example particle therapy systems described herein. Rather, the example implementations can be used in any appropriate system that directs accelerated particles to an output.

Additional information concerning the design of an example implementation of a particle accelerator that may be used in a system as described herein can be found in U.S. Provisional Application No. 60/760,788, entitled “High-Field Superconducting Synchrocyclotron” and filed Jan. 20, 2006; U.S. patent application Ser. No. 11/463,402, entitled “Magnet Structure For Particle Acceleration” and filed Aug. 9, 2006; and U.S. Provisional Application No. 60/850,565, entitled “Cryogenic Vacuum Break Pneumatic Thermal Coupler” and filed Oct. 10, 2006, all of which are incorporated herein by reference.

The following applications are incorporated by reference into the subject application: the U.S. Provisional Application entitled “CONTROLLING INTENSITY OF A PARTICLE BEAM” (Application No. 61/707,466), the U.S. Provisional Application entitled “ADJUSTING ENERGY OF A PARTICLE BEAM” (Application No. 61/707,515), the U.S. Provisional Application entitled “ADJUSTING COIL POSITION” (Application No. 61/707,548), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM USING MAGNETIC FIELD FLUTTER” (Application No. 61/707,572), the U.S. Provisional Application entitled “MAGNETIC FIELD REGENERATOR” (Application No. 61/707,590), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM” (Application No. 61/707,704), the U.S. Provisional Application entitled “CONTROLLING PARTICLE THERAPY (Application No. 61/707,624), and the U.S. Provisional Application entitled “CONTROL SYSTEM FOR A PARTICLE ACCELERATOR” (Application No. 61/707,645).

The following are also incorporated by reference into the subject application: U.S. Pat. No. 7,728,311 which issued on Jun. 1, 2010, U.S. patent application Ser. No. 11/948,359 which was filed on Nov. 30, 2007, U.S. patent application Ser. No. 12/275,103 which was filed on Nov. 20, 2008, U.S. patent application Ser. No. 11/948,662 which was filed on Nov. 30, 2007, U.S. Provisional Application No. 60/991,454 which was filed on Nov. 30, 2007, U.S. Pat. No. 8,003,964 which issued on Aug. 23, 2011, U.S. Pat. No. 7,208,748 which issued on Apr. 24, 2007, U.S. Pat. No. 7,402,963 which issued on Jul. 22, 2008, U.S. patent application Ser. No. 13/148,000 filed Feb. 9, 2010, U.S. patent application Ser. No. 11/937,573 filed on Nov. 9, 2007, U.S. patent application Ser. No. 11/187,633, titled “A Programmable Radio Frequency Waveform Generator for a Synchrocyclotron,” filed Jul. 21, 2005, U.S. Provisional Application No. 60/590,089, filed on Jul. 21, 2004, U.S. patent application Ser. No. 10/949,734, titled “A Programmable Particle Scatterer for Radiation Therapy Beam Formation”, filed Sep. 24, 2004, and U.S. Provisional Application No. 60/590,088, filed Jul. 21, 2005.

Any features of the subject application may be combined with one or more appropriate features of the following: the U.S. Provisional Application entitled “CONTROLLING INTENSITY OF A PARTICLE BEAM” (Application No. 61/707,466), the U.S. Provisional Application entitled “ADJUSTING ENERGY OF A PARTICLE BEAM” (Application No. 61/707,515), the U.S. Provisional Application entitled “ADJUSTING COIL POSITION” (Application No. 61/707,548), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM USING MAGNETIC FIELD FLUTTER” (Application No. 61/707,572), the U.S. Provisional Application entitled “MAGNETIC FIELD REGENERATOR” (Application No. 61/707,590), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM” (Application No. 61/707,704), the U.S. Provisional Application entitled “CONTROLLING PARTICLE THERAPY (Application No. 61/707,624), and the U.S. Provisional Application entitled “CONTROL SYSTEM FOR A PARTICLE ACCELERATOR” (Application No. 61/707,645), U.S. Pat. No. 7,728,311 which issued on Jun. 1, 2010, U.S. patent application Ser. No. 11/948,359 which was filed on Nov. 30, 2007, U.S. patent application Ser. No. 12/275,103 which was filed on Nov. 20, 2008, U.S. patent application Ser. No. 11/948,662 which was filed on Nov. 30, 2007, U.S. Provisional Application No. 60/991,454 which was filed on Nov. 30, 2007, U.S. patent application Ser. No. 13/907,601, which was filed on May 31, 2013, U.S. patent application Ser. No. 13/916,401, filed on Jun. 12, 2013, U.S. Pat. No. 8,003,964 which issued on Aug. 23, 2011, U.S. Pat. No. 7,208,748 which issued on Apr. 24, 2007, U.S. Pat. No. 7,402,963 which issued on Jul. 22, 2008, U.S. patent application Ser. No. 13/148,000 filed Feb. 9, 2010, U.S. patent application Ser. No. 11/937,573 filed on Nov. 9, 2007, U.S. patent application Ser. No. 11/187,633, titled “A Programmable Radio Frequency Waveform Generator for a Synchrocyclotron,” filed Jul. 21, 2005, U.S. Provisional Application No. 60/590,089, filed on Jul. 21, 2004, U.S. patent application Ser. No. 10/949,734, titled “A Programmable Particle Scatterer for Radiation Therapy Beam Formation”, filed Sep. 24, 2004, and U.S. Provisional Application No. 60/590,088, filed Jul. 21, 2005.

Other implementations not specifically described herein are also within the scope of the following claims.

Claims

1. A particle therapy system comprising: a particle accelerator to output a particle beam;a scanning system for the particle accelerator to scan the particle beam across at least part of an irradiation target in a patient, the scanning system being configured to scan the particle beam in at least two dimensions across the at least part of the irradiation target; anda collimator comprising multiple elements that are controllable to move in the at least two dimensions relative to the particle beam during scanning to track motion of the particle beam as the particle beam is scanned across the at least part of the irradiation target, the multiple elements comprising a material that inhibits transmission of the particle beam, each of the multiple elements comprising fingers that are extendible and retractable in one of the two dimensions to define an edge of the collimator that is movable between a first part of the particle beam and the patient to prevent the first part of the particle beam from reaching the patient while allowing a second part of the particle beam to reach the at least part of the irradiation target.
2. The particle therapy system of claim 1, wherein each of the multiple elements is rotatable.
3. The particle therapy system of claim 1, wherein the fingers are adjustable to vary a size of the edge.
4. The particle therapy system of claim 1, wherein the fingers are individually movable relative to the irradiation target.
5. The particle therapy system of claim 1, wherein the multiple elements comprise a first element and a second element, the first element for defining the edge, the edge being a first edge, and the second element for defining a second edge; and wherein the first edge and the second edge are controllable to move relative to the irradiation target.
6. The particle therapy system of claim 1, wherein the scanning system comprises at least one magnet to control movement of the particle beam to scan the particle beam, the at least one magnet for generating a magnetic field in response to applied current, the magnetic field affecting the movement.
7. The particle therapy system of claim 1, wherein the scanning system is configured to scan the particle beam more quickly in interior sections of the irradiation target than at a perimeter of the irradiation target.
8. The particle therapy system of claim 1, wherein the particle beam is movable within an area of a plane; and wherein the scanning system comprises an energy degrader having an area that is less than the area of the plane.
9. The particle therapy system of claim 8, wherein the energy degrader has an area that is less than half the area of the plane.
10. The particle therapy system of claim 8, wherein the energy degrader has an area that is less than a quarter the area of the plane.
11. The particle therapy system of claim 8, wherein the energy degrader has an area that is less than an eighth the area of the plane.
12. The particle therapy system of claim 8, wherein the energy degrader has an area that is less than ten times a cross-sectional area of the particle beam.
13. The particle therapy system of claim 1, wherein the scanning system is configured to scan the particle beam from different incident angles; and wherein the multiple elements are controllable to move based on movement of the particle beam as the particle beam is scanned from different incident angles.
14. The particle therapy system of claim 1, wherein the scanning system comprises: a magnet to affect a direction of the particle beam to scan the particle beam across the at least part of an irradiation target; anda degrader to change an energy of the beam prior to application of the particle beam to the irradiation target, the degrader being down-beam of the magnet relative to the particle accelerator;wherein the particle accelerator is a variable-energy synchrocyclotron.
15. The particle therapy system of claim 1, wherein the particle accelerator is a synchrocyclotron.
16. A particle therapy system comprising: a particle accelerator to output a particle beam to treat an irradiation target in a patient;a scanning system for the particle accelerator to scan the particle beam across at least part of the irradiation target, the scanning system being configured to scan the particle beam in at least two dimensions that are at an angle relative to a direction of the particle beam; anda collimator comprising multiple elements that are controllable to move in the at least two dimensions relative to the particle beam to track movement of the particle beam as the particle beam is scanned across the at least part of the irradiation target, the multiple elements comprising a material that inhibits transmission of the particle beam, and each of the multiple elements comprising fingers that are extendible and retractable in one of the two dimensions to define an edge of the collimator that is movable between a first part of the particle beam and the patient to prevent the first part of the particle beam from reaching the patient while allowing a second part of the particle beam to reach the at least part of the irradiation target;wherein the particle accelerator comprises: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, the cavity having a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity;an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity; anda regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel;wherein the magnetic field is between 4 Tesla (T) and 20 T and the magnetic field bump is at most 2 Tesla.
17. The particle therapy system of claim 16, wherein the multiple elements are rotatable.
18. The particle therapy system of claim 16, wherein the fingers are adjustable to vary a size of the edge.
19. The particle therapy system of claim 16, wherein the fingers are individually movable relative to the irradiation target.
20. The particle therapy system of claim 16, wherein the multiple elements comprise a first element and a second element, the first element for defining the edge, the edge being a first edge, and the second element for defining a second edge; and wherein the first edge and the second edge are controllable to move relative to the irradiation target.
21. The particle therapy system of claim 16, wherein the scanning system comprises at least one magnet to control movement of the particle beam to scan the particle beam, the at least one magnet for generating a magnetic field in response to applied current, the magnetic field affecting the movement.
22. The particle therapy system of claim 16, wherein the scanning system is configured to scan the particle beam more quickly in interior sections of the irradiation target than at a perimeter of the irradiation target.
23. The particle therapy system of claim 16, wherein the particle beam is movable within an area of a plane; and wherein the scanning system comprises an energy degrader having an area that is less than the area of the plane.
24. The particle therapy system of claim 23, wherein the energy degrader has an area that is less than half the area of the plane.
25. The particle therapy system of claim 23, wherein the energy degrader has an area that is less than a quarter the area of the plane.
26. The particle therapy system of claim 23, wherein the energy degrader has an area that is less than an eighth the area of the plane.
27. The particle therapy system of claim 23, wherein the energy degrader has an area that is less than ten times a cross-sectional area of the particle beam.
28. The particle therapy system of claim 16, wherein the scanning system is configured to scan the particle beam from different incident angles; and wherein the multiple elements are controllable to move based on movement of the particle beam as the particle beam is scanned from different incident angles.
29. The particle therapy system of claim 16, wherein the scanning system comprises: a magnet to affect a direction of the particle beam to scan the particle beam across the at least part of an irradiation target; anda degrader to change an energy of the particle beam prior to application of the particle beam to the irradiation target, the degrader being down-beam of the magnet relative to the particle accelerator;wherein the particle accelerator is a variable-energy synchrocyclotron.
30. The particle therapy system of claim 16, wherein the particle accelerator is a synchrocyclotron.
31. A particle therapy system comprising: a particle accelerator to output a particle beam to treat an irradiation target in a patient;a scanning system to perform scanning of at least part of the irradiation target with the particle beam;a collimator comprised of multiple elements that are controllable to move in at least two dimensions relative to the particle beam during scanning to track motion of the particle beam as the particle beam is scanned across the at least part of the irradiation target, the multiple elements comprising a material that inhibits transmission of the particle beam, and each of the multiple elements comprising fingers that are extendible and retractable in one of the two dimensions to define an edge of the collimator that is movable between a first part of the particle beam and the patient to prevent the first part of the particle beam from reaching the patient while allowing a second part of the particle beam to reach the at least part of irradiation target; anda gantry on which the particle accelerator is mounted, the gantry being configured to move the particle accelerator relative to the irradiation target.
32. The particle therapy system of claim 31, wherein the multiple elements comprise a first element and a second element, the first element for defining the edge, the edge being a first edge, and the second element for defining a second edge; and wherein the first edge and the second edge are controllable to move relative to the irradiation target.
33. The particle therapy system of claim 31, wherein the multiple elements are rotatable.
34. The particle therapy system of claim 31, wherein the scanning system is configured to scan the particle beam more quickly in interior sections of the irradiation target than at a perimeter of the irradiation target.
35. The particle therapy system of claim 31, wherein the scanning system is configured to scan the particle beam from different incident angles; and wherein the multiple elements are controllable to move based on movement of the particle beam as the particle beam is scanned from different incident angles.
36. The particle therapy system of claim 31, wherein the particle accelerator is a synchrocyclotron.
37. A particle therapy system comprising: a particle accelerator to output a particle beam;a scanning system for the particle accelerator, the scanning system being configured to move the particle beam across an irradiation field, the irradiation field comprising a maximum extent that the particle beam is movable in at least two dimensions; anda collimator that is down-beam of the scanning system, the collimator comprising multiple elements, at least one of the multiple elements comprising fingers that are extendible and retractable to define an edge of the collimator to block at least part of the particle beam, the multiple elements being controllable to move in the two dimensions relative to the particle beam within the irradiation field to track movement of the particle beam, the fingers of the at least one of the multiple elements being configurable during movement of the particle beam to define the edge based on a position of the particle beam relative to a target of the particle beam, wherein, for all configurations of the fingers, the edge extends across less than an extent of the irradiation field.
38. The particle therapy system of claim 37, wherein the multiple elements comprise a first element and a second element, the first element for defining the edge, the edge being a first edge, and the second element for defining a second edge; and wherein the first edge and the second edge are controllable to move relative to the target.
39. The particle therapy system of claim 37, wherein the multiple elements are rotatable.
40. The particle therapy system of claim 37, wherein the scanning system is configured to scan the particle beam more quickly in interior sections of the target than at a perimeter of the target.
41. The particle therapy system of claim 37, wherein the scanning system is configured to scan the particle beam from different incident angles; and wherein the multiple elements are controllable to move based on movement of the particle beam as the particle beam is scanned from different incident angles.
42. The particle therapy system of claim 37, wherein the particle accelerator is a synchrocyclotron.

US Referenced Citations (1135)

Number	Name	Date	Kind
463291	Dodson	Nov 1891	A
773508	Leblanc	Oct 1904	A
2280606	Van et al.	Apr 1942	A
2492324	Salisbury	Dec 1949	A
2615129	McMillan	Oct 1952	A
2616042	Weeks	Oct 1952	A
2659000	Salisbury	Nov 1953	A
2701304	Dickinson	Feb 1955	A
2789222	Martin	Apr 1957	A
3024379	Verster	Mar 1962	A
3175131	Burleigh et al.	Mar 1965	A
3432721	Naydan et al.	Mar 1969	A
3582650	Avery	Jun 1971	A
3679899	Dimeff	Jul 1972	A
3689847	Verster	Sep 1972	A
3757118	Hodge et al.	Sep 1973	A
3868522	Bigham et al.	Feb 1975	A
3886367	Castle, Jr.	May 1975	A
3925676	Bigham et al.	Dec 1975	A
3958327	Marancik et al.	Mar 1976	A
2958327	Marancik et al.	May 1976	A
3955089	McIntyre et al.	May 1976	A
3992625	Schmidt et al.	Nov 1976	A
4038622	Purcell	Jul 1977	A
4047068	Ress et al.	Sep 1977	A
4112306	Nunan	Sep 1978	A
4129784	Tschunt et al.	Dec 1978	A
4139777	Rautenbach	Feb 1979	A
4197510	Szu	Apr 1980	A
4220866	Taumann et al.	Sep 1980	A
4230129	LeVeen	Oct 1980	A
4256966	Heinz	Mar 1981	A
4293772	Stieber	Oct 1981	A
4336505	Meyer	Jun 1982	A
4342060	Gibson	Jul 1982	A
4345210	Tran	Aug 1982	A
4353033	Karasawa	Oct 1982	A
4425506	Brown et al.	Jan 1984	A
4490616	Cipollina et al.	Dec 1984	A
4507614	Prono et al.	Mar 1985	A
4507616	Blosser et al.	Mar 1985	A
4589126	Augustsson et al.	May 1986	A
4598208	Brunelli et al.	Jul 1986	A
4628523	Heflin	Dec 1986	A
4633125	Bosser et al.	Dec 1986	A
4641057	Blosser et al.	Feb 1987	A
4641104	Blosser et al.	Feb 1987	A
4651007	Perusek et al.	Mar 1987	A
4680565	Jahnke	Jul 1987	A
4705955	Mileikowsky	Nov 1987	A
4710722	Jahnke	Dec 1987	A
4726046	Nunan	Feb 1988	A
4734653	Jahnke	Mar 1988	A
4736106	Kashy et al.	Apr 1988	A
4736173	Blosser et al.	Apr 1988	A
4737727	Yamada et al.	Apr 1988	A
4739173	Blosser et al.	Apr 1988	A
4745367	Dustmann et al.	May 1988	A
4754147	Maughan et al.	Jun 1988	A
4763483	Olsen	Aug 1988	A
4767930	Stieber et al.	Aug 1988	A
4769623	Marsing et al.	Sep 1988	A
4771208	Jongen et al.	Sep 1988	A
4783634	Yamamoto et al.	Nov 1988	A
4808941	Marsing	Feb 1989	A
4812658	Koehler	Mar 1989	A
4843333	Marsing et al.	Jun 1989	A
4845371	Stieber	Jul 1989	A
4865284	Gosis et al.	Sep 1989	A
4868843	Nunan	Sep 1989	A
4868844	Nunan	Sep 1989	A
4870287	Cole et al.	Sep 1989	A
4880985	Jones	Nov 1989	A
4894541	Ono	Jan 1990	A
4896206	Denham	Jan 1990	A
4902993	Krevet	Feb 1990	A
4904949	Wilson	Feb 1990	A
4905267	Miller et al.	Feb 1990	A
4917344	Prechter et al.	Apr 1990	A
4943781	Wilson et al.	Jul 1990	A
4945478	Merickel et al.	Jul 1990	A
4968915	Wilson et al.	Nov 1990	A
4987309	Klasen et al.	Jan 1991	A
4992744	Fujita et al.	Feb 1991	A
4996496	Kitamura et al.	Feb 1991	A
5006759	Krispel	Apr 1991	A
5010562	Hernandez et al.	Apr 1991	A
5012111	Ueda	Apr 1991	A
5017789	Young et al.	May 1991	A
5017882	Finlan	May 1991	A
5036290	Sonobe et al.	Jul 1991	A
5039057	Prechter et al.	Aug 1991	A
5039867	Nishihara et al.	Aug 1991	A
5046078	Hernandez et al.	Sep 1991	A
5072123	Johnsen	Dec 1991	A
5111042	Sullivan et al.	May 1992	A
5111173	Matsuda et al.	May 1992	A
5117194	Nakanishi et al.	May 1992	A
5117212	Yamamoto et al.	May 1992	A
5117829	Miller et al.	Jun 1992	A
5144647	Kikuchi	Sep 1992	A
5148032	Hernandez	Sep 1992	A
5166531	Huntzinger	Nov 1992	A
5189687	Bova et al.	Feb 1993	A
5191706	Cosden	Mar 1993	A
5240218	Dye	Aug 1993	A
5260579	Yasuda et al.	Nov 1993	A
5260581	Lesyna et al.	Nov 1993	A
5278533	Kawaguchi	Jan 1994	A
5285166	Hiramoto et al.	Feb 1994	A
5317164	Kurokawa	May 1994	A
5336891	Crewe	Aug 1994	A
5341104	Anton et al.	Aug 1994	A
5349198	Takanaka	Sep 1994	A
5365742	Boffito et al.	Nov 1994	A
5374913	Pissantezky et al.	Dec 1994	A
5382914	Hamm et al.	Jan 1995	A
5401973	McKeown et al.	Mar 1995	A
5405235	Lebre et al.	Apr 1995	A
5434420	McKeown et al.	Jul 1995	A
5440133	Moyers et al.	Aug 1995	A
5451794	McKeown et al.	Sep 1995	A
5461773	Kawaguchi	Oct 1995	A
5463291	Carroll et al.	Oct 1995	A
5464411	Schulte et al.	Nov 1995	A
5492922	Palkowitz	Feb 1996	A
5511549	Legg et al.	Apr 1996	A
5521469	Laisne	May 1996	A
5538942	Koyama et al.	Jul 1996	A
5549616	Schulte et al.	Aug 1996	A
5561697	Takafuji et al.	Oct 1996	A
5585642	Britton et al.	Dec 1996	A
5633747	Nikoonahad	May 1997	A
5635721	Bardi et al.	Jun 1997	A
5668371	Deasy et al.	Sep 1997	A
5672878	Yao	Sep 1997	A
5691679	Ackermann et al.	Nov 1997	A
5726448	Smith et al.	Mar 1998	A
5727554	Kalend et al.	Mar 1998	A
5730745	Schulte et al.	Mar 1998	A
5748703	Cosman	May 1998	A
5751781	Brown et al.	May 1998	A
5764723	Weinberger et al.	Jun 1998	A
5778047	Mansfield et al.	Jul 1998	A
5783914	Hiramoto et al.	Jul 1998	A
5784431	Kalend et al.	Jul 1998	A
5797924	Schulte et al.	Aug 1998	A
5811944	Sampayan et al.	Sep 1998	A
5818058	Nakanishi et al.	Oct 1998	A
5821705	Caporaso et al.	Oct 1998	A
5825845	Blair et al.	Oct 1998	A
5841237	Alton	Nov 1998	A
5846043	Spath	Dec 1998	A
5851182	Sahadevan	Dec 1998	A
5866912	Slater et al.	Feb 1999	A
5874811	Finlan et al.	Feb 1999	A
5895926	Britton et al.	Apr 1999	A
5920601	Nigg et al.	Jul 1999	A
5929458	Nemezawa et al.	Jul 1999	A
5963615	Egley et al.	Oct 1999	A
5986274	Akiyama et al.	Nov 1999	A
5993373	Nonaka et al.	Nov 1999	A
6008499	Hiramoto et al.	Dec 1999	A
6034377	Pu	Mar 2000	A
6057655	Jongen	May 2000	A
6061426	Linders et al.	May 2000	A
6064807	Arai et al.	May 2000	A
6066851	Madono et al.	May 2000	A
6080992	Nonaka et al.	Jun 2000	A
6087670	Hiramoto et al.	Jun 2000	A
6087672	Matsuda et al.	Jul 2000	A
6094760	Nonaka et al.	Aug 2000	A
6118848	Reiffel	Sep 2000	A
6140021	Nakasuji et al.	Oct 2000	A
6144875	Sachweikard et al.	Nov 2000	A
6158708	Egley et al.	Dec 2000	A
6207952	Kan et al.	Mar 2001	B1
6219403	Nishihara	Apr 2001	B1
6222905	Yoda et al.	Apr 2001	B1
6241671	Ritter et al.	Jun 2001	B1
6246066	Yuehu	Jun 2001	B1
6256591	Yoda et al.	Jul 2001	B1
6265837	Akiyama et al.	Jul 2001	B1
6268610	Pu	Jul 2001	B1
6278239	Caporasco et al.	Aug 2001	B1
6279579	Riaziat et al.	Aug 2001	B1
6307914	Kunieda et al.	Oct 2001	B1
6316776	Hiramoto et al.	Nov 2001	B1
6366021	Meddaugh et al.	Apr 2002	B1
6369585	Yao	Apr 2002	B2
6380545	Yan	Apr 2002	B1
6407505	Bertsche	Jun 2002	B1
6417634	Bergstrom	Jul 2002	B1
6433336	Jongen et al.	Aug 2002	B1
6433349	Akiyama et al.	Aug 2002	B2
6433494	Kulish et al.	Aug 2002	B1
6441569	Janzow	Aug 2002	B1
6443349	Van Der Burg	Sep 2002	B1
6459769	Cosman	Oct 2002	B1
6465957	Whitham et al.	Oct 2002	B1
6472834	Hiramoto et al.	Oct 2002	B2
6476403	Dolinskii et al.	Nov 2002	B1
6492922	New	Dec 2002	B1
6493424	Whitham	Dec 2002	B2
6498444	Hanna et al.	Dec 2002	B1
6501981	Schweikard et al.	Dec 2002	B1
6519316	Collins	Feb 2003	B1
6593696	Ding et al.	Jul 2003	B2
6594336	Nishizawa et al.	Jul 2003	B2
6600164	Badura et al.	Jul 2003	B1
6617598	Matsuda	Sep 2003	B1
6621889	Mostafavi	Sep 2003	B1
6630675	Ghelmansarai	Oct 2003	B2
6639234	Badura et al.	Oct 2003	B1
6646383	Bertsche et al.	Nov 2003	B2
6670618	Hartmann et al.	Dec 2003	B1
6683162	Scheinberg et al.	Jan 2004	B2
6683318	Haberer et al.	Jan 2004	B1
6683426	Kleeven	Jan 2004	B1
6693283	Eickhoff et al.	Feb 2004	B2
6710362	Kraft et al.	Mar 2004	B2
6713773	Lyons et al.	Mar 2004	B1
6713976	Zumoto et al.	Mar 2004	B1
6714620	Caflisch et al.	Mar 2004	B2
6717162	Jongen	Apr 2004	B1
6736831	Hartmann et al.	May 2004	B1
6745072	Badura et al.	Jun 2004	B1
6769806	Moyers	Aug 2004	B2
6774383	Norimine et al.	Aug 2004	B2
6777689	Nelson	Aug 2004	B2
6777700	Yanagisawa et al.	Aug 2004	B2
6780149	Schulte	Aug 2004	B1
6792078	Kato et al.	Sep 2004	B2
6799068	Hartmann et al.	Sep 2004	B1
6800866	Amemiya et al.	Oct 2004	B2
6803591	Muramatsu et al.	Oct 2004	B2
6813336	Siochi	Nov 2004	B1
6814694	Pedroni	Nov 2004	B1
6819743	Kato et al.	Nov 2004	B2
6822244	Beloussov et al.	Nov 2004	B2
6823045	Kato et al.	Nov 2004	B2
6853142	Chistyakov	Feb 2005	B2
6853703	Svatos et al.	Feb 2005	B2
6864770	Nemoto et al.	Mar 2005	B2
6865254	Nafstadius	Mar 2005	B2
6873123	Marchand et al.	Mar 2005	B2
6878951	Ma	Apr 2005	B2
6891177	Kraft	May 2005	B1
6891924	Yoda et al.	May 2005	B1
6894300	Reimoser et al.	May 2005	B2
6897451	Kaercher et al.	May 2005	B2
6914396	Symons et al.	Jul 2005	B1
6931100	Kato et al.	Aug 2005	B2
6936832	Norimine et al.	Aug 2005	B2
6953943	Yanagisawa et al.	Oct 2005	B2
6965116	Wagner et al.	Nov 2005	B1
6969194	Nafstadius	Nov 2005	B1
6979832	Yanagisawa et al.	Dec 2005	B2
6984835	Harada	Jan 2006	B2
6992312	Yanagisawa et al.	Jan 2006	B2
6993112	Hesse	Jan 2006	B2
6998604	Nishizawa et al.	Feb 2006	B2
7008105	Amann et al.	Mar 2006	B2
7011447	Moyers	Mar 2006	B2
7012267	Moriyama et al.	Mar 2006	B2
7014361	Ein-Gal	Mar 2006	B1
7026636	Yanagisawa et al.	Apr 2006	B2
7038403	Mastrangeli et al.	May 2006	B2
7041479	Swartz et al.	May 2006	B2
7045781	Adamec et al.	May 2006	B2
7049613	Yanagisawa et al.	May 2006	B2
7053389	Yanagisawa et al.	May 2006	B2
7054801	Sakamoto et al.	May 2006	B2
7060997	Norimine et al.	Jun 2006	B2
7071479	Yanagisawa et al.	Jul 2006	B2
7073508	Moyers	Jul 2006	B2
7081619	Bashkirov et al.	Jul 2006	B2
7084410	Beloussov et al.	Aug 2006	B2
7091478	Haberer	Aug 2006	B2
7095823	Topolnjak	Aug 2006	B2
7102144	Matsuda et al.	Sep 2006	B2
7122811	Matsuda et al.	Oct 2006	B2
7122966	Norling et al.	Oct 2006	B2
7122978	Nakanishi et al.	Oct 2006	B2
7135678	Wang et al.	Nov 2006	B2
7138771	Bechthold et al.	Nov 2006	B2
7154107	Yanagisawa et al.	Dec 2006	B2
7154108	Tadokoro et al.	Dec 2006	B2
7154991	Earnst et al.	Dec 2006	B2
7162005	Bjorkholm	Jan 2007	B2
7173264	Moriyama et al.	Feb 2007	B2
7173265	Miller et al.	Feb 2007	B2
7173385	Caporasco et al.	Feb 2007	B2
7186991	Kato et al.	Mar 2007	B2
7193227	Hiramoto et al.	Mar 2007	B2
7199382	Rigney et al.	Apr 2007	B2
7208748	Sliski et al.	Apr 2007	B2
7212608	Nagamine et al.	May 2007	B2
7212609	Nagamine et al.	May 2007	B2
7221733	Takai et al.	May 2007	B1
7227161	Matsuda et al.	Jun 2007	B2
7247869	Tadokoro et al.	Jul 2007	B2
7257191	Sommer	Aug 2007	B2
7259529	Tanaka	Aug 2007	B2
7262424	Moriyama et al.	Aug 2007	B2
7262565	Fujisawa	Aug 2007	B2
7268358	Ma et al.	Sep 2007	B2
7274018	Adamec et al.	Sep 2007	B2
7280633	Cheng et al.	Oct 2007	B2
7295649	Johnsen	Nov 2007	B2
7297967	Yanagisawa et al.	Nov 2007	B2
7301162	Matsuda et al.	Nov 2007	B2
7307264	Brusasco et al.	Dec 2007	B2
7317192	Ma	Jan 2008	B2
7318805	Schweikard et al.	Jan 2008	B2
7319231	Moriyama et al.	Jan 2008	B2
7319336	Bauer et al.	Jan 2008	B2
7331713	Moyers	Feb 2008	B2
7332880	Ina et al.	Feb 2008	B2
7345291	Kats	Mar 2008	B2
7345292	Moriyama et al.	Mar 2008	B2
7348557	Armit	Mar 2008	B2
7348579	Pedroni	Mar 2008	B2
7351988	Naumann et al.	Apr 2008	B2
7355189	Yanagisawa et al.	Apr 2008	B2
7368740	Beloussov et al.	May 2008	B2
7372053	Yamashita et al.	May 2008	B2
7378672	Harada	May 2008	B2
7381979	Yamashita et al.	Jun 2008	B2
7386099	Kasper et al.	Jun 2008	B1
7397054	Natori et al.	Jul 2008	B2
7397901	Johnsen	Jul 2008	B1
7398309	Baumann et al.	Jul 2008	B2
7402822	Guertin et al.	Jul 2008	B2
7402823	Guertin et al.	Jul 2008	B2
7402824	Guertin et al.	Jul 2008	B2
7402963	Sliski	Jul 2008	B2
7405407	Hiramoto et al.	Jul 2008	B2
7425717	Matsuda et al.	Sep 2008	B2
7432516	Peggs et al.	Oct 2008	B2
7439528	Nishiuchi et al.	Oct 2008	B2
7446328	Rigney et al.	Nov 2008	B2
7446490	Jongen et al.	Nov 2008	B2
7449701	Fujimaki et al.	Nov 2008	B2
7453076	Welch et al.	Nov 2008	B2
7465944	Ueno et al.	Dec 2008	B2
7466085	Nutt	Dec 2008	B2
7468506	Rogers et al.	Dec 2008	B2
7473913	Hermann et al.	Jan 2009	B2
7476867	Fritsch et al.	Jan 2009	B2
7476883	Nutt	Jan 2009	B2
7482606	Groezinger et al.	Jan 2009	B2
7492556	Atkins et al.	Feb 2009	B2
7507975	Mohr	Mar 2009	B2
7525104	Harada	Apr 2009	B2
7531818	Brahme	May 2009	B2
7541905	Antaya	Jun 2009	B2
7547901	Guertin et al.	Jun 2009	B2
7554096	Ward et al.	Jun 2009	B2
7554097	Ward et al.	Jun 2009	B2
7554275	Amaldi	Jun 2009	B2
7555103	Johnsen	Jun 2009	B2
7557358	Ward et al.	Jul 2009	B2
7557359	Ward et al.	Jul 2009	B2
7557360	Ward et al.	Jul 2009	B2
7557361	Ward et al.	Jul 2009	B2
7560698	Rietzel	Jul 2009	B2
7560715	Pedroni	Jul 2009	B2
7560717	Matsuda et al.	Jul 2009	B2
7567694	Lu et al.	Jul 2009	B2
7574251	Lu et al.	Aug 2009	B2
7576499	Caporaso et al.	Aug 2009	B2
7579603	Birgy et al.	Aug 2009	B2
7579610	Grozinger et al.	Aug 2009	B2
7582866	Furuhashi et al.	Sep 2009	B2
7582885	Katagiri et al.	Sep 2009	B2
7582886	Trbojevic	Sep 2009	B2
7586112	Chiba et al.	Sep 2009	B2
7598497	Yamamoto et al.	Oct 2009	B2
7609009	Tanaka et al.	Oct 2009	B2
7609809	Kapatoes et al.	Oct 2009	B2
7609811	Siljamaki et al.	Oct 2009	B1
7615942	Sanders et al.	Nov 2009	B2
7626347	Sliski	Dec 2009	B2
7629598	Harada	Dec 2009	B2
7629599	Hashimoto	Dec 2009	B2
7639853	Olivera et al.	Dec 2009	B2
7639854	Schnarr et al.	Dec 2009	B2
7643661	Ruchala et al.	Jan 2010	B2
7656258	Antaya et al.	Feb 2010	B1
7659521	Pedroni	Feb 2010	B2
7659528	Uematsu	Feb 2010	B2
7668291	Nord et al.	Feb 2010	B2
7672429	Urano et al.	Mar 2010	B2
7679049	Rietzel	Mar 2010	B2
7679073	Urano et al.	Mar 2010	B2
7682078	Rietzel	Mar 2010	B2
7692166	Muraki et al.	Apr 2010	B2
7692168	Moriyama et al.	Apr 2010	B2
7696499	Miller et al.	Apr 2010	B2
7696847	Antaya	Apr 2010	B2
7701677	Schultz et al.	Apr 2010	B2
7709818	Matsuda et al.	May 2010	B2
7710051	Caporaso et al.	May 2010	B2
7718982	Sliski	May 2010	B2
7723036	Racila et al.	May 2010	B2
7728311	Gall	Jun 2010	B2
7746978	Cheng et al.	Jun 2010	B2
7755068	Ma et al.	Jul 2010	B2
7755305	Umezawa et al.	Jul 2010	B2
7759642	Nir	Jul 2010	B2
7763867	Birgy et al.	Jul 2010	B2
7763873	Flynn et al.	Jul 2010	B2
7767988	Kaiser et al.	Aug 2010	B2
7770231	Prater et al.	Aug 2010	B2
7772577	Saito et al.	Aug 2010	B2
7773723	Nord et al.	Aug 2010	B2
7773788	Lu et al.	Aug 2010	B2
7778488	Nord et al.	Aug 2010	B2
7783010	Clayton	Aug 2010	B2
7784124	Long et al.	Aug 2010	B2
7784127	Kuro et al.	Aug 2010	B2
7786433	Gunzert-Marx et al.	Aug 2010	B2
7786451	Ward et al.	Aug 2010	B2
7786452	Ward et al.	Aug 2010	B2
7789560	Moyers	Sep 2010	B2
7791051	Beloussov et al.	Sep 2010	B2
7796731	Nord et al.	Sep 2010	B2
7801269	Cravens et al.	Sep 2010	B2
7801270	Nord et al.	Sep 2010	B2
7801988	Baumann et al.	Sep 2010	B2
7807982	Nishiuchi et al.	Oct 2010	B2
7809107	Nord et al.	Oct 2010	B2
7812319	Diehl et al.	Oct 2010	B2
7812326	Grozinger et al.	Oct 2010	B2
7816657	Hansmann et al.	Oct 2010	B2
7817778	Nord et al.	Oct 2010	B2
7817836	Chao et al.	Oct 2010	B2
7818045	Rietzel	Oct 2010	B2
7825388	Nihongi et al.	Nov 2010	B2
7826593	Svensson et al.	Nov 2010	B2
7834334	Grozinger et al.	Nov 2010	B2
7834336	Boeh et al.	Nov 2010	B2
7835494	Nord et al.	Nov 2010	B2
7835502	Spence et al.	Nov 2010	B2
7839972	Ruchala et al.	Nov 2010	B2
7839973	Nord et al.	Nov 2010	B2
7848488	Mansfield	Dec 2010	B2
7857756	Warren et al.	Dec 2010	B2
7858592	Shames et al.	Dec 2010	B2
7860216	Jongen et al.	Dec 2010	B2
7860550	Saracen et al.	Dec 2010	B2
7868301	Diehl	Jan 2011	B2
7875846	Gunzert-Marx et al.	Jan 2011	B2
7875861	Huttenberger et al.	Jan 2011	B2
7875868	Moriyama et al.	Jan 2011	B2
7881431	Aoi et al.	Feb 2011	B2
7894574	Nord et al.	Feb 2011	B1
7903781	Foland et al.	Mar 2011	B2
7906769	Blasche et al.	Mar 2011	B2
7907987	Dempsey	Mar 2011	B2
7914734	Livingston	Mar 2011	B2
7919765	Timmer	Apr 2011	B2
7920040	Antaya et al.	Apr 2011	B2
7920675	Lomax et al.	Apr 2011	B2
7928415	Bert et al.	Apr 2011	B2
7934869	Ivanov et al.	May 2011	B2
7939809	Balakin	May 2011	B2
7940881	Jongen et al.	May 2011	B2
7940894	Balakin	May 2011	B2
7943913	Balakin	May 2011	B2
7947969	Pu	May 2011	B2
7949096	Cheng et al.	May 2011	B2
7950587	Henson et al.	May 2011	B2
7953205	Balakin	May 2011	B2
7957508	Brooks et al.	Jun 2011	B2
7960710	Kruip et al.	Jun 2011	B2
7961844	Takeda et al.	Jun 2011	B2
7977648	Westerly et al.	Jul 2011	B2
7977656	Fujimaki et al.	Jul 2011	B2
7977657	Flynn et al.	Jul 2011	B2
7982198	Nishiuchi et al.	Jul 2011	B2
7982416	Tanaka et al.	Jul 2011	B2
7984715	Moyers	Jul 2011	B2
7986768	Nord et al.	Jul 2011	B2
7987053	Schaffner	Jul 2011	B2
7989785	Emhofer et al.	Aug 2011	B2
7990524	Jureller et al.	Aug 2011	B2
7997553	Sloan et al.	Aug 2011	B2
8002466	Von Neubeck et al.	Aug 2011	B2
8003964	Stark et al.	Aug 2011	B2
8009803	Nord et al.	Aug 2011	B2
8009804	Siljamaki et al.	Aug 2011	B2
8016336	Messinger et al.	Sep 2011	B2
8039822	Rietzel	Oct 2011	B2
8041006	Boyden et al.	Oct 2011	B2
8044364	Yamamoto	Oct 2011	B2
8045679	Balakin	Oct 2011	B2
8049187	Tachikawa	Nov 2011	B2
8053508	Korkut et al.	Nov 2011	B2
8053739	Rietzel	Nov 2011	B2
8053745	Moore	Nov 2011	B2
8053746	Timmer et al.	Nov 2011	B2
8063381	Tsoupas et al.	Nov 2011	B2
8067748	Balakin	Nov 2011	B2
8069675	Radovinsky et al.	Dec 2011	B2
8071966	Kaiser et al.	Dec 2011	B2
8080801	Safai	Dec 2011	B2
8085899	Nord et al.	Dec 2011	B2
8089054	Balakin	Jan 2012	B2
8090074	Filiberti et al.	Jan 2012	B2
8093564	Balakin	Jan 2012	B2
8093568	Mackie et al.	Jan 2012	B2
8111125	Antaya et al.	Feb 2012	B2
8129694	Balakin	Mar 2012	B2
8129699	Balakin	Mar 2012	B2
8144832	Balakin	Mar 2012	B2
8153989	Tachikawa et al.	Apr 2012	B2
8154001	Flynn et al.	Apr 2012	B2
8163709	Kodym et al.	Apr 2012	B2
8173981	Trbojevic	May 2012	B2
8178859	Balakin	May 2012	B2
8183541	Wilkens et al.	May 2012	B2
8188688	Balakin	May 2012	B2
8189889	Pearlstein et al.	May 2012	B2
8190233	Dempsey	May 2012	B2
8198607	Balakin	Jun 2012	B2
8207656	Baumgartner et al.	Jun 2012	B2
8222613	Tajiri et al.	Jul 2012	B2
8227768	Smick et al.	Jul 2012	B2
8229072	Balakin	Jul 2012	B2
8232536	Harada	Jul 2012	B2
8238513	Ma	Aug 2012	B2
8253121	Gnutzmann et al.	Aug 2012	B2
8254521	Brooks et al.	Aug 2012	B2
8263954	Iwata	Sep 2012	B2
8283645	Guneysel	Oct 2012	B2
8288742	Balakin	Oct 2012	B2
8291717	Radovinsky et al.	Oct 2012	B2
8294127	Tachibana	Oct 2012	B2
8304725	Komuro et al.	Nov 2012	B2
8304750	Preikszas et al.	Nov 2012	B2
8309941	Balakin	Nov 2012	B2
8330132	Guertin et al.	Dec 2012	B2
8334520	Otaka et al.	Dec 2012	B2
8335397	Takane et al.	Dec 2012	B2
8344340	Gall et al.	Jan 2013	B2
8350214	Otaki et al.	Jan 2013	B2
8351571	Brinks et al.	Jan 2013	B2
8354656	Beloussov et al.	Jan 2013	B2
8368038	Balakin	Feb 2013	B2
8368043	Havelange et al.	Feb 2013	B2
8373143	Balakin	Feb 2013	B2
8373145	Balakin	Feb 2013	B2
8373146	Balakin	Feb 2013	B2
8374314	Balakin	Feb 2013	B2
8378299	Frosien	Feb 2013	B2
8378311	Balakin	Feb 2013	B2
8378312	Gordon et al.	Feb 2013	B1
8378321	Balakin	Feb 2013	B2
8382943	Clark	Feb 2013	B2
8384053	Balakin	Feb 2013	B2
8389949	Harada et al.	Mar 2013	B2
8399866	Balakin	Mar 2013	B2
8405042	Honda et al.	Mar 2013	B2
8405056	Amaldi et al.	Mar 2013	B2
8416918	Nord et al.	Apr 2013	B2
8421041	Balakin	Apr 2013	B2
8426833	Trbojevic	Apr 2013	B2
8436323	Iseki et al.	May 2013	B2
8436325	Noda et al.	May 2013	B2
8436327	Balakin	May 2013	B2
8440987	Stephani et al.	May 2013	B2
8445872	Behrens et al.	May 2013	B2
8459714	Pomper et al.	Jun 2013	B2
8461559	Lomax	Jun 2013	B2
8466441	Iwata et al.	Jun 2013	B2
8472583	Star-Lack et al.	Jun 2013	B2
8481951	Jongen et al.	Jul 2013	B2
8483357	Siljamaki et al.	Jul 2013	B2
8487278	Balakin	Jul 2013	B2
8487282	Iseki et al.	Jul 2013	B2
8507195	Richer et al.	Aug 2013	B2
8519365	Balakin	Aug 2013	B2
8415643	Balakin	Sep 2013	B2
8525419	Smith et al.	Sep 2013	B2
8525447	Antaya	Sep 2013	B2
8525448	Tanaka et al.	Sep 2013	B2
8536548	Otani et al.	Sep 2013	B2
8541762	Claereboudt et al.	Sep 2013	B2
8546769	Uno	Oct 2013	B2
8552406	Phaneuf et al.	Oct 2013	B2
8552408	Hanawa et al.	Oct 2013	B2
8558461	Poehlmann-Martins et al.	Oct 2013	B2
8558485	Antaya	Oct 2013	B2
8565377	Robar et al.	Oct 2013	B2
8569717	Balakin	Oct 2013	B2
8575563	Cameron et al.	Nov 2013	B2
8575564	Iwata	Nov 2013	B2
8575579	Moskvin et al.	Nov 2013	B2
8581215	Balakin	Nov 2013	B2
8581218	Fujimoto et al.	Nov 2013	B2
8581523	Gall et al.	Nov 2013	B2
8581525	Antaya et al.	Nov 2013	B2
8586948	Pu et al.	Nov 2013	B2
8598543	Balakin	Dec 2013	B2
8601116	Baumann et al.	Dec 2013	B2
8604454	Guertin et al.	Dec 2013	B2
8613694	Walsh	Dec 2013	B2
8614554	Balakin	Dec 2013	B2
8614612	Antaya et al.	Dec 2013	B2
8618519	Ueda	Dec 2013	B2
8618521	Loo et al.	Dec 2013	B2
8619242	Suzuki	Dec 2013	B2
8624528	Balakin	Jan 2014	B2
8625739	Balakin	Jan 2014	B2
8627822	Balakin	Jan 2014	B2
8632448	Schulte et al.	Jan 2014	B1
8633160	Belmares et al.	Jan 2014	B2
8637818	Balakin	Jan 2014	B2
8637839	Brauer	Jan 2014	B2
8642978	Balakin	Feb 2014	B2
8643314	Touchi	Feb 2014	B2
8644571	Schulte et al.	Feb 2014	B1
8653314	Pelati et al.	Feb 2014	B2
8653473	Yajima	Feb 2014	B2
8657354	Pomper et al.	Feb 2014	B2
8657743	Rietzel et al.	Feb 2014	B2
8688197	Balakin	Apr 2014	B2
8702578	Fahrig et al.	Apr 2014	B2
8710462	Balakin	Apr 2014	B2
8712011	Robar et al.	Apr 2014	B2
8716663	Brusasco et al.	May 2014	B2
8718231	Balakin	May 2014	B2
8735848	Asaba	May 2014	B2
8748852	Jongen	Jun 2014	B2
8750453	Cheng et al.	Jun 2014	B2
8754386	Iwata	Jun 2014	B2
8766217	Balakin	Jul 2014	B2
8766218	Jongen	Jul 2014	B2
8771754	Hallahan	Jul 2014	B2
8791435	Balakin	Jul 2014	B2
8791656	Zwart et al.	Jul 2014	B1
8796648	Fujimoto et al.	Aug 2014	B2
8822965	Asaba	Sep 2014	B2
8835885	Ogasawara	Sep 2014	B2
8847179	Fujitaka et al.	Sep 2014	B2
8859264	Bert et al.	Oct 2014	B2
8866109	Sasai	Oct 2014	B2
8890097	Iwata	Nov 2014	B2
8896239	Balakin	Nov 2014	B2
8897857	Tome et al.	Nov 2014	B2
8901509	Balakin	Dec 2014	B2
8901520	Tachibana et al.	Dec 2014	B2
8907309	Spotts	Dec 2014	B2
8907311	Gall et al.	Dec 2014	B2
8907594	Begg et al.	Dec 2014	B2
8916838	Claereboudt et al.	Dec 2014	B2
8916841	Totake et al.	Dec 2014	B2
8916843	Gall et al.	Dec 2014	B2
8927946	Behrens et al.	Jan 2015	B2
8927950	Gall	Jan 2015	B2
8933650	O'Neal, III et al.	Jan 2015	B2
8941083	Stark et al.	Jan 2015	B2
8941084	Balakin	Jan 2015	B2
8941086	Yajima	Jan 2015	B2
8947021	Tsutsui	Feb 2015	B2
8948341	Beckman	Feb 2015	B2
8952343	Stephani et al.	Feb 2015	B2
8952634	Sliski et al.	Feb 2015	B2
8957396	Balakin	Feb 2015	B2
8963111	Claereboudt et al.	Feb 2015	B2
8963112	Balakin	Feb 2015	B1
8964936	Brooks et al.	Feb 2015	B2
8969834	Balakin	Mar 2015	B2
8970137	Gall et al.	Mar 2015	B2
8971363	Levecq et al.	Mar 2015	B2
8975600	Balakin	Mar 2015	B2
8975602	Huber et al.	Mar 2015	B2
8975836	Bromberg et al.	Mar 2015	B2
8986186	Zhang et al.	Mar 2015	B2
8993522	Vidyasagar et al.	Mar 2015	B2
9006693	Sasai	Apr 2015	B2
9007740	Touchi	Apr 2015	B2
9012832	Bert et al.	Apr 2015	B2
9012866	Benna et al.	Apr 2015	B2
9012873	Fujimoto et al.	Apr 2015	B2
9018601	Balakin	Apr 2015	B2
9018603	Loo et al.	Apr 2015	B2
9024256	Ruan et al.	May 2015	B2
9029760	Beddar et al.	May 2015	B2
9044600	Balakin	Jun 2015	B2
9056199	Balakin	Jun 2015	B2
9058910	Balakin	Jun 2015	B2
9060998	Stockfleth	Jun 2015	B2
9061142	Vilsmeier	Jun 2015	B2
9061143	Sasai et al.	Jun 2015	B2
9084887	Schulte et al.	Jul 2015	B2
9084890	Iwata	Jul 2015	B2
9089696	Verhaegen et al.	Jul 2015	B2
9093209	Jongen	Jul 2015	B2
9095040	Balakin	Jul 2015	B2
9108050	Bula et al.	Aug 2015	B2
9114253	Dempsey	Aug 2015	B2
9142385	Iwanaga	Sep 2015	B1
9155186	Zwart et al.	Oct 2015	B2
9155908	Meltsner et al.	Oct 2015	B2
9185789	Zwart et al.	Nov 2015	B2
9186525	Prieels et al.	Nov 2015	B2
9188685	Takayanagi et al.	Nov 2015	B2
9196082	Pearlstein et al.	Nov 2015	B2
9220920	Schulte et al.	Dec 2015	B2
9220923	Yajima et al.	Dec 2015	B2
9237640	Abs et al.	Jan 2016	B2
9237642	Kleeven	Jan 2016	B2
9245336	Mallya et al.	Jan 2016	B2
9254396	Mihaylov	Feb 2016	B2
9259155	Bharat et al.	Feb 2016	B2
9271385	Verbruggen et al.	Feb 2016	B2
9283406	Prieels	Mar 2016	B2
9283407	Benna et al.	Mar 2016	B2
9289140	Ross et al.	Mar 2016	B2
9289624	Jongen	Mar 2016	B2
9297912	Campbell et al.	Mar 2016	B2
9301384	Zwart et al.	Mar 2016	B2
9302121	Totake et al.	Apr 2016	B2
9305742	Aptaker et al.	Apr 2016	B2
9324468	Mansfield et al.	Apr 2016	B2
9355784	Abs	May 2016	B2
9364688	Pausch et al.	Jun 2016	B2
9370089	Ungaro et al.	Jun 2016	B2
9381379	Beckman	Jul 2016	B2
9393443	Fujimoto et al.	Jul 2016	B2
9417302	Kuhn	Aug 2016	B2
9451688	Jongen	Sep 2016	B2
9451689	Tsutsui	Sep 2016	B2
9452300	Anferov	Sep 2016	B2
9452301	Gall et al.	Sep 2016	B2
9468608	Lin et al.	Oct 2016	B2
9492684	Takayanagi et al.	Nov 2016	B2
9776017	Flynn et al.	Oct 2017	B2
20010022502	Akiyama et al.	Sep 2001	A1
20020058007	Scheinberg et al.	May 2002	A1
20020101959	Kato et al.	Aug 2002	A1
20020172317	Maksimchuk et al.	Nov 2002	A1
20030048080	Amemiya et al.	Mar 2003	A1
20030125622	Schweikard et al.	Jul 2003	A1
20030136924	Kraft et al.	Jul 2003	A1
20030152197	Moyers	Aug 2003	A1
20030163015	Yanagisawa et al.	Aug 2003	A1
20030183779	Norimine et al.	Oct 2003	A1
20030234369	Glukhoy	Dec 2003	A1
20040000650	Yanagisawa et al.	Jan 2004	A1
20040017888	Seppi et al.	Jan 2004	A1
20040056212	Yanagisawa et al.	Mar 2004	A1
20040061077	Muramatsu et al.	Apr 2004	A1
20040061078	Muramatsu et al.	Apr 2004	A1
20040085023	Chistyakov	May 2004	A1
20040098445	Baumann et al.	May 2004	A1
20040111134	Muramatsu et al.	Jun 2004	A1
20040118081	Reimoser et al.	Jun 2004	A1
20040149934	Yanagisawa et al.	Aug 2004	A1
20040155206	Marchand et al.	Aug 2004	A1
20040159795	Kaercher et al.	Aug 2004	A1
20040164254	Beloussov et al.	Aug 2004	A1
20040173763	Moriyama et al.	Sep 2004	A1
20040174958	Moriyama et al.	Sep 2004	A1
20040183033	Moriyama et al.	Sep 2004	A1
20040183035	Yanagisawa et al.	Sep 2004	A1
20040190680	Chang	Sep 2004	A1
20040200982	Moriyama et al.	Oct 2004	A1
20040200983	Fujimaki et al.	Oct 2004	A1
20040213381	Harada	Oct 2004	A1
20040227104	Matsuda et al.	Nov 2004	A1
20040232356	Norimine et al.	Nov 2004	A1
20040240626	Moyers	Dec 2004	A1
20050029472	Ueno et al.	Feb 2005	A1
20050051740	Yanagisawa et al.	Mar 2005	A1
20050058245	Ein-Gal	Mar 2005	A1
20050072940	Beloussov et al.	Apr 2005	A1
20050079235	Stockfleth	Apr 2005	A1
20050087700	Tadokoro et al.	Apr 2005	A1
20050089141	Brown	Apr 2005	A1
20050099145	Nishiuchi et al.	May 2005	A1
20050113327	Roiz et al.	May 2005	A1
20050127306	Yanagisawa et al.	Jun 2005	A1
20050139787	Chiba et al.	Jun 2005	A1
20050161618	Pedroni	Jul 2005	A1
20050167616	Yanagisawa et al.	Aug 2005	A1
20050184686	Caporasco et al.	Aug 2005	A1
20050186179	Harats et al.	Aug 2005	A1
20050205806	Tadokoro et al.	Sep 2005	A1
20050228255	Saracen et al.	Oct 2005	A1
20050231138	Nakanishi et al.	Oct 2005	A1
20050234327	Saracen et al.	Oct 2005	A1
20050247890	Norimine et al.	Nov 2005	A1
20050259779	Abraham-Fuchs et al.	Nov 2005	A1
20060017015	Sliski et al.	Jan 2006	A1
20060067468	Rietzel	Mar 2006	A1
20060126792	Li	Jun 2006	A1
20060127879	Fuccione	Jun 2006	A1
20060145088	Ma	Jul 2006	A1
20060175991	Fujisawa	Aug 2006	A1
20060192146	Yanagisawa et al.	Aug 2006	A1
20060204478	Harats et al.	Sep 2006	A1
20060219948	Ueno et al.	Oct 2006	A1
20060284562	Hruby et al.	Dec 2006	A1
20070001128	Sliski et al.	Jan 2007	A1
20070013273	Albert et al.	Jan 2007	A1
20070014654	Haverfield et al.	Jan 2007	A1
20070018120	Beloussov et al.	Jan 2007	A1
20070023699	Yamashita et al.	Feb 2007	A1
20070029510	Hermann et al.	Feb 2007	A1
20070031337	Schulte	Feb 2007	A1
20070034812	Ma et al.	Feb 2007	A1
20070051904	Kaiser et al.	Mar 2007	A1
20070053484	Chiba et al.	Mar 2007	A1
20070059387	Stockfleth	Mar 2007	A1
20070075273	Birgy et al.	Apr 2007	A1
20070083101	Rietzel	Apr 2007	A1
20070092812	Caporasco et al.	Apr 2007	A1
20070061937	Gall	May 2007	A1
20070108922	Amaldi	May 2007	A1
20070114464	Birgy et al.	May 2007	A1
20070114471	Birgy et al.	May 2007	A1
20070114945	Mattaboni et al.	May 2007	A1
20070145916	Caporasco et al.	Jun 2007	A1
20070171015	Antaya	Jul 2007	A1
20070181519	Khoshnevis	Aug 2007	A1
20070217575	Kaiser et al.	Sep 2007	A1
20070262269	Trbojevic	Nov 2007	A1
20070284548	Kaiser et al.	Dec 2007	A1
20080023644	Pedroni	Jan 2008	A1
20080029706	Kaiser et al.	Feb 2008	A1
20080031414	Coppens	Feb 2008	A1
20080061241	Rietzel	Mar 2008	A1
20080063147	Juschka et al.	Mar 2008	A1
20080073591	Mohr	Mar 2008	A1
20080078942	Rietzel	Apr 2008	A1
20080093567	Gall	Apr 2008	A1
20080123816	Mori et al.	May 2008	A1
20080131419	Roiz et al.	Jun 2008	A1
20080159478	Keall	Jul 2008	A1
20080179544	Kaiser et al.	Jul 2008	A1
20080191142	Pedroni	Aug 2008	A1
20080191152	Grozinger et al.	Aug 2008	A1
20080205599	Hashimoto	Aug 2008	A1
20080218102	Sliski	Sep 2008	A1
20080219407	Kaiser et al.	Sep 2008	A1
20080219410	Gunzert-Marx et al.	Sep 2008	A1
20080219411	Gunzert-Marx et al.	Sep 2008	A1
20080237494	Beloussov et al.	Oct 2008	A1
20080237495	Grozinger et al.	Oct 2008	A1
20080267349	Rietzel	Oct 2008	A1
20080270517	Baumann et al.	Oct 2008	A1
20080272284	Rietzel	Nov 2008	A1
20080290299	Hansmann et al.	Nov 2008	A1
20080298550	Otto	Dec 2008	A1
20080301872	Fahrig et al.	Dec 2008	A1
20080315111	Sommer	Dec 2008	A1
20090008575	Okazaki et al.	Jan 2009	A1
20090032742	Kaiser et al.	Feb 2009	A1
20090050819	Ma et al.	Feb 2009	A1
20090060130	Wilkens et al.	Mar 2009	A1
20090065717	Kaiser et al.	Mar 2009	A1
20090069640	Rietzel et al.	Mar 2009	A1
20090077209	Schneider	Mar 2009	A1
20090096179	Stark et al.	Apr 2009	A1
20090098145	Mata et al.	Apr 2009	A1
20090101833	Emhofer et al.	Apr 2009	A1
20090114847	Grozinger et al.	May 2009	A1
20090140671	O'Neal et al.	Jun 2009	A1
20090140672	Gall	Jun 2009	A1
20090175414	Messinger et al.	Jul 2009	A1
20090189095	Flynn et al.	Jul 2009	A1
20090200483	Gall et al.	Aug 2009	A1
20090230327	Rietzel	Sep 2009	A1
20090234237	Ross et al.	Sep 2009	A1
20090242789	Tachikawa	Oct 2009	A1
20090261275	Rietzel	Oct 2009	A1
20090274269	Foland et al.	Nov 2009	A1
20090296885	Boeh et al.	Dec 2009	A1
20090309046	Balakin	Dec 2009	A1
20090309047	Gunzert-Marx et al.	Dec 2009	A1
20090309520	Balakin	Dec 2009	A1
20090314960	Balakin	Dec 2009	A1
20090314961	Balakin	Dec 2009	A1
20090321656	Rietzel et al.	Dec 2009	A1
20100006106	Balakin	Jan 2010	A1
20100006770	Balakin	Jan 2010	A1
20100008466	Balakin	Jan 2010	A1
20100014639	Balakin	Jan 2010	A1
20100014640	Balakin	Jan 2010	A1
20100020932	Yi	Jan 2010	A1
20100027745	Balakin	Feb 2010	A1
20100038552	Trbojevic	Feb 2010	A1
20100045213	Sliski et al.	Feb 2010	A1
20100046697	Balakin	Feb 2010	A1
20100046713	Nord	Feb 2010	A1
20100060209	Balakin	Mar 2010	A1
20100090122	Balakin	Apr 2010	A1
20100091948	Balakin	Apr 2010	A1
20100126964	Smith et al.	May 2010	A1
20100127184	Balakin	May 2010	A1
20100128846	Balakin	May 2010	A1
20100133444	Balakin	Jun 2010	A1
20100133446	Balakin	Jun 2010	A1
20100141183	Balakin	Jun 2010	A1
20100166150	Perkins et al.	Jul 2010	A1
20100171045	Guneysel	Jul 2010	A1
20100171447	Balakin	Jul 2010	A1
20100176309	Mackie et al.	Jul 2010	A1
20100207552	Balakin	Aug 2010	A1
20100230617	Gall	Sep 2010	A1
20100230620	Tsoupas et al.	Sep 2010	A1
20100252754	Brown	Oct 2010	A1
20100264327	Bonig et al.	Oct 2010	A1
20100266100	Balakin	Oct 2010	A1
20100288945	Gnutzmann et al.	Nov 2010	A1
20100296534	Levecq et al.	Nov 2010	A1
20100308235	Sliski	Dec 2010	A1
20100320404	Tanke	Dec 2010	A1
20100327187	Beloussov et al.	Dec 2010	A1
20110006214	Bonig	Jan 2011	A1
20110009736	Maltz et al.	Jan 2011	A1
20110011729	Poehlmann-Martins et al.	Jan 2011	A1
20110027853	Bert et al.	Feb 2011	A1
20110047469	Baumann et al.	Feb 2011	A1
20110049396	Furth	Mar 2011	A1
20110051891	O'Connor et al.	Mar 2011	A1
20110101236	Cameron et al.	May 2011	A1
20110118529	Balakin	May 2011	A1
20110118531	Balakin	May 2011	A1
20110124976	Sabczynski et al.	May 2011	A1
20110127443	Comer et al.	Jun 2011	A1
20110147608	Balakin	Jun 2011	A1
20110150180	Balakin	Jun 2011	A1
20110166219	Stockfleth	Jul 2011	A1
20110180720	Balakin	Jul 2011	A1
20110180731	Welsh	Jul 2011	A1
20110182410	Balakin	Jul 2011	A1
20110186720	Jongen et al.	Aug 2011	A1
20110196223	Balakin	Aug 2011	A1
20110204262	Pu et al.	Aug 2011	A1
20110214588	Grubling et al.	Sep 2011	A1
20110218430	Balakin	Sep 2011	A1
20110220794	Censor et al.	Sep 2011	A1
20110220798	Baurichter et al.	Sep 2011	A1
20110231147	Takayanagi et al.	Sep 2011	A1
20110233423	Balakin	Sep 2011	A1
20110238440	Leuschner	Sep 2011	A1
20110248188	Brusasco et al.	Oct 2011	A1
20110278477	Balakin	Nov 2011	A1
20110284757	Butuceanu et al.	Nov 2011	A1
20110284760	Balakin	Nov 2011	A1
20110285327	Begg et al.	Nov 2011	A1
20110297850	Claereboudt et al.	Dec 2011	A1
20110299657	Havelange et al.	Dec 2011	A1
20110299919	Stark	Dec 2011	A1
20110306870	Kuhn	Dec 2011	A1
20110313232	Balakin	Dec 2011	A1
20120001085	Fujimoto et al.	Jan 2012	A1
20120043481	Mansfield et al.	Feb 2012	A1
20120043482	Prince	Feb 2012	A1
20120056099	Behrens et al.	Mar 2012	A1
20120056109	Lomax	Mar 2012	A1
20120069961	Pomper et al.	Mar 2012	A1
20120077748	Vidyasagar et al.	Mar 2012	A1
20120099704	Ruan et al.	Apr 2012	A1
20120112092	Pomper et al.	May 2012	A1
20120119114	Brauer	May 2012	A1
20120136194	Zhang et al.	May 2012	A1
20120143051	Balakin	Jun 2012	A1
20120205551	Balakin	Aug 2012	A1
20120207276	Pomper et al.	Aug 2012	A1
20120209109	Balakin	Aug 2012	A1
20120223246	Stephani et al.	Sep 2012	A1
20120224667	Cheng et al.	Sep 2012	A1
20120242257	Balakin	Sep 2012	A1
20120248325	Balakin	Oct 2012	A1
20120256103	Luzzara	Oct 2012	A1
20120264998	Fujitaka et al.	Oct 2012	A1
20120267543	Noda et al.	Oct 2012	A1
20120267544	Ueda	Oct 2012	A1
20120273666	Bert et al.	Nov 2012	A1
20120280150	Jongen	Nov 2012	A1
20120303384	Stepaniak et al.	Nov 2012	A1
20120313003	Trbojevic	Dec 2012	A1
20120326722	Weinberg et al.	Dec 2012	A1
20130001432	Jongen	Jan 2013	A1
20130043403	Gordon et al.	Feb 2013	A1
20130053616	Gall	Feb 2013	A1
20130053617	Pu et al.	Feb 2013	A1
20130068938	Heese	Mar 2013	A1
20130072743	Fieres et al.	Mar 2013	A1
20130072744	Moskvin et al.	Mar 2013	A1
20130086500	Kane et al.	Apr 2013	A1
20130090549	Meltsner et al.	Apr 2013	A1
20130108014	Tome et al.	May 2013	A1
20130127375	Sliski	May 2013	A1
20130131424	Sliski	May 2013	A1
20130131433	Katscher et al.	May 2013	A1
20130150647	Chen et al.	Jun 2013	A1
20130163723	Tacke	Jun 2013	A1
20130187060	Jongen	Jul 2013	A1
20130208867	Beckman	Aug 2013	A1
20130209450	Cohen et al.	Aug 2013	A1
20130211482	Piipponen	Aug 2013	A1
20130217946	Balakin	Aug 2013	A1
20130217948	Mihaylov	Aug 2013	A1
20130217950	Partanen et al.	Aug 2013	A1
20130218009	Balakin	Aug 2013	A1
20130221213	Takayanagi et al.	Aug 2013	A1
20130237425	Leigh et al.	Sep 2013	A1
20130237822	Gross et al.	Sep 2013	A1
20130243722	Basile et al.	Sep 2013	A1
20130245113	Stockfleth	Sep 2013	A1
20130259335	Mallya et al.	Oct 2013	A1
20130267756	Totake et al.	Oct 2013	A1
20130277569	Behrens et al.	Oct 2013	A1
20130299721	Sasai	Nov 2013	A1
20130303824	Stephani et al.	Nov 2013	A1
20130324479	Zhang et al.	Dec 2013	A1
20130345489	Beloussov et al.	Dec 2013	A1
20140005463	Jongen	Jan 2014	A1
20140005464	Bharat et al.	Jan 2014	A1
20140014851	Asaba	Jan 2014	A1
20140028220	Bromberg et al.	Jan 2014	A1
20140042934	Hiroshi	Feb 2014	A1
20140046113	Fujimoto et al.	Feb 2014	A1
20140061493	Prieels et al.	Mar 2014	A1
20140066755	Matteo et al.	Mar 2014	A1
20140077699	Boswell et al.	Mar 2014	A1
20140091238	Miyashita et al.	Apr 2014	A1
20140091734	Gall et al.	Apr 2014	A1
20140094371	Zwart et al.	Apr 2014	A1
20140094637	Zwart et al.	Apr 2014	A1
20140094638	Gall et al.	Apr 2014	A1
20140094639	Zwart et al.	Apr 2014	A1
20140094640	Gall et al.	Apr 2014	A1
20140094641	Gall et al.	Apr 2014	A1
20140094643	Gall et al.	Apr 2014	A1
20140097920	Goldie et al.	Apr 2014	A1
20140107390	Brown et al.	Apr 2014	A1
20140112453	Prince et al.	Apr 2014	A1
20140113388	Bitter et al.	Apr 2014	A1
20140121441	Huber et al.	May 2014	A1
20140128719	Longfield	May 2014	A1
20140145090	Jongen	May 2014	A9
20140193058	Bharat et al.	Jul 2014	A1
20140200448	Schulte et al.	Jul 2014	A1
20140203186	Iwamoto et al.	Jul 2014	A1
20140221816	Franke et al.	Aug 2014	A1
20140257011	Spotts	Sep 2014	A1
20140257099	Balakin	Sep 2014	A1
20140275699	Benna et al.	Sep 2014	A1
20140308202	Matusik et al.	Oct 2014	A1
20140316184	Fujimoto et al.	Oct 2014	A1
20140330063	Balakin	Nov 2014	A1
20140332691	Campbell et al.	Nov 2014	A1
20140336438	Bharat et al.	Nov 2014	A1
20140350322	Schulte et al.	Nov 2014	A1
20140369958	Basile	Dec 2014	A1
20140371076	Jongen	Dec 2014	A1
20140371511	Zwart et al.	Dec 2014	A1
20150015167	Ungaro et al.	Jan 2015	A1
20150030223	Pearlstein et al.	Jan 2015	A1
20150031933	Yamamoto et al.	Jan 2015	A1
20150041665	Hollebeek et al.	Feb 2015	A1
20150076370	Totake et al.	Mar 2015	A1
20150080633	Anferov	Mar 2015	A1
20150080634	Huber et al.	Mar 2015	A1
20150087883	Boudreau et al.	Mar 2015	A1
20150087885	Boisseau et al.	Mar 2015	A1
20150087887	Iwata	Mar 2015	A1
20150087960	Treffert	Mar 2015	A1
20150090894	Zwart et al.	Apr 2015	A1
20150099917	Bula et al.	Apr 2015	A1
20150099918	Takayanagi et al.	Apr 2015	A1
20150126797	Aptaker et al.	May 2015	A1
20150146856	Beckman	May 2015	A1
20150148584	Gall et al.	May 2015	A1
20150174429	Zwart et al.	Jun 2015	A1
20150196534	Vidyasagar et al.	Jul 2015	A1
20150196779	Tonner	Jul 2015	A1
20150209601	Benna et al.	Jul 2015	A1
20150217138	Fujimoto et al.	Aug 2015	A1
20150217140	Balakin	Aug 2015	A1
20150231411	O'Neal, III et al.	Aug 2015	A1
20150273239	Hsu	Oct 2015	A1
20150321025	Freud et al.	Nov 2015	A1
20150328483	Odawara et al.	Nov 2015	A1
20150335463	De Gruytere	Nov 2015	A1
20150335919	Behar et al.	Nov 2015	A1
20150337393	Keller et al.	Nov 2015	A1
20150343238	Balakin	Dec 2015	A1
20150352372	Takayanagi et al.	Dec 2015	A1
20150352374	Gattiker et al.	Dec 2015	A1
20150374324	Nishimura et al.	Dec 2015	A1
20160000387	Buchsbaum et al.	Jan 2016	A1
20160008631	Harada et al.	Jan 2016	A1
20160016010	Schulte et al.	Jan 2016	A1
20160048981	Pearlstein et al.	Feb 2016	A1
20160059039	Liu	Mar 2016	A1
20160067316	Sunavala-Dossabhoy	Mar 2016	A1
20160071623	Schewiola et al.	Mar 2016	A1
20160074675	Moskvin et al.	Mar 2016	A1
20160113884	Lin et al.	Apr 2016	A1
20160136457	Jung et al.	May 2016	A1
20160144201	Schulte	May 2016	A1
20160172066	Claereboudt	Jun 2016	A1
20160172067	Claereboudt et al.	Jun 2016	A1
20160175052	Kumar et al.	Jun 2016	A1
20160175617	Spatola et al.	Jun 2016	A1
20160199667	Flynn	Jul 2016	A1
20160199670	Michaud et al.	Jul 2016	A1
20160199671	Jongen	Jul 2016	A1
20160220846	Matteo et al.	Aug 2016	A1
20160220847	Benna et al.	Aug 2016	A1
20160243232	Pickett	Aug 2016	A1
20160250501	Balakin	Sep 2016	A1
20160250503	Balakin et al.	Sep 2016	A1
20160256712	Vahala et al.	Sep 2016	A1
20160263404	Mougenot	Sep 2016	A1
20160270203	Ungaro et al.	Sep 2016	A1
20160271424	Lee et al.	Sep 2016	A1
20160287899	Park et al.	Oct 2016	A1
20160296766	El Fakhri et al.	Oct 2016	A1
20160303399	Balakin	Oct 2016	A1
20160331999	Hartman et al.	Nov 2016	A1
20170128746	Zwart et al.	May 2017	A1
20170157422	Zwart et al.	Jun 2017	A1
20170157424	Zwart et al.	Jun 2017	A1
20170157425	Zwart et al.	Jun 2017	A1
20170182338	Zwart et al.	Jun 2017	A1

Foreign Referenced Citations (159)

Number	Date	Country
2629333	May 2007	CA
1377521	Oct 2002	CN
1537657	Oct 2004	CN
1816243	Aug 2006	CN
101932361	Dec 2010	CN
101933405	Dec 2010	CN
101933406	Dec 2010	CN
101061759	May 2011	CN
2753397	Jun 1978	DE
31 48 100	Jun 1983	DE
35 30 446	Aug 1984	DE
3711245	Oct 1988	DE
41 01 094	May 1992	DE
4411171	Oct 1995	DE
102011089235	Aug 2012	DE
0 194 728	Sep 1986	EP
0 277 521	Aug 1988	EP
0 208 163	Jan 1989	EP
0 222 786	Jul 1990	EP
0 221 987	Jan 1991	EP
0 499 253	Aug 1992	EP
0 306 966	Apr 1995	EP
0 388 123	May 1995	EP
0751532	Jan 1997	EP
0 465 597	May 1997	EP
0 911 064	Jun 1998	EP
0 864 337	Sep 1998	EP
0 776 595	Dec 1998	EP
1 069 809	Jan 2001	EP
1 153 398	Apr 2001	EP
1 294 445	Mar 2003	EP
1 348 465	Oct 2003	EP
1 358 908	Nov 2003	EP
1 371 390	Dec 2003	EP
1 402 923	Mar 2004	EP
1 430 932	Jun 2004	EP
1 454 653	Sep 2004	EP
1 454 654	Sep 2004	EP
1 454 655	Sep 2004	EP
1 454 656	Sep 2004	EP
1 454 657	Sep 2004	EP
1 477 206	Nov 2004	EP
1 738 798	Jan 2007	EP
1 826 778	Aug 2007	EP
1 949 404	Jul 2008	EP
2183753	Jul 2008	EP
2114529	Nov 2009	EP
2394498	Feb 2010	EP
2232961	Sep 2010	EP
2232962	Sep 2010	EP
2227295	May 2011	EP
1 605 742	Jun 2011	EP
2363170	Sep 2011	EP
2363171	Sep 2011	EP
2514482	Oct 2012	EP
2524718	Nov 2012	EP
3088048	Nov 2016	EP
2 560 421	Aug 1985	FR
2911843	Aug 2008	FR
0 957 342	May 1964	GB
2 015 821	Sep 1979	GB
2 361 523	Oct 2001	GB
43-23267	Oct 1968	JP
U48-108098	Dec 1973	JP
57-162527	Oct 1982	JP
58-141000	Aug 1983	JP
61-80800	Apr 1986	JP
61-225798	Oct 1986	JP
62-150804	Jul 1987	JP
62-186500	Aug 1987	JP
10-071213	Mar 1988	JP
63-149344	Jun 1988	JP
63-218200	Sep 1988	JP
63-226899	Sep 1988	JP
64-89621	Apr 1989	JP
01-276797	Nov 1989	JP
01-302700	Dec 1989	JP
4-94198	Mar 1992	JP
04-128717	Apr 1992	JP
04-129768	Apr 1992	JP
04-273409	Sep 1992	JP
04-337300	Nov 1992	JP
05-341352	Dec 1993	JP
06-233831	Aug 1994	JP
06-036893	Oct 1994	JP
07-260939	Oct 1995	JP
07-263196	Oct 1995	JP
08-173890	Jul 1996	JP
08-264298	Oct 1996	JP
09-162585	Jun 1997	JP
11-47287	Feb 1999	JP
H 1128252	Feb 1999	JP
H1128252	Feb 1999	JP
11-102800	Apr 1999	JP
11-243295	Sep 1999	JP
2000-243309	Sep 2000	JP
2000-294399	Oct 2000	JP
2001-6900	Jan 2001	JP
2001-009050	Jan 2001	JP
2001-129103	May 2001	JP
2001-276238	Oct 2001	JP
2001-346893	Dec 2001	JP
2002-164686	Jun 2002	JP
A2003-504628	Feb 2003	JP
2003-517755	May 2003	JP
2004-031115	Jan 2004	JP
2005-526578	Sep 2005	JP
2006-032282	Feb 2006	JP
2007-307223	Nov 2007	JP
05-046928	Mar 2008	JP
2008-068092	Mar 2008	JP
2008-507826	Mar 2008	JP
2009-515671	Apr 2009	JP
2009-516905	Apr 2009	JP
2010-536130	Nov 2010	JP
2011-505191	Feb 2011	JP
2011-505670	Feb 2011	JP
2011-507151	Mar 2011	JP
2012-223259	Nov 2012	JP
2013-106981	Jun 2013	JP
300137	Nov 1969	SU
569 635	Aug 1977	SU
200930160	Jul 2009	TW
200934682	Aug 2009	TW
200939908	Sep 2009	TW
200940120	Oct 2009	TW
WO 198607229	Dec 1986	WO
WO 1990012413	Oct 1990	WO
WO 199203028	Feb 1992	WO
WO 199302536	Feb 1993	WO
WO 199817342	Apr 1998	WO
WO 199939385	Aug 1999	WO
WO 200040064	Jul 2000	WO
WO 200049624	Aug 2000	WO
WO 2001026230	Apr 2001	WO
WO 2001126569	Apr 2001	WO
WO 2002007817	Jan 2002	WO
WO 2003039212	May 2003	WO
WO 2003092812	Nov 2003	WO
WO 2004026401	Apr 2004	WO
WO 2004101070	Nov 2004	WO
WO 2006-012467	Feb 2006	WO
WO 2007061937	May 2007	WO
WO 2007084701	Jul 2007	WO
WO 2007130164	Nov 2007	WO
WO 2007145906	Dec 2007	WO
WO 2008030911	Mar 2008	WO
WO 2008081480	Oct 2008	WO
WO 2009048745	Apr 2009	WO
WO 2009070173	Jun 2009	WO
WO-2009070173	Jun 2009	WO
WO 2009070588	Jun 2009	WO
WO 2009073480	Jun 2009	WO
WO2014018706	Jan 2014	WO
WO2014018876	Jan 2014	WO
WO-2015003111	Jan 2015	WO
WO 2015095678	Jun 2015	WO
WO-2015107660	Jul 2015	WO
WO-2017082984	May 2017	WO

Non-Patent Literature Citations (264)

Entry
Machine translation of JP11-028252A from jpo website Jul. 17, 2015.
Invitation to Pay Additional Fees and, where applicable, protest fee issued in PCT application PCT/US2014/071448 dated Apr. 13, 2015 (11 pages).
File History of U.S. Appl. No. 13/303,110.
Tilly, et al., “Development and verification of the pulsed scanned proton beam at The Svedberg Laboratory in Uppsala”, Physics in Medicine and Biology, Phys. Med. Biol. 52, pp. 2741-2454, 2007.
U.S. Appl. No. 61/676,377, filed Jul. 27, 2012, including the USPTO electronic file for U.S. Appl. No. 61/676,377.
U.S. Appl. No. 13/949,459, filed Jul. 24, 2013, including the USPTO electronic file for U.S. Appl. No. 13/949,459.
U.S. Appl. No. 13/830,792, filed Mar. 14, 2013, including the USPTO electronic file for U.S. Appl. No. 13/830,792.
International Search Report and Written Opinion issued in corresponding PCT application No. PCT/US2014/071448 dated Jul. 24, 2015 (18 pages).
“Beam Delivery and Properties,” Journal of the ICRU, 2007, 7(2):20 pages.
“510(k) Summary: Ion Beam Applications S.A.”, FDA, Jul. 12, 2001, 5 pages.
“510(k) Summary: Optivus Proton Beam Therapy System”, Jul. 21, 2000, 5 pages.
“An Accelerated Collaboration Meets with Beaming Success,” Lawrence Livermore National Laboratory, Apr. 12, 2006, S&TR, Livermore, California, pp. 1-3, http://www.llnl.gov/str/April06/Caporaso.html.
“CPAC Highlights Its Proton Therapy Program at ESTRO Annual Meeting”, TomoTherapy Incorporated, Sep. 18, 2008, Madison, Wisconsin, pp. 1-2.
“Indiana's mega-million proton therapy cancer center welcomes its first patients” [online] Press release, Health & Medicine Week, 2004, retrieved from NewsRx.com, Mar. 1, 2004, pp. 119-120.
“LLNL, UC Davis Team Up to Fight Cancer,” Lawrence Livermore National Laboratory, Apr. 28, 2006, SF-06-04-02, Livermore, California, pp. 1-4.
“Patent Assignee Search 'Paul Scherrer Institute,” Library Services at Fish & Richardson P.C., Mar. 20, 2007, 40 pages.
“Patent Prior Art Search for ‘Proton Therapy System’,” Library Services at Fish & Richardson P.C., Mar. 20, 2007, 46 pages.
“Superconducting Cyclotron Contract” awarded by Paul Scherrer Institute (PSI), Villigen, Switzerland, http://www.accel.de/News/superconducting_cyclotron_contract.htm, Jan. 2009, 1 page.
“The Davis 76-Inch Isochronous Cyclotron”, Beam On: Crocker Nuclear Laboratory, University of California, 2009, 1 page.
“The K100 Neutron-therapy Cyclotron,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/tech/accelerators/k100, Feb. 2005, 1 page.
“The K250 Proton therapy Cyclotron,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/tech/accelerators/k250.html , Feb. 2005, 2 pages.
“The K250 Proton-therapy Cyclotron Photo Illustration,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/media/image/experimental-equipment-technology/250.html, Feb. 2005, 1 page.
18th Japan Conference on Radiation and Radioisotopes [Japanese], Nov. 25-27, 1987, 9 pages.
Abrosimov et al., “1000MeV Proton Beam Therapy facility at Petersburg Nuclear Physics Institute Synchrocyclotron,” Medical Radiology (Moscow) 32, 10 (1987) revised in Journal of Physics, Conference Series 41, 2006, pp. 424-432, Institute of Physics Publishing Limited.
Abrosimov et al., “Neutron Time-of-flight Spectrometer Gneis at the Gatchina 1 GeV Protron Syncrhocyclotron”, Mar. 9, 1985 and revised form Jul. 31, 1985, Lemingrad Nuclear Physics Institute, Gatchina, 188350, USSR (15 pages).
Adachi et al., “A 150MeV FFAG Synchrotron with “Return-Yoke Free” Magent,” Proceedings of the 2001 Particle Accelerator Conference, Chicago, 2001, 3 pages.
Ageyev et al., “The IHEP Accelerating and Storage Complex (UNK) Status Report,” 11th International Conference on High-Energy Accelerators, 1980, pp. 60-70.
Agosteo et al., “Maze Design of a gantry room for proton therapy,” Nuclear Instruments & Methods in Physics Research, 1996, Section A, 382, pp. 573-582.
Alexeev et al., “R4 Design of Superconducting Magents for Proton Synchrotrons,” Proceedings of the Fifth International Cryogenic Engineering Conference, 1974, pp. 531-533.
Allardyce et al., “Performance and Prospects of the Reconstructed CERN 600 MeV Synchrocyclotron,” IEEE Transactions on Nuclear Science USA, Jun. 1977, ns-24:(3)1631-1633.
Alonso, “Magnetically Scanned Ion Beams for Radiation Therapy,” Accelerator & Fusion Research Division, Lawrence Berkeley Laboratory, Berkeley, CA, Oct. 1988, 13 pages.
Amaldi et al., “The Italian project for a hadrontherapy centre” Nuclear Instruments and Methods in Physics Research A, 1995, 360, pp. 297-301.
Amaldi, “Overview of the world landscape of Hadrontherapy and the projects of the TERA foundation,” Physica Medica, An International journal Devoted to the Applications of Physics to Medicine and Biology, Jul. 1998, vol. XIV, Supplement 1, 6th Workshop on Heavy Charged Particles in Biology and Medicine, Instituto Scientific Europeo (ISE), Sep. 29-Oct. 1, 1977, Baveno, pp. 76-85.
Anferov et al., “Status of the Midwest Proton Radiotherapy Institute,” Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 699-701.
Anferov et al., “The Indiana University Midwest Proton Radiation Institute,” Proceedings of the 2001 Particle Accelerator Conference, 2001, Chicago, pp. 645-647.
Appun, “Various problems of magnet fabrication for high-energy accelerators,” Journal for All Engineers Interested in the Nuclear Field, 1967, pp. 10-16 (1967) [Lang.: German], English bibliographic information (http://www.osti.gov/energycitations/product.biblio.jsp?osti_id=4442292).
Arduini et al. “Physical specifications of clinical proton beams from a synchrotron,” Med. Phys, Jun. 1996, 23 (6): 939-951.
Badano et al., “Proton-Ion Medical Machine Study (PIMMS) Part I,” PIMMS, Jan. 1999, 238 pages.
Beeckman et al., “Preliminary design of a reduced cost proton therapy facility using a compact, high field isochronous cyclotron,” Nuclear Instruments and Methods in Physics Research B56/57, 1991, pp. 1201-1204.
Bellomo et al., “The Superconducting Cyclotron Program at Michigan State University,” Bulletin of the American Physical Society, Sep. 1980, 25(7):767.
Benedikt and Carli, “Matching to Gantries for Medical Synchrotrons” IEEE Proceedings of the 1997 Particle Accelerator Conference, 1997, pp. 1379-1381.
Bieth et al., “A Very Compact Protontherapy Facility Based on an Extensive Use of High Temperature Superconductors (HTS)” Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Jun. 14-19, 1998, pp. 669-672.
Bigham, “Magnetic Trim Rods for Superconducting Cyclotrons,” Nuclear Instruments and Methods (North-Holland Publishing Co.), 1975, 141:223-228.
Bimbot, “First Studies of the Extemal Beam from the Orsay S.C. 200 MeV,” Institut de Physique Nucleaire, BP 1, Orsay, France, IEEE, 1979, pp. 1923-1926.
Blackmore et al., “Operation of the Triumf Proton Therapy Facility,” IEEE Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 19973:3831-3833.
Bloch, “The Midwest Proton Therapy Center,” Application of Accelerators in Research and Industry, Proceedings of the Fourteenth Int'l. Conf., Part Two, Nov. 1996, pp. 1253-1255.
Blosser et al., “Problems and Accomplishments of Superconducting Cyclotrons,” Proceedings of the 14th International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 674-684.
Blosser et al., “Superconducting Cyclotrons”, Seventh International Conference on Cyclotrons and their Applications, Aug. 19-22, 1975, pp. 584-594.
Blosser et al., “Progress toward an experiment to study the effect of RF grounding in an internal ion source on axial oscillations of the beam in a cyclotron,” National Superconducting Cyclotron Laboratory, Michigan State University, Report MSUCL-760, CP600, Cyclotrons and their Applications 2011, Sixteenth International Conference, 2001, pp. 274-276.
Blosser et al., “A Compact Superconducting Cyclotron for the Production of High Intensity Protons,” Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, 1:1054-1056.
Blosser et al., “Advances in Superconducting Cyclotrons at Michigan State University,” Proceedings of the 11th International Conference on Cyclotrons and their Applications, Oct. 1986, pp. 157-167, Tokyo.
Blosser et al., “Characteristics of a 400 (Q2/A) MeV Super-Conducting Heavy-Ion Cyclotron,” Bulletin of the American Physical Society, Oct. 1974, p. 1026.
Blosser et al., “Medical Accelerator Projects at Michigan State Univ.” IEEE Proceedings of the 1989 Particle Accelerator Conference, Mar. 20-23, 1989, 2:742-746.
Blosser et al., “Superconducting Cyclotron for Medical Application”, IEEE Transactions on Magnetics, Mar. 1989, 25(2): 1746-1754.
Blosser, “Application of Superconductivity in Cyclotron Construction,” Ninth International Conference on Cyclotrons and their Applications, Sep. 1981, pp. 147-157.
Blosser, “Applications of Superconducting Cyclotrons,” Twelfth International Conference on Cyclotrons and Their Applications, May 8-12, 1989, pp. 137-144.
Blosser, “Future Cyclotrons,” AIP, The Sixth International Cyclotron Conference, 1972, pp. 16-32.
Blosser, “Medical Cyclotrons,” Physics Today, Special Issue Physical Review Centenary, Oct. 1993, pp. 70-73.
Blosser, “Preliminary Design Study Exploring Building Features Required for a Proton Therapy Facility for the Ontario Cancer Institute”, Mar. 1991, MSUCL-760a, 53 pages.
Blosser, “Progress on the Coupled Superconducting Cyclotron Project,” Bulletin of the American Physical Society, Apr. 1981, 26(4):558.
Blosser, “Synchrocyclotron Improvement Programs,” IEEE Transactions on Nuclear Science USA, Jun. 1969, 16(3):Part I, pp. 405-414.
Blosser, “The Michigan State University Superconducting Cyclotron Program,” Nuclear Science, Apr. 1979, NS-26(2):2040-2047.
Blosser, H., Present and Future Superconducting Cyclotrons, Bulletin of the American Physical Society, Feb. 1987, 32(2):171 Particle Accelerator Conference, Washington, D.C.
Blosser, H.G., “Superconducting Cyclotrons at Michigan State University”, Nuclear Instruments & Methods in Physics Research, 1987,vol. B 24/25, part II, pp. 752-756.
Botha et al., “A New Multidisciplinary Separated-Sector Cyclotron Facility,” IEEE Transactions on Nuclear Science, 1977, NS-24(3):1118-1120.
Chichili et al., “Fabrication of Nb3Sn Shell-Type Coils with Pre-Preg Ceramic Insulation,” American Institute of Physics Conference Proceedings, AIP USA, No. 711, (XP-002436709, ISSN: 0094-243X), 2004, pp. 450-457.
Chong et al., Radiology Clinic North American 7, 3319, 1969, 27 pages.
Chu et al., “Performance Specifications for Proton Medical Facility,” Lawrence Berkeley Laboratory, University of California, Mar. 1993, 128 pages.
Chu et al., “Instrumentation for Treatment of Cancer Using Proton and Light-ion Beams,” Review of Scientific Instruments, Aug. 1993, 64 (8):2055-2122.
Chu, “Instrumentation in Medical Systems,” Accelerator and Fusion Research Division, Lawrence Berkeley Laboratory, University of California, Berkeley, CA, May 1995, 9 pages.
Cole et al., “Design and Application of a Proton Therapy Accelerator,” Fermi National Accelerator Laboratory, IEEE, 1985, 5 pages.
Collins, et al., “The Indiana University Proton Therapy System,” Proceedings of EPAC 2006, Edinburgh, Scotland, 2006, 3 pages.
Conradi et al., “Proposed New Facilities for Proton Therapy at iThemba Labs,” Proceedings of EPAC, 2002, pp. 560-562.
C/E Source of Ions for Use in Sychro-Cyclotrons Search, Jan. 31, 2005, 9 pages.
Source Search “Cites of U.S. and Foreign Patents/Published applications in the name of Mitsubishi Denki Kabushiki Kaisha and Containing the Keywords (Proton and Synchrocyclotron),” Jan. 2005, 8 pages.
Cosgrove et al., “Microdosimetric Studies on the Orsay Proton Synchrocyclotron at 73 and 200 MeV,” Radiation Protection Dosimetry, 1997, 70(1-4):493-496.
Coupland, “High-field (5 T) pulsed superconducting dipole magnet,” Proceedings of the Institution of Electrical Engineers, Jul. 1974, 121(7):771-778.
Coutrakon et al. “Proton Synchrotrons for Cancer Therapy,” Application of Accelerators in Research and Industry—Sixteenth International Conf., American Institute of Physics, Nov. 1-5, 2000, vol. 576, pp. 861-864.
Coutrakon et al., “A prototype beam delivery system for the proton medical accelerator at Loma Linda,” Medical Physics, Nov./Dec. 1991, 18(6):1093-1099.
Cuttone, “Applications of a Particle Accelerators in Medical Physics,” Istituto Nazionale di Fisica Nucleare-Laboratori Nazionali del Sud, V.S. Sofia, 44 Cantania, Italy, Jan. 2010, 17 pages.
Dahl P, “Superconducting Magnet System,” American Institute of Physics, AIP Conference Proceedings, 1987-1988, 2: 1329-1376.
Dialog Search, Jan. 31, 2005, 17 pages.
Dugan et al., “Tevatron Status” IEEE, Particle Accelerator Conference, Accelerator Science & Technology, 1989, pp. 426-430.
Eickhoff et al., “The Proposed Accelerator Facility for Light Ion Cancer Therapy in Heidelberg,” Proceedings of the 1999 Particle Accelerator Conference, New York, 1999, pp. 2513-2515.
Enchevich et al., “Minimizing Phase Losses in the 680 MeV Synchrocyclotron by Correcting the Accelerating Voltage Amplitude,” Atomnaya Energiya, 1969, 26:(3):315-316.
Endo et al., “Compact Proton and Carbon Ion Synchrotrons for Radiation Therapy,” Proceedings of EPAC 2002, Paris France, 2002, pp. 2733-2735.
Flanz et al., “Treating Patients with the NPTC Accelerator Based Proton Treatment Facility,” Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 690-693.
Flanz et al., “Large Medical Gantries,” Particle Accelerator Conference, Massachusetts General Hospital, 1995, pp. 1-5.
Flanz et al., “Operation of a Cyclotron Based Proton Therapy Facility”, Massachusetts General Hospital, Boston, MA 02114, pp. 1-4, retrieved from Internet in 2009.
Flanz et al., “The Northeast Proton Therapy Center at Massachusetts General Hospital,” Fifth Workshop on Heavy Charge Particles in Biology and Medicine, GSI, Darmstadt, Aug. 1995, 11 pages.
Flood and Frazier, “The Wide-Band Driven RF System for the Berkeley 88-Inch Cyclotron,” American Institute of Physics, Conference Proceedings., No. 9, 1972, 459-466.
Foster and Kashikhin, “Superconducting Superferric Dipole Magent with Cold Iron Core for the VLHC,” IEEE Transactions on Applied Superconductivity, Mar. 2002, 12(1):111-115.
Friesel et al., “Design and Construction Progress on the IUCF Midwest Proton Radiation Institute,” Proceedings of EPAC 2002, 2002, pp. 2736-2738.
Fukumoto et al., “A Proton Therapy Facility Plan” Cyclotrons and their Applications, Proceedings of the 13th International Conference, Vancouver, Canada, Jul. 6-10, 1992, pp. 258-261.
Fukumoto, “Cyclotron Versus Synchrotron for Proton Beam Therapy,” KEK Prepr., No. 95-122, Oct. 1995, pp. 533-536.
Goto et al., “Progress on the Sector Magnets for the Riken SRC,” American Institute of Physics, CP600, Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 319-323.
Graffman et al., “Design Studies for a 200 MeV Proton Clinic for Radiotherapy,” AIP Conference Proceedings: Cyclotrons—1972, 1972, No. 9, pp. 603-615.
Graffman et al., Acta Radiol. Therapy Phys. Biol. 1970, 9, 1 (1970).
Graffman, et. al. “Proton radiotherapy with the Uppsala cyclotron. Experience and plans” Strahlentherapie, 1985, 161(12):764-770.
Hede, “Research Groups Promoting Proton Therapy “Lite,”” Journal of the National Cancer Institute, Dec. 6, 2006, 98(23):1682-1684.
Heinz, “Superconducting Pulsed Magnetic Systems for High-Energy Synchrotrons,” Proceedings of the Fourth International Cryogenic Engineering Conference, May 24-26, 1972, pp. 55-63.
Hentschel et al., “Plans for the German National Neutron Therapy Centre with a Hospital-Based 70 MeV Proton Cyclotron at University Hospital Essen/Germany,” Cyclotrons and their Applications, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Franco, Jun. 14-19, 1998, pp. 21-23.
Hepburn et al., “Superconducting Cyclotron Neutron Source for Therapy,” International Journal of Radiation Oncology Biology Physics, vol. 3 complete, 1977, pp. 387-391.
Hirabayashi, “Development of Superconducting Magnets for Beam Lines and Accelerator at KEK,” IEEE Transaction on Magnetics, Jan. 1981, Mag-17(1):728-731.
Ishibashi and McInturff, “Winding Design Study of Superconducting 10 T Dipoles for a Synchrotron,” IEEE Transactions on Magnetics, May 1983, MAG-19(3):1364-1367.
Ishibashi and McInturff, “Stress Analysis of Superconducting 10T Magnets for Synchrotron,” Proceedings of the Ninth International Cryogenic Engineering Conference, May 11-14, 1982, pp. 513-516.
Jahnke et al., “First Superconducting Prototype Magnets for a Compact Synchrotron Radiation Source in Operation,” IEEE Transactions on Magnetics, Mar. 1988, 24(2):1230-1232.
Jones and Dershem, “Synchrotron Radiation from Proton in a 20 TEV, 10 TESLA Superconducting Super Collide,r” Proceedings of the 12th International Conference on High-Energy Accelerator, Aug. 11-16, 1983, pp. 138-140.
Jones and Mills, “The South African National Accelerator Centre: Particle Therapy and Isotope Production Programmes,” Radiation Physics and Chemistry, Apr.-Jun. 1998, 51(4-6):571-578.
Jones et al., “Status Report of the NAC Particle Therapy Programme,” Stralentherapie and Onkologie, vol. 175, Suppl. II, Jun. 1999, pp. 30-32.
Jones, “Progress with the 200 MeV Cyclotron Facility at the National Accelerator Centre,” Commission of the European Communities Radiation Protection Proceedings, Fifth Symposium on Neutron Dosimetry, Sep. 17-21, 1984, vol. II, pp. 989-998.
Jones, “Present Status and Future Trends of Heavy Particle Radiotherapy,” Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 14-19, 1998, pp. 13-20.
Jongen et al., “Development of a Low-cost Compact Cyclotron System for Proton Therapy,” National Institute of Radiol. Sci,1991, No. 81, pp. 189-200.
Jongen et al., “Progress report on the IBA-SHI small cyclotron for cancer therapy” Nuclear Instruments and Methods in Physics Research, Section B, vol. 79, issue 1-4, 1993, pp. 885-889.
Jongen et al., “The proton therapy system for the NPTC: Equipment Description and progress report,” Nuclear Instruments and methods in physics research, 1996, Section B, 113(1): 522-525.
Jongen et al., “The proton therapy system for MGH's NPTC: equipment description and progress report,” Bulletin du Cancer/Radiotherapie, Proceedings of the meeting of the European Heavy Particle Therapy Group, 1996, 83(Suppl. 1):219-222.
Kanai et al., “Three-dimensional Beam Scanning for Proton Therapy,” Nuclear Instruments and Methods in Physic Research, Sep. 1, 1983, The Netherlands, 214(23):491-496.
Karlin et al., “Medical Radiology” (Moscow), 1983, 28, 13.
Karlin et al., “The State and Prospects in the Development of the Medical Proton Tract on the Synchrocyclotron in Gatchina,” Med. Radiol., Moscow, 28(3):28-32 (Mar. 1983)(German with English Abstract on end of p. 32).
Kats and Druzhinin, “Comparison of Methods for Irradiation Prone Patients,” Atomic Energy, Feb. 2003, 94(2):120-123.
Kats and Onosovskii, “A Simple, Compact, Flat System for the Irradiation of a Lying Patient with a Proton Beam from Different Directions,” Instruments and Experimental Techniques, 1996, 39(1): 132-134.
Kats and Onosovskii, “A Planar Magnetooptical System for the Irradiation of a Lying Patient with a Proton Beam from Various Directions,” Instruments and Experimental Techniques, 1996, 39(1):127-131.
Khoroshkov et al.,“Moscow Hospital-Based Proton Therapy Facility Design,” Am. Journal Clinical Oncology: CCT, Apr. 1994, 17(2):109-114.
Kim and Blosser, “Optimized Magnet for a 250 MeV Proton Radiotherapy Cyclotron,” Cyclotrons and Their Applications 2001, May 2001, Sixteenth International Conference, pp. 345-347.
Kim and Yun, “A Light-Ion Superconducting Cyclotron System for Multi-Disciplinary Users,” Journal of the Korean Physical Society, Sep. 2003, 43(3):325-331.
Kim et al., “Construction of 8T Magnet Test Stand for Cyclotron Studies,” IEEE Transactions on Applied Superconductivity, Mar. 1993, 3(1):266-268.
Kim et al., “Design Study of a Superconducting Cyclotron for Heavy Ion Therapy,” Cyclotrons and Their Applications 2001, Sixteenth International Conference, May 13-17, 2001, pp. 324-326.
Kim et al., “Trim Coil System for the Riken Cyclotron Ring Cyclotron,” Proceedings of the 1997 Particle Accelerator Conference, IEEE, Dec. 1981, vol. 3, pp. 214-235 OR 3422-3424, 1998.
Kim, “An Eight Tesla Superconducting Magnet for Cyclotron Studies,” Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1994, 138 pages.
Kimstrand, “Beam Modelling for Treatment Planning of Scanned Proton Beams,” Digital Comprehensive Summaries of Uppsala dissertations from the Faculty of Medicine 330, Uppsala Universitet, 2008, 58 pages.
Kishida and Yano, “Beam Transport System for the RIKEN SSC (II),” Scientific Papers of the Institute of Physical and Chemical Research, Dec. 1981, 75(4):214-235.
Koehler et al., “Range Modulators for Protons and Heavy Ions,” Nuclear Instruments and Methods, 1975, vol. 131, pp. 437-440.
Koto and Tsujii, “Future of Particle Therapy,” Japanese Journal of Cancer Clinics, 2001, 47(1):95-98 [Lang.: Japanese], English abstract (http://sciencelinks.jp/j-east/article/200206/000020020601A0511453.php).
Kraft et al., “Hadrontherapy in Oncology,” U. Amaldi and Larrsson, editors Elsevier Science, 1994, 390 pages.
Krevet et al., “Design of a Strongly Curved Superconducting Bending Magnet for a Compact Synchrotron Light Source,” Advances in Cryogenic Engineering, 1988, vol. 33, pp. 25-32.
Laisne et aI., “The Orsay 200 MeV Synchrocyclotron,” IEEE Transactions on Nuclear Science, Apr. 1979, NS-26(2):1919-1922.
Larsson et al., Nature, 1958, 182:1222.
Larsson, “Biomedical Program for the Converted 200-MeV Synchrocyclotron at the Gustaf Werner Institute,” Radiation Research, 1985, 104:S310-S318.
Lawrence et al., “Heavy particles in acromegaly and Cushing's Disease,” in Endocrine and Norendocrine Hormone Producing Tumors (Year Book Medical Chicago, 1973, pp. 29-61.
Lawrence et al., “Successful Treatment of Acromegaly: Metabolic and Clinical Studies in 145 Patients,” The Journal of Clinical Endrocrinology and Metabolism, Aug. 1970, 31(2), 21 pages.
Lawrence et al., “Treatment of Pituitary Tumors,” (Excerpta medica, Amsterdam/American Elsevier, New York, 1973, pp. 253-262.
Lawrence, Cancer, 1957, 10:795.
Lecroy et al., “Viewing Probe for High Voltage Pulses,” Review of Scientific Instruments USA, Dec. 1960, 31(12):1354.
Lin et al., “Principles and 10 Year Experience of the Beam Monitor System at the PSI Scanned Proton Therapy Facility”, Center for Proton Radiation Therapy, Paul Scherrer Institute, CH-5232, Villigen PSI, Switzerland, 2007, 21 pages.
Linfoot et al., “Acromegaly,” in Hormonal Proteins and Peptides, edited by C.H. Li, 1975, pp. 191-246.
Literature Author and Keyword Search, Feb. 14, 2005, 44 pages.
Literature Keyword Search, Jan. 24, 2005, 98 pages.
Literature Search and Keyword Search for Synchrocyclotron, Jan. 25, 2005, 68 pages.
Literature Search by Company Name/Component Source, Jan. 24, 2005, 111 pages.
Literature Search, Jan. 26, 2005, 37 pages.
Livingston et al., “A capillary ion source for the cyclotron,” Review Science Instruments, Feb. 1939, 10:63.
Mandrillon, “High Energy Medical Accelerators,” EPAC 90, 2nd European Particle Accelerator Conference, Jun. 12-16, 1990, 2:54-58.
Marchand et aI., “IBA Proton Pencil Beam Scanning: an Innovative Solution for Cancer Treatment,” Proceedings of EPAC 2000, Vienna, Austria, 3 pages.
Marti et al., “High Intensity Operation of a Superconducting Cyclotron,” Proceedings of the 14the International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 45-48 (Oct. 1995).
Martin, “Operational Experience with Superconducting Synchrotron Magnets” Proceedings of the 1987 IEEE Particle Accelerator Conference, Mar. 16-19, 1987, vol. 3 of 3:1379-1382.
Meote et al., “ETOILE Hadrontherapy Project, Review of Design Studies” Proceedings of EPAC 2002, 2002, pp. 2745-2747.
Miyamoto et al., “Development of the Proton Therapy System,” The Hitachi Hyoron, 79(10):775-779 (1997) [Lang: Japanese], English abstract (http://www.hitachi.com/rev/1998/revfeb98/rev4706.htm).
Montelius et al., “The Narrow Proton Beam Therapy Unit at the Svedberg Laboratory in Uppsala,” ACTA Oncologica, 1991, 30:739-745.
Moser et al., “Nonlinear Beam Optics with Real Fields in Compact Storage Rings,” Nuclear Instruments & Methods in Physics Research/Section B, B30, Feb. 1988, No. 1, pp. 105-109.
Moyers et al., “A Continuously Variable Thickness Scatterer for Proton Beams Using Self-compensating Dual Linear Wedges” Lorna Linda University Medical Center, Dept. of Radiation Medicine, Lorna Linda, CA, Nov. 2, 1992, 21 pages.
National Cancer Institute Funding (Senate—Sep. 21, 1992) (www.thomas.loc.gov/cgi-bin/query/z?r102:S21SE2-712 (2 pages).
Nicholson, “Applications of Proton Beam Therapy,” Journal of the American Society of Radiologic Technologists, May/Jun. 1996, 67(5): 439-441.
Nolen et al., “The Integrated Cryogenic—Superconducting Beam Transport System Planned for MSU,” Proceedings of the 12th International Conference on High-Energy Accelerators, Aug. 1983, pp. 549-551.
Norimine et al., “A Design of a Rotating Gantry with Easy Steering for Proton Therapy,” Proceedings of EPAC 2002, 2002, pp. 2751-2753.
Ogino, Takashi, “Heavy Charged Particle Radiotherapy-Proton Beam”, Division of Radiation Oncology, National Cancer Hospital East, Kashiwa, Japan, Dec. 2003, 7 pages.
Okumura et al., “Overview and Future Prospect of Proton Radiotherapy,” Japanese Journal of Cancer Clinics, 1997, 43(2):209-214 [Lang.: Japanese].
Okumura et al., “Proton Radiotherapy” Japanese Journal of Cancer and Chemotherapy, 1993, 10. 20(14):2149-2155[Lang.: Japanese].
Outstanding from Search Reports, “Accelerator of Polarized Portons at Fermilab,” 2005, 20 pages.
Paganetti et al., “Proton Beam Radiotherapy—The State of the Art,” Springer Verlag, Heidelberg, ISBN 3-540-00321-5, Oct. 2005,36 pages.
Palmer and Tollestrup, “Superconducting Magnet Technology for Accelerators,” Annual Review of Nuclear and Particle Science, 1984, vol. 34, pp. 247-284.
Patent Assignee and Keyword Searches for Synchrocyclotron, Jan. 25, 2005, 78 pages.
Pavlovic, “Beam-optics study of the gantry beam delivery system for light-ion cancer therapy,” Nuclear Instruments and Methods in Physics Research, Section A, Nov. 1997, 399(2):439-454(16).
Pedroni and Enge, “Beam optics design of compact gantry for proton therapy” Medical & Biological Engineering & Computing, May 1995, 33(3):271-277.
Pedroni and Jermann, “SGSMP: Bulletin Mar. 2002 Proscan Project, Progress Report on the PROSCAN Project of PSI” [online] retrieved from www.sgsmp.ch/protA23.htm, Mar. 2002, 5 pages.
Pedroni et al., “A Novel Gantry for Proton Therapy at the Paul Scherrer Institute,” Cycloctrons and Their Applications 2001: Sixteenth International Conference. AIP Conference Proceedings, 2001, 600:13-17.
Pedroni et al., “The 200-MeV proton therapy project at the Paul Scherrer Institute: Conceptual design and practical realization,” Medical Physics, Jan. 1995, 22(1):37-53.
Pedroni, “Accelerators for Charged Particle Therapy: Performance Criteria from the User Point of View,” Cyclotrons and their Applications, Proceedings of the 13th International Conference, Jul. 6-10, 1992, pp. 226-233.
Pedroni, “Latest Developments in Proton Therapy” Proceedings of EPAC 2000, pp. 240-244, 2000.
Pedroni, “Status of Proton Therapy: results and future trends,” Paul Scherrer Institute, Division of Radiation Medicine, 1994, 5 pages.
Peggs et al., “A Survey of Hadron Therapy Accelerator Technologies,” Particle Accelerator Conference, Jun. 25-29, 2007, 7 pages.
Potts et al., “MPWP6-Therapy III: Treatment Aids and Techniques” Medical Physics, Sep./Oct. 1988, 15(5):798.
Pourrahimi et al., “Powder Metallurgy Processed Nb3Sn(Ta) Wire for High Field NMR magnets,” IEEE Transactions on Applied Superconductivity, Jun. 1995, 5(2):1603-1606.
Prieels et al., “The IBA State-of-the-Art Proton Therapy System, Performances and Recent Results,” Application of Accelerators in Research and industry—Sixteenth Int'l. Conf., American Institute of Physics, Nov. 1-5, 2000, 576:857-860.
Rabin et al., “Compact Designs for Comprehensive Proton Beam Clinical Facilities,” Nuclear Instruments & Methods in Physics Research, Apr. 1989, Section B, vol. 40-41, Part II, pp. 1335-1339.
Research & Development Magazine, “Proton Therapy Center Nearing Completion.” Aug. 1999, 41(9): 2 pages, (www.rdmag.com).
Resmini, “Design Characteristics of the K=800 Superconducting Cyclotron at M.S.U.,” Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, IEEE Transaction on Nuclear Science, vol. NS-26, No. 2, Apr. 1979, 8 pages.
RetroSearch “Berkeley 88-Inch Cyclotron ‘RF’ or ‘Frequency Control’,” Jan. 21, 2005, 36 pages.
RetroSearch “Berkeley 88-Inch Cyclotron,” Jan. 24, 2005, 170 pages.
RetroSearch “Bernard Gottschalk, Cyclotron, Beams, Compensated Upstream Modulator, Compensated Scatter,” Jan. 21, 2005, 20 pages.
RetroSearch “Cyclotron with ‘RF’ or ‘Frequency Control’,” Jan. 21, 2005, 49 pages.
RetroSearch Gottschalk, Bernard, Harvard Cyclotron Wheel, Jan. 21, 2005, 20 pages.
RetroSearch “Loma Linda University Beam Compensation,” Jan. 21, 2005, 60 pages.
RetroSearch “Loma Linda University, Beam Compensation Foil Wedge,” Jan. 21, 2005, 15 pages.
Revised Patent Keyword Search, Jan. 25, 2005, 88 pages.
Rifuggiato et, al., “Status Report of the LNS Superconducting Cyclotron” Nukleonika, 2003, 48: S131-S134, Supplement 2.
Rode, “Tevatron Cryogenic System,” Proceedings of the 12th International Conference on High-energy Accelerators, Fermilab, Aug. 11-16, 1983, pp. 529-535.
Salzburger et al., “Superconducting Synchrotron Magnets Supraleitende Synchrotronmagnete,” Siemens A.G., Erlangen (West Germany). Abteilung Technische Physik, Report No. BMFT-FB-T-75-25, Oct. 1975, p. 147, Journal Announcement: GRAI7619; STAR1415, Subm-Sponsored by Bundesmin. Fuer Forsch. U. Technol. In German; English Summary.
Schillo et al,. “Compact Superconducting 250 MeV Proton Cyclotron for the PSI Proscan Proton Therapy Project,” Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 37-39.
Schneider et al., “Nevis Synchrocyclotron Conversion Program—RF System,” IEEE Transactions on Nuclear Science USA, Jun. 1969, ns. 16(3): 430-433.
Schneider et al., “Superconducting Cyclotrons,” IEEE Transactions on Magnetics, vol. MAG-11, No. 2, Mar. 1975, New York, pp. 443-446.
Schreuder et al., “The Non-orthogonal Fixed Beam Arrangement for the Second Proton Therapy Facility at the National Accelerator Centre,” Application of Accelerators in Research and Industry, American Institute of Physics, Proceedings of the Fifteenth International Conference, Nov. 1998, Part Two, pp. 963-966.
Schreuder, “Recent Developments in Superconducting Cyclotrons,” Proceedings of the 1995 Particle Accelerator Conference, May 1-5, 1995, vol. 1, pp. 317-321.
Schubert and Blosser, “Conceptual Design of a High Field Ultra-Compact Cyclotron for Nuclear Physics Research,” Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, vol. 1, 3 pp. 1060-1062.
Schubert, “Extending the Feasibility Boundary of the Isochronous Cyclotron,” Dissertation submitted to Michigan State University, 1997, Abstract http://adsabs.harvard.edu/abs/1998PhDT . . . 147S.
Shelaev et al., “Design Features of a Model Superconducting Synchrotron of JINR,” Proceedings of the 12th International Conference on High-energy Accelerators, Aug. 11-16, 1983, pp. 416-418.
Shintomi et. Al, “Technology and Materials for the Superconducting Super Collider (SSC) Project,” [Lang.: Japanese], The Iron and Steel Institute of Japan 00211575, 78(8): 1305-1313, 1992, http://ci.nii.ac.jp/naid/110001493249/en/.
Sisterson, “World Wide Proton Therapy Experience in 1997,” The American Insitute of Physics, Applications of Accelerators in Research and Industry, Proceedings of the Fifteenth International Conference, Part Two, Nov. 1998, pp. 959-962.
Sisterson, “Clinical use of proton and ion beams from a world-wide perspective,” Nuclear Instruments and Methods in Physics Research, Section B, 1989, 40-41:1350-1353.
Slater et al., “Developing a Clinical Proton Accelerator Facility: Consortium-Assisted Technology Transfer,” Conference Record of the 1991 IEEE Particle Accelerator Conference: Accelerator Science and Technology, vol. 1, May 6-9, 1991, pp. 532-536.
Slater et al., “Development of a Hospital-Based Proton Beam Treatment Center,” International Journal of Radiation Oncology Biology Physics, Apr. 1988, 14(4):761-775.
Smith et al., “The Northeast Proton Therapy Center at Massachusetts General Hospital” Journal of Brachytherapy International, Jan. 1997, pp. 137-139.
Snyder and Marti, “Central region design studies for a proposed 250 MeV proton cyclotron,” Nuclear Instruments and Methods in Physics Research, Section A, 1995, vol. 355, pp. 618-623.
Soga, “Progress of Particle Therapy in Japan,” Application of Accelerators in Research and Industry, American Institute of Physics, Sixteenth International Conference, Nov. 2000, pp. 869-872.
Spiller et al., “The GSI Synchrotron Facility Proposal for Acceleration of High Intensity Ion and Proton Beams” Proceedings of the 2003 Particle Accelerator Conference, May 12-16, 2003, vol. 1, pp. 589-591.
Stanford et al., “Method of Temperature Control in Microwave Ferroelectric Measurements,” Sperry Microwave Electronics Company, Clearwater, Florida, Sep. 19, 1960, 1 page.
Tadashi et al., “Large superconducting super collider (SSC) in the planning and materials technology,” 78(8):1305-1313, The Iron and Steel Institute of Japan 00211575, Aug. 1992.
Takada, “Conceptual Design of a Proton Rotating Gantry for Cancer Therapy,” Japanese Journal of Medical Physics, 1995, 15(4):270-284.
Takayama et al., “Compact Cyclotron for Proton Therapy,” Proceedings of the 8th Symposium on Accelerator Science and Technology, Japan, Nov. 25-27, 1991, pp. 380-382.
Teng, “The Fermilab Tevatron,” Coral Gables 1981, Proceedings, Gauge Theories, Massive Neutrinos, and Proton Decay, 1981, pp. 43-62.
The Journal of Practical Pharmacy, 1995, 46(1):97-103 [Japanese].
Tobias et al., Cancer Research,1958, 18, 121 (1958).
Tom, “The Use of Compact Cyclotrons for Producing Fast Neutrons for Therapy in a Rotatable Isocentric Gantry,” IEEE Transaction on Nuclear Science, Apr. 1979, 26(2):2294-2298.
Toyoda, “Proton Therapy System”, Sumitomo Heavy Industries, Ltd., 2000, 5 pages.
Trinks et. al., “The Tritron: A Superconducting Separated-Orbit Cyclotron,” Nuclear Instruments and Methods in Physics Research, Section A, 1986, vol. 244, pp. 273-282.
Tsuji, “The Future and Progress of Proton Beam Radiotherapy,” Journal of Japanese Society for Therapeutic Radiology and Oncology, 1994, 6(2):63-76.
UC Davis School of Medicine, “Unlikely Partners Turn Military Defense into Cancer Offense”, Current Issue Summer 2008, Sacramento, California, pp. 1-2.
Umegaki et al., “Development of an Advanced Proton Beam Therapy System for Cancer Treatment” Hitachi Hyoron, 2003, 85(9):605-608 [Lang.: Japanese], English abstract, http://www.hitachi.com/ICSFiles/afieldfile/2004/06/01/r2003_04_104.pdf or http://www.hitachi.com/rev/archive/2003/2005649_12606.html (full text) [Hitachi, 52(4), Dec. 2003].
Umezawa et al., “Beam Commissioning of the new Proton Therapy System for University of Tsukuba,” Proceedings of the 2001 Particle Accelerator Conference, vol. 1, Jun. 18-22, 2001, pp. 648-650.
van Steenbergen, “Superconducting Synchroton Development at BNL,” Proceedings of the 8th International Conference on High-Energy Accelerators CERN 1971, 1971, pp. 196-198.
van Steenbergen, “The CMS, a Cold Magnet Synchrotron to Upgrade the Proton Energy Range of the BNL Facility,” IEEE Transactions on Nuclear Science, Jun. 1971, 18(3):694-698.
Vandeplassche et al., “235 MeV Cyclotron for MGH's Northeast Proton Therapy Center (NPTC): Present Status,” EPAC 96, Fifth European Partical Accelerator Conference, vol. 3, Jun. 10-14, 1996, pp. 2650-2652.
Vorobiev et al., “Concepts of a Compact Achromatic Proton Gantry with a Wide Scanning Field”, Nuclear Instruments and Methods in Physics Research, Section A., 1998, 406(2):307-310.
Vrenken et al., “A Design of a Compact Gantry for Proton Therapy with 2D-Scanning,” Nuclear Instruments and Methods in Physics Research, Section A, 1999, 426(2):618-624.
Wikipedia, “Cyclotron” http://en.wikipedia.org/wiki/Cyclotron (originally visited Oct. 6, 2005, revisited Jan. 28, 2009), 7pages.
Wikipedia, “Synchrotron” http://en.wikipedia.org/wiki/Synchrotron (originally visited Oct. 6, 2005, revisited Jan. 28, 2009), 7 pages.
Worldwide Patent Assignee Search, Jan. 24, 2005, 224 pages.
Worldwide Patent Keyword Search, Jan. 24, 2005, 94 pages.
Wu, “Conceptual Design and Orbit Dynamics in a 250 MeV Superconducting Synchrocyclotron,” Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1990, 172 pages.
York et al., “Present Status and Future Possibilities at NSCL-MSU,” EPAC 94, Fourth European Particle Accelerator Conference, pp. 554-556, Jun. 1994.
York et al., “The NSCL Coupled Cyclotron Project—Overview and Status,” Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 1998, pp. 687-691.
Yudelev et al., “Hospital Based Superconducting Cyclotron for Neutron Therapy: Medical Physics Perspective,” Cyclotrons and their applications 2001, 16th International Conference. American Institute of Physics Conference Proceedings, vol. 600, May 13-17, 2001, pp. 40-43.
Zherbin et al., “Proton Beam Therapy at the Leningrad Synchrocyclotron (Clinicomethodological Aspects and Therapeutic Results)”, Aug. 1987, 32(8):17-22, (German with English abstract on pp. 21-22).
Invitation to Pay Additional Fees and, where applicable, protest fee issued in PCT application PCT/US2016/048037 dated Oct. 20, 2016 (8 pages).
International Preliminary Report on Patentability for PCT/US2014/071448, 14 pages (dated Jun. 30, 2016).
Communication pursuant to Rules 161(1) and 162 EPC in EP14830919.8, 2 pages (dated Sep. 2, 2016).
International Search Report for PCT/US2016/048037, 11 pages (dated Feb. 6, 2017).
Written Opinion for PCT/US2016/048037, 12 pages (dated Feb. 6, 2017).
Boyer, A. et al., Basic Applications of Multi-leaf Collimators: Report of Task Group No. 50—Radiation Therapy Committee, AAPM Report No. 72, American Association of Physicists in Medicine by Medical Physics Publishing, 62 pages (2001).
Daartz, J. et al., Characterization of a mini-multileaf collimator in a proton beamline, Med. Phys., 36(5):9 pages (2009).
File History of U.S. Appl. No. 61/843,092, 84 pages (downloaded Oct. 14, 2016).
File History of U.S. Appl. No. 61/900,455, 43 pages (downloaded Oct. 14, 2016).
File History of U.S. Appl. No. 61/946,074, 137 pages (downloaded Oct. 14, 2016).
Fredriksson, Albin, Robust optimization of radiation therapy accounting for geometric uncertainty, Doctoral Thesis, 57 pages (2013).
Gelover, E. et al., A method for modeling laterally asymmetric proton beamlets resulting from collimation, Medical Physics, 42:1321-1334 (2015).
Moignier, A. et al., Toward improved target conformity for two spot scanning proton therapy delivery systems using dynamic collimation, Medical Physics, 43:1421-1427 (2014).
Bues, M. et al., Therapeutic Step and Shoot Proton Beam Spot-Scanning With a Mulit-Leaf Collimator: A Monte Carlo Study, Radiation Protection Dosimetry, 115(1-4):164-169 (2005).
Hyer, D. et al., A dynamic collimation system for penumbra reduction in spot-scanning proton therapy: Proof of concept; Medical Physics, 41(9):091701-1-091701-9 (2014).
Torikoshi, M. et al., Irradiation System for HIMAC, J. Radiat. Res, 48: Suppl. A15-A25 (2007).
Office Action for U.S. Appl. No. 15/438,544, 27 pages (dated Oct. 12, 2017).
Communication pursuant to Article 94(3) EPC for EP14830919.8, 6 pages (dated May 12, 2017).
First Office Action (English translation) for JP2016-541203, 10 pages (dated Jul. 31, 2017).
First Office Action (Japanese translation) for JP2016-541203, 7 pages (dated Jul. 31, 2017).
Office Action for U.S. Appl. No. 14/937,048, 94 pages (dated Oct. 13, 2017).
Office Action for U.S. Appl. No. 15/399,250, 78 pages (dated Jan. 19, 2018).

Related Publications (1)

	Number	Date	Country
	20150174429 A1	Jun 2015	US

Collimator and energy degrader

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC